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1  OBJECTIVES OF THE THESIS 
 
 
The overall aim of this thesis was to investigate the immunogenicity of antibody 
aggregates in wild-type animals.  
This work dealt only with homogeneous aggregates, meaning aggregates that consist 
only of protein drug but not of foreign substances such as glass particles or silicone oil droplets. 
With regard to anti-drug antibody formation some crucial points of protein aggregation were 
touched: the size of aggregates, the conformation and structural changes of the protein were 
investigated with regard to the induced immune response.  
First of all, stress methods that can trigger aggregation of the protein drug had to be 
evaluated. The work focused on monoclonal antibodies, which currently are the largest 
category of biopharmaceuticals. Antibodies seem to be more stable than many other proteins, 
thus suitable conditions for aggregation had to be found. On the one side the applied conditions 
needed to be relevant for processing and handling steps a protein might suffer from. Therefore, 
methods resembling steps during production (such as stirring), during shipment and storage 
(such as freeze-thawing, light exposure, and elevated temperatures), and during handling (such 
as shaking) were chosen to induce aggregation. The suitability of the methods had to be 
estimated according to the amount of generated aggregates provoked by the respective stress. 
Since the immune response to the aggregates should be investigated, not the immunogenicity 
of the native drug or its fragments, a sufficient amount of aggregates had to be generated to 
enable separation from concomitant native protein species.  
The separation of aggregates was the second major aim of this thesis. If sufficient 
amounts of soluble aggregates are gained by any stress method, a method to fractionate them 
from the monomeric protein needed to be established. Ideally, asymmetric flow field-flow 
fractionation (AF4) or size exclusion chromatography would be used. Particulate aggregates 
have to be separated from soluble species as well. The separated aggregates had to be 
physicochemically characterized to the extent possible before being used in animal studies. 
The final and pivotal aim of this work was the immunogenicity investigation of 
separated aggregates of a monoclonal antibody in vivo. Therefore, a proper animal model had 
to be found and suitable analytical methods to detect immune responses had to be developed. 
A murine monoclonal antibody was used in a mouse model, thus no transgenic animals were 
needed. It was aimed to relate the immune response to the characteristics of the aggregates. If 
differences in the immunogenic potential of aggregates would be detected, a classification of 
protein aggregates of a monoclonal antibody with respect to their immunogenicity would be 
possible for the first time.  
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2  INTRODUCTION  
 
 
2.1  BIOPHARMACEUTICALS 
 
The outstanding advances in recombinant DNA techniques and biotechnology during 
the last decades enabled the large-scale production and facilitated the development of highly 
purified recombinant therapeutic proteins, a new class of drugs. In 1982, human insulin 
(Humulin, Genentech), the first recombinant engineered protein for therapeutic use, was 
approved. Since that time numerous products of biotechnological origin entered the market and 
now make up to 30% of the marketed drugs [Brinks et al., 2011]. Furthermore, large numbers of 
protein drugs are in development [Leader et al., 2008]. The market for “biopharmaceuticals” is 
still fast growing and their chance of success is estimated to be much higher compared to 
conventional synthetic chemical drugs [Pavlou et al., 2005; Pavlou et al., 2004]. In general, 
biopharmaceuticals encompass products based on cell or tissue-engineering as well as nucleic-
acid products, besides the above mentioned recombinant therapeutic proteins [Walsh, 2010]. 
For the purpose of this work the term “biopharmaceutical” is referred to as therapeutic proteins.  
Therapeutic proteins benefit from their extremely high activity and specifity at low 
concentrations [Wang, W., 1999], thus resulting in minimized side effects. These promising 
molecules are nowadays widely used as therapeutics, mainly in the treatment of life-threatening 
and severe diseases particularly in the field of oncology, auto-immunogenicity, and 
inflammation [Berger et al., 2002; Walsh, 2006]. They should either modify a disease process or 
adjust a deficiency of a native human protein; either inherited or acquired [Van Regenmortel, 
2001]. 
The main difference of therapeutic proteins to the conventional chemical drugs is their 
molecular weight. Therapeutic proteins consist of long polypeptide chains and usually possess 
molar masses of several kDa, whereas the molar mass of chemical drugs is usually below 
1 kDa. The complex and delicate structure of protein therapeutics is subject to a variety of 
instabilities and degradation pathways that may occur during development, production, and 
handling. This implicates a wealth of engineering challenges to achieve a convenient, stable, 
and safe formulation [Frokjaer et al., 2005; Randolph et al., 2007]. The most obvious challenge 
concerns the insufficient oral availability of protein drugs. Firstly, proteins are not resistant 
against enzymatic and hydrolytic degradation in the gastrointestinal (GI) tract. Secondly, due to 
their features of a hydrophilic surface and a high molar mass, proteins are not able to pass the 
membranes in the GI-tract and therefore resorption and bioavailability are poor. Except very few 
products, proteins are administered parenterally in form of aqueous solutions or suspensions.  
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2.1.1 Stability of therapeutic protein formulations 
The poor stability of the proteins` structural composition pose challenges to maintain 
stability throughout their shelf-life which is typically between 18 - 24 months at 2-8°C [Chang et 
al., 2002; Randolph et al., 2007]. The possible degradation pathways proteins can undergo are 
manifold and are generally subdivided in chemical and physical degradation [Bee et al., 2011; 
Mahler et al., 2009; Manning et al., 1989; Wang, W., 1999]. Changes of the structure of the 
protein including the loss or the formation of new covalent bonds are referred to as chemical 
degradation [Liu et al., 2008; Manning et al., 1989]. The large numbers of functional groups 
within the amino acid sequence make proteins prone to various chemical reactions. The most 
common chemical degradation pathways proteins can undergo are deamidation, oxidation, 
aspartate isomerization, disulfide bond formation, and breakage, and hydrolysis of the peptide 
bonds [Liu et al., 2008; Shahrokh et al., 1994; Wakankar et al., 2007; Wang, 2005; Wang, W. et 
al., 2006a; Yang et al., 2007]. Besides the primary structure of the molecules, the therapeutic 
protein additionally has to maintain its native steric conformation in the higher order structure 
(secondary and above) to assure the correct binding to the site of action. Biological activity and 
efficacy essentially require a definite conformation. Physical degradation of proteins often leads 
to unfolding and misfolding of the protein, altering this conformation [Manning et al., 1989; 
Wang, W., 1999]. Moreover, these partially or fully unfolded molecules are prone to interactions 
and can easily aggregate [Chi et al., 2003a]. 
However, both types of protein degradation depend on each other and a clear 
classification is not always possible [Wang, 2005]. During the manufacturing and handling 
processes of therapeutic proteins many stages, such as production, filling, storage and shipping 
have to be passed. It is of utmost importance for the pharmaceutical industry and for the 
authorities to avoid any kind of degradation, assure chemical and conformational stability and 
finally to achieve stable formulations. 
 
2.2 PROTEIN AGGREGATION 
 
2.2.1 Mechanisms of protein aggregation 
Aggregation is the most common physical instability of biopharmaceutical products and 
a major problem during their formulation, shipping and handling processes. Aggregation was 
first investigated and described more than 50 years ago by the Lumry-Eyring model [Lumry et 
al., 1954]. In general, two different phenomena can be differentiated. “Protein aggregation” 
denotes the formation of irreversible oligomers from non-native species. The “self-association” 
of proteins merely includes the formation of small oligomers from native species, which are 
soluble and reversible upon dilution [Saluja et al., 2008]. However, in general the term “protein 
aggregation” refers to any type of interaction between the protein molecules that lead to self-
associated oligomers of higher molecular weight than the requested species [Singh, S.K. et al., 
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2010]. Throughout this thesis the latter mentioned and more general definition will form the 
basis of the investigation and discussion.  
According to the Lumry-Eyring model self-association is proposed to be linked to the 
existence of even low amounts of partially unfolded intermediate states of proteins (Figure 2-1), 
since the aggregation of such intermediate states of proteins are energetically favored [Wang, 
2005].  
 
The native protein (N) can form reversible unfolding intermediate states (I) which then can either form 
reversible unfolded states (U) or irreversible/reversible aggregates (A). [Manning et al., 1989; Wang, 2005] 
 
The transitional/intermediate species can be prone to association and aggregation 
[Lumry et al., 1954]. The latter can be facilitated by (partial) unfolding, because patterns of 
contiguous hydrophobic side chains can initiate the process [Wang, 2005].   
The pathways that protein aggregation underlies were investigated in more detail 
during the last decades. Five important aggregation mechanisms (1 – 5) were described by 
Philo and Arakawa [Philo et al., 2009]. They classified these mechanisms concerning the 
conformation of the interacting protein molecules and the process of interaction. The first 
pathway (1) is based on a high propensity of the native monomer to reversibly associate in 
order to form small oligomers which might grow larger over time. Powered by the law of mass 
action, especially high protein concentration can accelerate oligomer growth and the formation 
of potentially irreversible larger aggregates can occur [Philo et al., 2009]. Insulin is known to 
associate in this manner [Pekar et al., 1972]. In the second pathway (2), the monomer has no 
clear tendency to associate in the native state. However, slight transient changes like partial 
unfolding (see Figure 1) can lead to an immense aggregation of the conformationally altered 
monomer. Factors that may precede and initially trigger the conformational alteration can be 
e.g. shearing or heating. This most dominant pathway of aggregation [Chi et al., 2003a; 
Krishnamurthy et al., 2002; Wang, 2005] was exemplarily shown to appear in G-CSF [Krishnan 
et al., 2002] and interferon-γ formulations [Kendrick et al., 1998]. If the initial conformational 
alteration implies different covalent structures another pathway (3) can occur. The onset of this 
mechanism is based on chemical degradations, like deamidation, proteolysis or oxidation of 
tryptophan or methionine [Philo et al., 2009; Roy et al., 2009]. Similarly to the process of 
Figure 2-1 – Lumry-Eyring model of protein self-association. 
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crystal-growth, protein aggregates can also originate from nucleation processes (4). Nucleation 
is independent of the initial conformation of the interacting molecules and describes the 
increase in size and number of aggregates. At the same time the population of the monomer is 
decreasing. The growth of a “critical nucleus” of sufficient size can be very fast, due to a 
thermodynamically favored addition of monomers to these species [Philo et al., 2009]. 
Therefore, a rapid formation of very large aggregates, which eventually might precipitate and 
form visible particles, is possible [Chi et al., 2003a]. Usually, the formation of such large 
particles exhibits a lag-phase. Meanwhile, subvisible small oligomers arise. But when a certain 
size of the nucleus has been reached they appear rather suddenly [Philo et al., 2009]. Such 
nucleation-controlled processes can either be “homogeneous” if the nucleus consists of protein 
molecules or “heterogeneous” if the nucleus is made from an impurity or contaminant such as 
stainless steel particles [Tyagi et al., 2009], silica particles [Chi et al., 2005] or silicone oil 
droplets [Jones et al., 2005; Thirumangalathu et al., 2009]. In general, the interaction of 
monomer molecules with such nuclei could be considered as interaction with a surface. 
Aggregation at interfaces (5) is another phenomenon that can occur in protein solutions during 
manufacturing. The trigger can either be an air-liquid interface, ice-water interface or a 
container surface [Cleland et al., 1993; Mahler et al., 2005; Wang, W., 1999].  
2.2.2 Factors inducing protein aggregation 
The aggregation phenomenon can be induced or affected by certain environmental 
conditions or simply with time. Wei Wang reviewed several key biopharmaceutical processes 
that are linked to protein aggregation. The phenomenon was observed in upstream processes, 
such as fermentation, downstream processes, such as purification, formulation process, such 
as drying and reconstitution, as well as during storage [Kiese, 2008; Wang, 2005]. The 
underlying physical stress principles the protein can be exposed to during manufacturing are 
manifold. Besides others, temperature variations during freezing and thawing [Cao et al., 2003; 
Kueltzo et al., 2008], UV-light exposure during purification [Kerwin et al., 2007; Qi et al., 2009; 
Roy et al., 2009] and the interactions with different types of solid surfaces [Mollmann et al., 
2005; Randolph et al., 2007] or air-liquid interfaces [Chang et al., 1996; Kiese, 2008] can trigger 
aggregation.  
Each stress principle can result in different forms of aggregates. Temperature is the 
major factor affecting protein stability. In general proteins have melting temperatures (Tm) 
between 40°C and 80°C [Wang, W., 1999]. When exposed to temperatures close to Tm the 
protein can become partially or completely unfolded and more prone to aggregation. Chemical 
degradation can be increased as well since the amino acid sequence can be altered by heat. 
Furthermore, Brownian motion, hydrophobic interactions and reaction kinetics are enhanced 
[Chi et al., 2003a; Wang, 2005]. Generally it can be stated that an increase in temperature goes 
along with a decrease in protein stability. Thus, protein formulations are typically stored clearly 
below the unfolding temperature, meaning frozen or at 2 – 8°C [Kiese, 2008]. 
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The exposure to light can occur at several stages during manufacturing. 
Chromatographic purification is usually monitored by absorption to UV light at 280 nm and 
every molecule of the eluting protein is exposed to that wavelength for a short period of time. 
During formulation and inspection operations the protein can be exposed to daylight or ambient 
light as well [Roy et al., 2009]. Finally, the self-administration from patients entails insecurity of 
storage conditions including inadvertent light exposure. The chemical and physical stability of a 
protein can be affected by the absorption of light [Davies et al., 2001; Kerwin et al., 2007]. 
Aggregation and conformational changes of proteins are known to be triggered by light in the 
UV-B range (280 nm – 320 nm) [Kim et al., 2007; Miller et al., 2003; Prompers et al., 1999]. The 
photoreactions within these studies mainly based on the irradiation of tryptophan (Trp) since it 
is the chromophore that is able to absorb light most efficiently in this region [Lakowicz, 1983]. 
Subsequently to the irradiation of Trp, disulfide bonds can be reduced and cleaved enabling the 
formation of new intermolecular bonds and crosslinking [Prompers et al., 1999]. The underlying 
mechanism is not yet fully understood. However, the spatial proximity between the disulfide 
bond forming cysteine and aromatic residues like Trp is found in many proteins and can 
attribute to these observations [Petersen et al., 1999].  
Agitation stresses such as shaking, stirring, and pumping can lead to different types of 
aggregates as well [Kiese, 2008]. Volkin and Klibanov showed that shaking creates air/water 
interfaces. Due to their hydrophobicity protein molecules align at the interface, expose 
hydrophobic areas by unfolding and eventually aggregate [Volkin et al., 1989]. Besides creating 
air/water interfaces stirring and pumping operations expose solid surfaces to the protein as well. 
Furthermore, these shearing processes may also change protein conformation and lead to 
transitional exposure of hydrophobic patches of the protein. Such mechanical stress leads often 
to the formation of non-covalent and native oligomers that can either be soluble or insoluble.  
The amphiphilic properties of protein molecules cause a strong propensity to 
accumulate at interfaces.  The air-water interface is very hydrophobic and the most important 
during manufacturing processes like agitation, pumping and filtration [Jones et al., 1997; Kiese, 
2008]. The majority of therapeutic proteins tend to adsorb at hydrophobic surfaces by partial 
unfolding. The interaction with a hydrophobic surface may entail the exposition of parts the 
hydrophobic core of the protein resulting in conformational changes [Chi et al., 2005; Wang, W., 
1999]. Vermeer et al. showed that the secondary structure of an immunoglobulin G significantly 
changed by adsorption to a surface [Vermeer et al., 1998]. The high concentration of protein 
molecules with altered structures near/at the interface, can result in destabilization, and finally 
in aggregation processes [Carpenter, John F. et al., 1999; Randolph et al., 2002] 
2.2.3 Classification and conformation of protein aggregates  
Depending on the aggregation mechanism and the type of protein, the properties of the 
resulting aggregates can strongly differ. A generally accepted classification of such protein 
aggregates differentiates between: 
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a) covalent and non-covalent aggregates  
b) reversible and irreversible aggregates 
c) soluble and insoluble aggregates 
d) native and non-native aggregates [Cromwell et al., 2006; Kiese, 2008; Liu et al., 
2007; Mahler et al., 2009] 
Covalent aggregates originate from the formation of chemical bonds such as disulfide 
bridges between the native protein molecules, whereas non-covalent aggregates are formed by 
weak electrostatic or hydrophobic interactions, or hydrogen bonding [Demeule et al., 2007]. 
During heat stress the formation of intermolecular anti-parallel β-sheet structures was observed 
in various proteins [Wang, 2005]. The underlying formation of hydrogen bonds between the 
molecules occurred independent from the initially existing secondary structure of the native 
molecule [Dong et al., 1995]. During aggregation some amino acid chains and molecular 
regions of the protein might become accessible to the formation of new intermolecular 
interactions. Hydrophobic regions or free thiol-groups might be exposed at the proteins surface 
enabling association through non-covalent or disulfide bonds. 
Especially the weak non-covalent interactions often lead to the formation of reversible 
protein aggregates, which might appear in equilibrium with the monomer depending on the 
environmental conditions in the formulation [Cromwell et al., 2006]. Occasionally, these 
reversible self-association processes come along with an increase in viscosity of the solution 
[Liu et al., 2005]. Reversible oligomers usually can be dissolved by dilution with buffer or during 
application. Instead, irreversible aggregates cannot be dissolved by dilution and no equilibrium 
with the monomer exists. Reversibility was shown by Patro and Przybycien 1996 to depend on 
the surface characteristics and the distribution of hydrophobic and hydrophilic patches of the 
protein [Patro et al., 1996]. Soluble aggregates are mainly defined by a small size. Thus, they 
can be defined as non-visible and cannot be removed by a sterile filter having a 0.22 µm pore 
size [Cromwell et al., 2006]. In contrast, insoluble aggregates can be visible under specified 
inspection conditions and may be removed by filtration. However, there is no consistent 
borderline between these two types of aggregates [Cromwell et al., 2006; Narhi et al., 2009]. 
Aggregates that arose from an association of the native monomer usually form small reversible 
oligomers that are difficult to detect and quantify due to possible disruption of the oligomers 
during analysis [Demeule et al., 2007; Philo et al., 2009]. If the conformation of the underlying 
monomer is altered or it is chemically modified non-native aggregates might originate.  
Though there is no distinct specification in the guidelines of USP or PhEur, the 
presence of even small amounts (> 1%) of any non-native protein species can be considered 
unacceptable for product release [Randolph et al., 2007]. 
  
  ANGELIKA FREITAG                            DISSERTATION          INTRODUCTION 
 
9 
 
2.3 ANALYTICAL METHODS TO DETECT PROTEIN AGGREGATES 
 
The sizes of protein aggregates cover a wide range: from small oligomers in nanometer 
range, starting with dimers, to large visible aggregates or precipitates of several µm. This 
makes it obviously impossible to find the one and only analytical tool that will give the complete 
answer about the product in all situations. However, controlling the aggregation process is of 
major concern for all biopharmaceutical products and therefore the development of reliable 
analytical methods is of utmost importance. The most critical problem with such methods is that 
many of these techniques have the potential to perturb the distribution of aggregates, altering 
their size and structure. Aggregates can be either destroyed or created for example by dilution 
or shear forces.  
2.3.1 Detection of insoluble protein aggregates 
Insoluble protein aggregates are large assemblies of protein species and for the 
purpose of this thesis defined as aggregates that are larger than 0.1 µm and therefore are 
usually not detectable during analysis like size exclusion chromatography (SEC) [Mahler et al., 
2009]. Zölls et al. and Narhi et al. defined species above 0.1 µm as particles [Narhi et al., 2009; 
Zoells et al., 2012]. Moreover, these large oligomers are subdivided in visible and subvisible 
particles. For the unaided eye particles of 100 µm and larger in size are visible. The resulting 
gap between 0.1 µm and 100 µm is commonly referred to the size of subvisible particles 
[Carpenter et al., 2009; Narhi et al., 2009; Sharma et al., 2010; Singh, S.K. et al., 2010; Zoells 
et al., 2012]. The presence of visible aggregates is unacceptable for product release in general. 
For example the European Pharmacopoeia (PhEur) requires labels claiming “…without visible 
particles” or “…practically free from particles” and the Pharmacopoeia of the United States 
(USP) requests drug formulations “…essentially free from visible particulates”. Besides, both 
Pharmacopoeias require clear limitations on subvisible particle numbers of ≥ 10 µm and ≥ 25 
µm in size in parenteral pharmaceutical preparations [PhEur 2.9.19., 2011; USP/NF, 2008]. 
These guidelines originally evolved from potential safety issues like the occlusion of blood 
vessels after administration and immunogenicity, which may appear from the presence of larger 
particulates [Carpenter et al., 2009; Narhi et al., 2009].  
2.3.1.1 Light obscuration  
The most widely used method to quantify subvisible particles is light obscuration (LO). 
The very fast and simple method is not capable of distinguishing between proteinaceous and 
non-proteinaceous particles or air bubbles but can be utilized to quantify particles between 1 
and 600 µm [Zoells et al., 2012]. Light obscuration instruments create a laser beam irradiating 
through a flow cell where particles are passing by. Each particle blocks part of the laser light 
depending on its cross-sectional area. Finally, a photo diode detector collects the residual light 
of the beam. This principle entails a restricted particle concentration within the sample, since 
overloading would lead to interference of the particles and miscounting. Another downside of 
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LO analysis of therapeutic protein formulations for quality control, is the huge required volume 
of 25 mL per analysis in PhEur as well as USP [PhEur 2.9.19., 2011; USP/NF, 2008]. That 
usually entails pooling of several vials and makes the measurement cost-intensive. In general, 
the instruments are calibrated by polystyrene beads calculating the equivalent circular diameter 
of the analytes. However, these synthetic beads differ a lot from protein particles, concerning 
refractive index, shape and transparency. Thus, translucent analytes can even be missed, 
because parts of light still pass through these particles reaching the detector [Huang et al., 
2009].  
2.3.1.2 Microscopic methods 
Several different microscopic techniques are available to detect and visualize 
particulate materials and protein aggregates. Due to the drawback of all microscopic methods 
to visualize only small fractions of the sample, the results of these methods are only 
representative when large volumes are analyzed, which makes this technique rather time 
consuming. The widely spread optical microscopy is limited to species larger than 1 µm [Zoells 
et al., 2012]. The PhEur and the USP have approved this technique for the quantification of 
subvisible particles [PhEur 2.9.19., 2011; USP/NF, 2008]. The particles are isolated by filtration 
of the entire sample and subsequently the determination of size and counting is performed by 
microscopy [Narhi et al., 2009]. The detection of unstained protein particles can be 
sophisticated since those particles are often translucent. Besides, it can be challenging to 
distinguish between foreign particles and intrinsic particles of proteinaceous origin on the filter 
material. Because of shear forces during the filtration step, proteinaceous particles can be 
dissociated into smaller species which might either pass through the filter or sink into the pores. 
This is probably one reason why optical microscopy usually results in much lower particle 
counts compared to light obscuration [Narhi et al., 2009].  
Other microscopic techniques to detect protein aggregates are fluorescence 
microscopy, atomic force microscopy or electron microscopy which will not be described in 
detail. A meaningful example was reported in 2009 by Demeule et al.: The combination of 
fluorescence microscopy and transmission electron microscopy (TEM) was shown to be a 
valuable tool to detect protein aggregates of different (but not overlapping) size ranges, 
covering large parts of the nm and µm fields [Demeule et al., 2009].  
A method that recently has increasingly been used to detect protein aggregates 
especially in early stages of aggregation is flow imaging microscopy (FIM); commonly also 
known as Micro-Flow Imaging (MFI) [Barnard et al., 2011]. The particles are not isolated by a 
filter but instead pass a flow cell where they are illuminated and visualized by a camera. 
Particles sized from approximately 1 to 400 µm can be counted and additional information 
about shape, size and special features like transparency can be obtained. The latter enables 
the distinction between proteinaceous and non-proteinaceous particles such as silicone oil 
droplets [Sharma et al., 2010; Strehl et al., 2011]. A disadvantage of these methods is the 
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necessity of dilution, thereby possibly altering the sample properties when particle count limits 
are reached. Additionally, like all light-based techniques, flow imaging microscopy requires a 
substantial difference of refractive index between the surrounding liquid and the particles 
[Demeule et al., 2010; Zoells et al., 2012].  
2.3.1.3 Light scattering methods 
Traditionally turbidimetry is also used to detect subvisible particles. This technique 
relies on the measurement of the optical density of the sample, but is not able to quantify the 
species of interest.  
The methods to detect subvisible particles are currently subject of debate since it has 
been shown that light obscuration underestimates proteinaceous particles due to their non-
spherical shape and their transparency [Sharma et al., 2010]. Light obscuration determines the 
equivalent circular diameter (ECD) of all particles and is not able to distinguish between 
different species like silicone oil droplets or air bubbles which might be present as well. The 
interest in alternative methods steadily increased in the last years and several publications 
showed that especially Micro-Flow Imaging seems to be a suitable technique to complementary 
monitor subvisible particles in addition to light obscuration [Huang et al., 2009; Narhi et al., 
2009; Sharma et al., 2010; Singh, S.K. et al., 2010]. However, more experience is needed to 
confirm the capabilities of MFI. One advantage of MFI is the possibility of discrimination 
between particles of different origin based on their translucency and particle shape. In general, 
proteinaceous particles appear more translucent and possess a more irregular shape than for 
example silicone oil droplets. Another innovative technique which is capable of distinguishing 
between particles of different origin is the Archimedes method, developed by Affinity 
biosensors. The particle size determination is based on resonant mass measurements. 
Furthermore, Coulter counter and nanoparticle tracking analysis (NTA) should be mentioned as 
alternative methods to determine subvisible particles in nm and µm range. 
2.3.2 Detection of soluble protein aggregates 
For the detection of soluble protein aggregates several analytical methods have been 
established. The most important ones are 
• High performance size exclusion chromatography (HP-SEC) 
• Asymmetrical flow field-flow fractionation (AF4) 
• Sedimentation velocity analytical ultracentrifugation (SV-AUC) 
• Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) 
• Dynamic light scattering (DLS). 
[Mahler et al., 2009; Wang, 2005] 
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Throughout this thesis only HP-SEC, AF4, SDS-PAGE, and DLS were utilized for 
qualitative and quantitative determination of protein aggregates. Hence, these three techniques 
are solely taken into consideration.  
2.3.2.1 High performance size exclusion chromatography  
The most commonly used technique to detect and quantify small oligomers is HP-SEC, 
also referred as gel permeation chromatography (GPC). Due to the usually prepended filter of 
0.1 to 0.22 µm pore size to avoid clogging of the column, any particle larger will be removed 
and HP-SEC is limited to the determination of soluble aggregates. The separation is based on 
size since the different molecules permeate in the pores exposed by the inert, stationary phase 
in the column [Gabrielson et al., 2006]. The separation depends on a globular shape of a 
protein or its aggregates. The analytes are separated concerning their hydrodynamic radii (Rh). 
Therefore, the size of a protein species can be overestimated if the hydrodynamic radius 
exceeds that of a spherical shaped protein due to for example highly coiled structures. The 
steric extension of two species of the same molar mass is decisive for the correct determination 
of the molecular weight simply based on elution profile. When using on-line light scattering 
detection combined with refractive index determination the size determination is independent of 
the elution time [Wang, 2005; Wen et al., 1996]. Additionally, coupling to ultraviolet-visible (UV-
Vis) spectroscopy detectors and fluorescence spectroscopy detectors is widely used to 
determine concentrations of proteins and aggregates. It was recently reported, that HP-SEC 
can also be coupled to mass spectrometry (MS) to accurately determine the molecular mass of 
the protein species [Brady et al., 2008; Kuekrer et al., 2010]. HP-SEC is the “gold-standard” in 
the analysis of protein aggregates, since it can cover a wide range of polarities and molecular 
weights. Considering the numerous different materials of the solid phase, the fractionation 
range is approximately in between 5 and 1000 kDa [Unger, 1983]. Analytes which are too large 
to penetrate into the pores of the solid matrix will quickly be eluted within the void volume, 
without being separated [Barth et al., 2006; Mahler et al., 2009]. For a good precision a 
difference in molecular weight of 50 – 100% is typically required [Goetz et al., 2004]. However, 
the HP-SEC technique has also some essential drawbacks in the analysis of protein 
aggregates. First, the sample is highly diluted by the mobile phase possibly dissociating 
reversible or loosely associated aggregates [Philo, 2006]. Second, the species of interest can 
more or less interact with the material of the solid phase. This might change the conformation of 
the analytes and result in an altered elution profile and an inaccurate determination of the 
molecular weight of the initial species [Wen et al., 1996]. 
2.3.2.2 Asymmetrical flow field-flow fractionation 
The latter disadvantage of HP-SEC can be excluded when using orthogonal 
techniques. Field-flow fractionation (FFF) is one of these methods and is meanwhile widely 
used to detect protein aggregates. It was first conceptualized in the 1960s by Giddings et al. 
[Giddings et al., 1976]. Instead of the packed column in HP-SEC the component separation 
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takes place in is an empty, narrow, elongated flow chamber (also referred to as “channel”). The 
establishment of a laminar flow profile within that channel is the mutual feature of all FFF 
variants (channel flow). In flow field-flow fractionation (FFFF) the underlying force to separate 
the species, the so called cross flow, is a physical field directed perpendicular to the laminar 
flow of the mobile phase [Fraunhofer et al., 2004; Reschiglian et al., 2005]. Across the resulting 
parabolic profile the different components of the sample distribute according to their diffusion 
coefficients and by that to their hydrodynamic radii [Litzen et al., 1993]. The separation principle 
is shown in Figure 2-2. Two contrarily directed forces are created in the chamber: the cross flow 
accumulating the analytes at the membrane/accumulation wall, versus the diffusion of the 
analytes back to the center of the channel. Before elution is starting, the sample is injected in 
the channel and subsequently focused in a narrow band at the accumulation wall. In normal 
elution mode, the smaller diffusion coefficients of large species entail their accumulation near 
the ultrafiltration membrane with slow flow rates of the channel flow. In contrast, smaller species 
tend to diffuse to the center of the parabolic flow profile with a faster flow rate. This principle 
results in the elution of species according to their size with those species of lower molecular 
weight eluting first and large species eluting subsequently [Arakawa et al., 2007; Fraunhofer et 
al., 2004; Jonsson, 2001].  
 
In case the sample components are larger than a critical size, the operating mode 
might invert. This critical size strongly depends on the channel height and is usually reached in 
the range between 0.5 and 1 µm channel height. The so called steric mode is characterized by 
an inversed elution profile; larger species elute prior to smaller ones. This inversion is caused 
by the large radius of the particles impeding the approximation near the wall. The centers of 
gravity protrude in faster fractions of the laminar flow profile leading to faster elution [Fraunhofer 
et al., 2004]. 
Figure 2-2 – Separation principle of flow field-flow fractionation. (Adopted from Fraunhofer et al., 
2004)  
The separation principle is based on two contrarily directed forces: cross flow and diffusion.  
Normal operation mode. 
 
 
The separation principle is based on two contrarily directed forces: cross flow and diffusion.  
Normal operation mode. 
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FFFF has the ability to separate very broad ranges of size since the lower limit is 
determined by the molecular weight cut-off of the ultrafiltration membrane that is 300 Da 
(Postnova Analytics, Landsberg am Lech, Germany), and the upper limit is around 50 – 100 µm 
depending on the channel height which is defined by a spacer [Fraunhofer et al., 2004; Litzen et 
al., 1991; Liu et al., 2006]. This entails the versatile field’s application FFFF is used for, such as 
the detection of macromolecules, polymers, colloids and solid particles of various origins 
[Fraunhofer et al., 2004; Giddings, 1993; Qureshi et al., 2011; Reschiglian et al., 2005; Schimpf, 
2000].  
 
Figure 2-3 – Comparison of separation principles of symmetric and asymmetric flow field-flow 
fractionation. (Adopted from Qureshi et al., 2011) 
In symmetric FFFF both channel walls are porous and a second pump initiates a flow of the same carrier 
liquid perpendicular to the channel flow through both walls. In asymmetric FFFF the upper wall of the 
channel is solid and impermeable for liquids. Only one pump is needed to create the flow of carrier liquid 
through the system (FIn), since this flow is split in two parts. The channel flow (FOut) is axially flushed 
through the channel towards the detection outlet; whereas the cross flow (Fx) leaves the channel through 
the ultrafiltration membrane and the porous wall.  
 
Most commonly used is asymmetrical flow field-flow fractionation (AF4), where the 
channel possesses only one wall permeable for the carrier liquid. Hence, the cross flow is 
generated as part of the inlet channel flow. This technique is well established for the separation 
of protein aggregates [Arakawa et al., 2007; Liu et al., 2006; Williams et al., 2006] and reported 
to be successful for various biomolecules [Caldwell et al., 2005; Giddings, 1993; Wahlund, 
2002]. 
When comparing AF4 to HP-SEC, in AF4 the analytes should theoretically interact with 
almost no solid matrix. However, the AF4 method relies on a membrane that is permeable for 
the mobile phase, the so called accumulation wall (see Figure 2-3). That gives rise to a much 
smaller interfacial area between solid and liquid than in HP-SEC, though the possibility of 
interactions cannot be totally excluded. The samples do not necessarily have to be filtered 
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before injection since no porous stationary phase can be clogged [Augsten et al., 2008]. In 
addition, AF4 is distinguished by much lower shear forces and lower pressures than HP-SEC. 
These characteristics appear to be advantageous for the analysis of protein aggregates since 
structural changes and probable dissolving of weak bonds of the species should be reduced 
[Jonsson, 2001]. Moreover, the separation can be performed in various buffer conditions, 
probably even in the formulation buffer [Liu et al., 2006]. Undesirable limitations of AF4 are for 
example the possible artificial association of protein molecules during analysis since the sample 
is accumulated in a narrow band near the ultrafiltration membrane before separation and 
elution. Besides, the dilution of the samples of interest is still high during analysis facilitating 
probable dissolving of aggregates. 
2.3.2.3 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
Traditionally, polyacrylamide gel electrophoresis (PAGE) was used to determine protein 
aggregation. A molecular weight range of 5 to 500 kDa can be covered with this technique 
[Mahler et al., 2009]. It is a rather simple technique and in most cases it is run under denaturing 
conditions by adding sodium dodecyl sulfate (SDS-PAGE). The presence of this anionic 
surfactant dissociates loose aggregates and is only useful to detect covalently linked 
aggregates. Alternatively, a native PAGE can be performed particularly if non-covalent 
aggregates associated by weak bonds shall be investigated. Utilizing PAGE under reducing and 
non-reducing conditions one has the ability to differentiate between aggregates originating from 
disulfide bridges and those that originate from other bindings [Wang, 2005]. SDS-PAGE is first 
and foremost employed for qualitative analysis. However, quantification is possible by UV 
detection after staining the separated protein bands. SDS-PAGE is a valuable method to detect 
protein aggregates and to discriminate between those associated by disulfide bonds and those 
that are associated in another way. However, like in HP-SEC and AF4, subtle conformational or 
oxidative alterations cannot be differentiated. 
2.3.2.4 Dynamic light scattering 
Dynamic light scattering (DLS) is a valuable tool to determine the diffusion coefficients 
and hydrodynamic radii of proteins, their aggregates and particles in solution in the size range 
of 1 nm to 10 µm [Arakawa et al., 2006]. DLS is also referred to quasi-elastic light scattering 
(QELS) and photon correlation spectroscopy (PCS) and can be performed in cuvette or plate 
reader based systems [Zoells et al., 2012]. The analytes are moving in Brownian motion and 
thereby scatter the light of a monochromatic laser beam. Hence, a time-dependent fluctuation 
of the laser light intensity is observed, which correlates to the diffusion coefficient and thus the 
size of the analytes [Schmidt, 2010]. The measurements strongly depend on temperature and 
viscosity of the samples. Beside the mean diameter of the analyte (Z-average diameter) 
information on the polydispersity of the sample can be achieved by this non-destructive and 
quick analytical method.  
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2.4 IMMUNOGENICITY OF BIOPHARMACEUTICALS 
 
The implementation of proteins as therapeutics is very much dependent on their 
potential to circumvent any recognition by the immune system (excluding those drugs that are 
supposed to inhibit or stimulate specific immune reactions) [Foged et al., 2008]. Most 
biopharmaceuticals approved for clinical use are known to be immunogenic and provoke the 
formation of antibodies in a significant fraction of patients [Chirino et al., 2004; Porter, 2001]. 
The formation of antibodies can be associated with minor or major adverse reactions and 
therapeutic failure by reducing the drug`s efficacy and potency [Bendtzen, 2011; Chirino et al., 
2004]. With the possibility of the recombinant production of “self” proteins with a near identity to 
human counterparts it was hoped to solve the immunogenicity problem, because those 
biopharmaceuticals should theoretically be accepted as self-molecules by the immune system 
and thus should be tolerated [De Groot et al., 2007; Foged et al., 2008]. However, interestingly, 
those proteins that have an identical or nearly identical amino acid sequence to endogenous 
human proteins were shown to be immunogenic as well although the incidence of immune 
reactions is much lower [Chirino et al., 2004; Patten et al., 2003; van Regenmortel et al., 2005]. 
A second aspect that is considered to be the cause of immunogenicity is a lack of tolerance, 
either in patients with an inherent immune deficiency (minor immune competence) or in healthy 
individuals [Hermeling et al., 2004; Rosenberg, 2003]. But, the overall immunogenicity problem 
is more complex and cannot simply be explained by a “self” versus “nonself” model and a 
lacking tolerance to endogenous proteins existing in minor concentrations [Patten et al., 2003; 
Rosenberg, 2003]. The underlying processes of immune responses to biopharmaceuticals are 
still elusive. Numerous other factors attributable to host and product may cause the 
immunogenicity of those molecules, some of them are yet unknown [Rosenberg, 2006; 
Schellekens, 2002; Scott et al., 2010].  
2.4.1 Factors influencing immunogenicity 
Alterations in the molecular structure of the protein, such as variations in the amino acid 
sequence or different glycosylation patterns, most comprehensibly - though not necessarily - 
result in immunogenicity [Hermeling et al., 2004]. Biopharmaceuticals that are known to be 
subject to these triggers are salmon calcitonin [Grauer et al., 1994], granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and streptokinase [Malucchi et al., 2008; Rosenschein et 
al., 1991]. However, there are also some converse examples like interferon-α2a [Kontsek et al., 
1999], where alterations in the molecular pattern did not result in an increased immunogenicity. 
The glycosylation pattern strongly depends on the host cell used for the production of the 
protein. Products derived from bacteria, like Escherichia coli, are generally non-glycosylated, 
reduce shielding effects and expose unknown patches of the proteins which might act as 
antigen. Instead, mammalian cell lines such as Chinese Hamster Ovary (CHO) cell lines 
produce glycosylated molecules that have to be purified since initially the result of this 
posttranslational modification can be very heterogeneous. Since the glycosylation pattern also 
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depends on the culture conditions Hermeling et al. hypothesized that recombinant human 
glycoproteins, such as monoclonal antibodies, will always differ more or less from their 
endogenous counterparts [Hermeling et al., 2004]. 
In general, the subcutaneous and intramuscular administrations have been shown to be 
more immunogenic than other administration routes [Perini et al., 2001; Schellekens, 2002; 
Wierda et al., 2001]. In comparison, intravenous administration is much less immunogenic 
[Peng et al., 2009]. Nevertheless, many therapeutic proteins, such as the large group of 
monoclonal antibodies, are commonly applied via the subcutaneous route. Besides, also the 
frequency of the administration and the dose are associated with immunogenicity [Hwang et al., 
2005; Kuus-Reichel et al., 1994]. Chronic administration of a therapeutic protein generally is 
more likely related to immunogenic side effects than one acute application [Ross et al., 2000]. 
Product-related impurities or contaminants such as host-cell proteins, arising from the 
formulation of biopharmaceuticals, may mimic pathogen-associated molecular patterns 
(PAMPs) [Foged et al., 2008] and have shown to be linked to immunogenicity [Hermeling et al., 
2004; Schellekens, 2002; Singh, 2011]. Due to the increasing purity of manufacturing 
processes and the final products these risks could be minimized by purification procedures, but 
some are still of relevance. Crucial factors for immunogenicity are considered to be particulate 
structures existent in the formulation of the biopharmaceuticals [Carpenter et al., 2009; 
Rosenberg, 2006]. Such materials can for instance be subvisible or visible particles in the 
micron range and smaller protein aggregates in the nanometer range. Several studies were 
published indicating an enhanced immunogenicity of therapeutic protein formulations containing 
aggregates [Braun et al., 1997; Fradkin et al., 2009; Hermeling et al., 2006; Perini et al., 2004; 
Ring et al., 1979; Rosenberg, 2006]. Protein aggregates as a special type of particulate 
impurities can also activate immune reactions by imitation of PAMPs. In 2006 Rosenberg stated 
that protein aggregates and their repetitive structures might resemble the repetitive 
characteristics of external surfaces of microbial pathogens [Rosenberg, 2006]. However, the 
exact mode of activation of the immune system by aggregates is still unclear [Barbosa et al., 
2007; De Groot et al., 2007]. In addition, there is uncertainty whether only some aggregates or 
aggregates in general can be made responsible for unwanted immune responses [Hermeling et 
al., 2004]. Therefore it is a major challenge for development and approval of 
biopharmaceuticals to prevent aggregation and to establish reliable, sensitive, and suitable 
analytical methods for detection and quantitation of trace amounts of aggregated proteins 
[Arakawa et al., 2006; Chi et al., 2003b; John P. Gabrielson, 2007].  
2.4.2 Responses of the immune system to therapeutic proteins 
A therapeutic protein interacts with several types of immune cells such as antigen 
presenting cells (APCs), B-cells and T-cells, to trigger an immune response. Each interaction 
step is based on distinct antigen properties. 
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First of all, the protein has to be recognized by the immune system (see Figure 2-4). 
This recognition can proceed by different cells of the immune system. APCs will first encounter 
the molecules and incorporate them by receptor-mediated endocytosis, pinocytosis or 
phagocytosis. Dendritic cells (DC) will be the first responders if the protein is administered 
subcutaneously since they numerously are present in the skin. After this uptake of the antigen, 
dendritic cells migrate from the peripheral tissues to the lymphatic organs spleen and lymph 
nodes. The cells will subsequently break the molecules down and present the resulting peptides 
by major histocompatibility complexes class II (MHC-II) on their surface to other cells of the 
immune system. Some co-stimulating signals have to be presented as well and are decisive for 
the recognition by specific T cells present in the lymph nodes. Due to the concurrent production 
and release of cytokines of the dendritic cells, these T cells are activated and start to proliferate. 
Dendritic cells are thus able to efficiently stimulate the production of CD4+ cells (T helper cells, 
Th1 and Th2) [Janeway et al., 2004; Vollmar, 2005]. Proliferating helper T cells can differentiate 
into two subtypes. The Th1 cells are involved in the cellular immune response, whereas Th2 
cells promote the stimulation of the humoral immune response by activating B cells. Those 
B cells express B cell receptors directed against the antigen on their surface and start to 
proliferate into antibody-secreting plasma B cells, once they are activated by the corresponding 
antigen [Sauerborn et al., 2010].  
 
Figure 2-4 – Immune recognition of therapeutic proteins 
(1) The protein is taken up by APCs, (2) the molecules are processed to peptides, (3) in presence of co-
stimulating molecules e.g. from inflammation complexes are formed between peptide, major 
histocompatibility complex and T cell receptor, (4) maturation of the T cells, (5) interaction of B cells and 
T cells, comprising the peptide-MHC-TCR complexes and the therapeutic protein binding to BCRs, (6) 
maturation of the B cells, (7) release of specific antibodies binding the protein molecules. 
 
In vaccines, particulate materials are often used as adjuvants, to enhance the immune 
response towards the antigens. These structures can on the one hand side bind the antigen 
and entail a sustained release of it. On the other hand side, particulate adjuvants are taken up 
by macrophages and DCs. Adjuvants are, at least in part, needed to fully activate dendritic cells 
to the antigen-presenting status and thus initiate a strong, unspecific, adaptive immune 
response, although an infection is absent [Janeway et al., 2004]. The prolonged exposure of 
particulate materials to APCs such as DCs, and T cells, is thought to play an important role in 
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eliciting immunogenicity [Chirino et al., 2004]. This mechanism might be at least part of the 
processes underlying the immunogenicity of protein aggregates, although it is likely that other 
factors play an important part as well.  
The elicitation of antibodies towards antigens can also be independent of T cells. 
Polyvalent antigens such as viral capsids and lipopolysaccharides from bacteria are able to 
crosslink B cell receptors (BCRs) due to repetitive epitopes on their surface that are arranged in 
certain steric distance [De Groot et al., 2007; Rosenberg, 2006]. Dintzis et al. defined clusters 
of polymers that fit to this model and thus are able to induce T cell-independent immune 
responses as “immunons” [Dintzis et al., 1976]. Protein aggregates can, due to their high 
molecular weight and the composition of multiple monomeric molecules, possess multivalent 
surface structures resembling bacteria or viruses and crosslink BCRs [Sauerborn et al., 2010]. 
Especially protein aggregates of high molecular weight and proteins adsorbed on particles from 
impurities are thought to elicit antibody responses that way. The difference of both 
immunological mechanisms to elicit antibody responses is the subclass switching and affinity 
maturation. The T cell-dependent activation of B cells generally leads to a more robust antibody 
response and the generation of memory B cells [De Groot et al., 2007]. This implies the 
switching of immunoglobulin subclasses by changing the constant part of the antibody but the 
variable region, and hence the antigen specificity, remains the same. Therefore, the antibodies 
can interact with different effector molecules, resulting in versatile activations or inhibitions of 
proteins in the immune system. Affinity maturation occurs in B cells after repeated exposures to 
the antigen and a T cell-dependent activation. In the secondary response these cells are able to 
elicit antibodies of greater affinity to the antigen and thus show an enhanced reaction and high 
effectiveness upon re-exposure of the antigen [Hermeling et al., 2004]. 
2.4.3 Impact of antibody induction 
The clinical consequences of the induction of antibodies against the therapeutic protein 
can be various, depending on the epitopes the immune response is directed to. The antibodies 
can be directed towards an epitope which is specific for the recombinant protein variation. 
These antibodies can be either neutralizing or non-neutralizing. The latter will merely interact 
with the therapeutic protein by forming immune complexes and possibly induce a quick 
elimination and reduced bioavailability of the drug [Pendley et al., 2003; Schellekens, 2003].  
Neutralizing antibodies usually bind to the protein as well, but are furthermore either able to 
inhibit the interaction with the molecules responsible for the biological effect or to neutralize the 
effect subsequently. Pharmacokinetics and efficacy of the therapeutic protein can be influenced 
[Pendley et al., 2003]. Serious clinical consequences can arise if the immune response is 
directed toward an epitope which is also present in the endogenous counterpart. The 
occurrence of pure red cell aplasia in numerous patients treated with recombinant 
erythropoietin is one tremendous example for that [Casadevall et al., 2002; Schellekens, 2005]. 
Other safety concerns like allergic or anaphylactic reactions can also be related to antibody 
generation and might occur as well.  
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2.5 MONOCLONAL ANTIBODIES 
 
In 1975 Kohler and Milstein developed the first monoclonal antibodies (mAbs) leading 
to a revolution in immunology [Koehler et al., 1975]. This discovery initiated an impressive 
development of plethora of drugs. Today monoclonal antibodies are an important class of 
protein-based drugs due to their ability of antibodies to specifically identify and eliminate a 
certain antigen within the immune system [Harris et al., 2004; Roque et al., 2004] and coevally 
implying a desirable marginal off-target toxicity [Wang, W. et al., 2008]. 
2.5.1 Structure of monoclonal antibodies 
Due to the structural similarity with human antibodies mAbs are classified into murine, 
chimeric, humanized and human antibodies [Pendley et al., 2003; Reichert, Janice M., 2001; 
Reichert, Janice M. et al., 2005]. The first therapeutic antibodies developed were of murine 
origin generated by the use of hybridoma technology and entered the market in 1980s [Walsh, 
2005]. Muromonab-CD3 (Orthoclone, OKT3
®
) was approved by the FDA in 1986 for the 
treatment of acute rejection of transplanted organs. Based on the foreign origin, up to 80% of 
the patients treated with murine antibodies generated human anti-mouse antibodies (HAMA) 
potentially influencing safety, efficacy and pharmacokinetics of these drugs [Aksentijevich et al., 
2002; Walsh, 2004]. To reduce this antigenicity the molecules were altered by exchanging the 
murine parts in the constant region to constant regions of human origin [Boulianne et al., 1984; 
Morrison et al., 1984]. Such modified mAbs are called chimeric antibodies and many of those 
are already therapeutically used. Significant research efforts were devoted to further reduce the 
amount of murine part, developing humanized and human antibodies for use in human patients 
[Berger et al., 2002]. Humanized antibodies are mostly of human origin and solely include the 
hyper variable CDR-regions (complementary determining regions) from mice. Fully human 
antibodies can be produced by phage display technology or by using human hybridoma cells, 
instead of murine ones [Roque et al., 2004]. They are completely made of human sequences. 
Humanized mAbs as well as human mAbs showed reduced immunogenicity in humans in 
contrast to the murine and chimeric mAbs [Clark, 2000; Reichert, Janice M. et al., 2005].  
In 2006 the first entirely human recombinant monoclonal antibody was approved. 
Adalimumab (Humira
©
) is of IgG1 subtype and targets the inhibition of tumor necrosis factor 
alpha (TNFα) in rheumatoid arthritis patients. Most mAbs in therapeutic use are of 
immunoglobulin isotype IgG [Piggee, 2008]. The general structure of IgG antibodies is 
displayed in Figure 2-5. 
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Figure 2-5 – General structure of immunoglobulin G.  
The molar mass of an IgG is approximately 150 kDa since the molecule is composed of two identical light 
chains (L, 25 kDa) and heavy chains (H, 50 kDa). The subunits are linked by disulfide bonds. The two 
antigen binding regions are situated in the Fab parts and consist of the variable regions of light (VL) and 
heavy (VH) chain. The three CDR-regions per variable chain entail the particular surface structure and 
assure the high specificity of the antigen binding [Wang, W. et al., 2006b]. 
 
The family of immunoglobulin G can be subdivided into four subclasses: IgG1, IgG2, 
IgG3 and IgG4. The structural differences between these are in the heavy chains in the Fc part 
of the molecules. The relevant part for binding to cell surfaces and the resulting induction of a 
cellular response is the Fc part. It is composed of the constant domains CH2 and CH3 of the two 
heavy chains. Besides, the CH2 domains usually are glycosylated. The glycosylation pattern is 
of importance for modulating the effector functions and strongly depends on the expression 
system used for production [Chadd et al., 2001; Harris et al., 2004; Roque et al., 2004; Wright 
et al., 1997].  
2.5.2 The pharmacokinetics of monoclonal antibodies 
Several pharmacokinetic properties of monoclonal antibodies entail the utility of these 
molecules as therapeutics. The half-life of entire recombinant human monoclonal antibody is 
usually relatively long. It varies according to the subclass of the antibody but is very similar 
between different patients [Roskos et al., 2004]. For example the most important isotype in 
humans, IgG1, has a half-life of 3 weeks [Waldmann et al., 1970]. This allows infrequent 
administrations to the patient and enhances patient compliance. The bioavailability and half-
lifes of mAbs are determined by the catabolism of the antibody, such as the interaction with the 
FcRn receptor. This receptor protects immunoglobulins from intracellular catabolism by 
recycling them to the cell surface after endocytotic uptake and therefore impeding its 
degradation in the lysosomes. The currently marketed antibodies are administered either 
intravenously (IV), subcutaneously (SC) or intramuscularly (IM). IV administration allows the 
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absorption of larger volumes. But it is not very convenient for the patient, since hospitalization is 
often required. The absorption after SC and IM administration usually proceeds slowly by the 
lymphatic system, implying that the time to reach maximal plasma concentrations lasts several 
days. However, the absolute bioavailability of these administration routes typically lies between 
50 and 100% [Lobo et al., 2004]. These properties in particular qualify such extravascular 
administrations for therapies were slow absorption is desired. The downside of IM and SC 
dosing is the limitation on the volume that can be injected, which is ~5 mL for IM and 2.5 mL for 
SC administration. Besides, the solubility of monoclonal antibodies in solution is relatively 
limited to ~ 100-200 mg/mL and therefore large doses of mAbs cannot be injected IM or SC. 
The antibodies administered in such a way need to have high dose potency or repeated 
injections are necessary [Wang, W. et al., 2008].  
2.5.3 The market of monoclonal antibodies 
In 2005, mAbs provided about 50% of the biopharmaceuticals in development. Recent 
numbers from March 2011 showed 32 therapeutic antibodies in total, that were already 
approved or in review in the United States and the European Union [Reichert, 2011]. Nearly 
three-quarters are either humanized or human mAbs. The major indications mAbs are used for 
are autoimmune diseases, such as arthritis, and oncology [Berger et al., 2002]. As probably 
most important group of biopharmaceuticals, monoclonal antibodies have proven to be 
economically very successful drugs. Their sales are forecast to annually grow by 9.5% between 
2009 and 2015  [Datamonitor, 2010]. Accordingly, the sales of other therapeutic proteins, 
vaccines and small molecule drugs are outpaced. These impressive forecast numbers 
especially will be commanded by the “Big 5” therapeutic antibodies on the market (Adalimumab, 
Bevacizumab, Infliximab, Rituximab and Trastuzumab). Each of them has sales of over US $ 1 
billion/year worldwide [IMS Health, 2010]. This profitability and the versatility of monoclonal 
antibodies as therapeutics give reason to the current high efforts and investments in research 
and development of mAbs that are realized by the manufacturing biopharmaceutical industry.  
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3  AGGREGATION STUDIES ON A HUMAN 
MONOCLONAL ANTIBODY 
 
 
 
3.1 INTRODUCTION 
 
According to the aggregation subject elaborately discussed in the previous chapter an 
immense versatility of aggregate structures is feasible, depending on the environmental 
conditions triggering the aggregation process. Considerable differences in the properties of 
aggregates of monoclonal antibodies in diverging stress studies were exemplarily reported by 
Kiese et al. and Hawe et al. [Hawe et al., 2009; Kiese et al., 2010]. 
This chapter aims to distinguish between the physicochemical characteristics of a 
monoclonal human antibody formulation, serving as model protein for follow-up studies after 
exposure to selective stress conditions. A variety of stress conditions is applied to the model 
antibody and the resulting aggregate pattern is analyzed quantitatively as well as qualitatively. 
Thus, meticulous analytics of the stressed antibody formulations will be performed and a critical 
evaluation of promising stress conditions will be performed based on these results. The 
objective is to obtain sufficient amounts of aggregates of well-defined physicochemical 
properties and structural conformation. Later on, the selected stress conditions shall be 
transferred to a murine monoclonal antibody in preparation of in vivo studies.  
3.1.1 Temperature 
Temperature is the most common and most critical factor in affecting protein stability. In 
general an increase in temperature lowers the protein stability. Several proteins are most stable 
in a certain temperature range, indicating that both high and low temperatures outside this 
range may destabilize or unfold the protein. This unfolding is often promptly followed by 
aggregation. At low temperatures, beneath the specific temperature range, hydrophobic 
interactions are weakened. Thus, the hydrophobic regions may become more exposed to 
solvent and may lead to an increase in intermolecular interactions and aggregation [Brandts et 
al., 1970; Privalov, 1990]. The denaturation of proteins at high temperatures is a more broadly 
known phenomenon, usually starting with an endothermic process of unfolding of the native 
protein. Upon unfolding the hydrophobic residues of the protein become exposed to the 
surface, while the tertiary structure degrades. Additionally, higher temperature leads to a 
strengthening of hydrophobic interactions. Both, the exposure of hydrophobic patches and the 
enhancement of hydrophobic interactions trigger the formation of different aggregates by 
intermolecular hydrophobic binding. [Vermeer et al., 2000]. Furthermore an increased 
temperature implies an acceleration of the Brownian movement of the formulation ingredients, 
enhancing the incidence of protein-protein contact [Speed et al., 1997]. Typically, heat stress 
causes irreversible denaturation of a protein, perturbing the native conformation [Chi et al., 
2003b]. Several studies investigated the resulting structure of aggregates after heating. 
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Augener et al. determined aggregation by non-covalent interaction as well as disulfide bond 
formation in a human IgG formulation [Augener et al., 1970]. Examples of thermally induced 
irreversible unfolding and aggregation are immunoglobulines, human interferon-γ, and 
streptokinase [Azuaga et al., 2002; Mulkerrin et al., 1989; Vermeer et al., 2000; Zlateva et al., 
1999]. 
3.1.2 Mechanical stress 
Mechanical stresses, such as shaking and stirring, create new interfaces within the 
protein formulation. The most common one is the air/water interface which is created by 
shaking as well as stirring. However, stirring studies have already been performed with Teflon
®
 
coated stirring bars, which create an additional hydrophobic Teflon
®
 surface [Kiese, 2008; 
Mahler et al., 2005]. Due to the amphiphilic structure of proteins and the hydrophobic surface of 
the air respectively Teflon
®
, protein molecules strongly tend to accumulate and align at this new 
interface exposing their hydrophobic patches to the more hydrophobic area of the interface. 
This highly concentrated rearrangement at the interface can lead to hydrophobic interactions 
and unfolding since the protein exposes parts of its hydrophobic core. The proximity to similar 
molecules at the new interface increases the incidence of protein-protein interactions leading to 
substantial aggregation [Carpenter, John F. et al., 1999; Mahler et al., 2010b]. Numerous 
proteins were shown to be prone to aggregation induced by agitation, including monoclonal 
antibodies [Bam et al., 1998; Carpenter, John F. et al., 1999; Colombie et al., 2001; Mahler et 
al., 2009]. However, the aggregation characteristics already strongly differ within the class of 
monoclonal antibodies. Some mAbs were reported to quickly aggregate within hours of 
mechanical stress exposure [Fesinmeyer et al., 2009; Kiese, 2008]. In comparison, other IgGs 
were reported to be remarkably resistant to agitation stress and the exposure to air-water 
interfaces [Mahler et al., 2009; Paborji et al., 1994]. For the development of new therapeutic 
proteins, surface-induced aggregation has to be circumvented to reduce potential implications 
concerning efficacy and safety. Approaches for an avoidance of agitation induced aggregates 
should involve processing steps, like stirring and shaking, as well as the properties of the drug 
candidate itself.  
3.1.3 Freeze-thaw stress 
Freeze-thawing can accidentally or by design arise to the protein during many stages in 
production, storing and shipping. Proteins that are formulated by lyophilization are dried in a 
frozen state, whereas proteins formulated as liquids are sometimes frozen for long-term storage 
and thawed prior to use [Arakawa et al., 2001]. The formation of ice is the most crucial step 
during freezing, since the protein is excluded from the ice phase and thus concentration of all 
solutes in the liquid phase increases strongly. This artificial concentration can additionally 
involve pH changes, as reported for phosphate buffers, for example [van den Berg et al., 1959]. 
The complexity of environmental changes during freezing can have a major impact on protein 
stability and lead to aggregation and denaturation [Carpenter, John F. et al., 1988]. Therefore, a 
maximum stability of the protein in non-frozen aqueous solution should be chosen during 
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formulation development, since it is qualitatively related to stability during freezing and thawing 
[Arakawa et al., 2001]. The use of cryoprotectants can stabilize proteins with low inherent 
stability to freeze-thaw stress [Arakawa et al., 1991]. Cryoprotectants are of great chemical 
diversity including sugars, amino acids, polyols, polymers, and salts. Besides others, the most 
important underlying stabilizing effect is preferential exclusion, a mechanism described in detail 
by Timasheff and his colleagues [Arakawa et al., 1982; Timasheff, 1995]. They reported that 
substances like sucrose and glycerol are preferentially excluded from the immediate 
environment of a protein in aqueous systems, thereby stabilizing the protein in solution. Thus 
solutes which are preferentially excluded from the surface of the protein are capable of 
preventing protein denaturation during freezing and thawing [Arakawa et al., 2001].  
3.1.4 Light exposure 
Therapeutic proteins typically are exposed to light numerous times amongst their 
production process and the administration to the patient. Almost all proteins are subject to 
chromatographic purification, which includes detection by absorption of UV light after elution 
from the column. In general, these columns are made of glass. Therefore, protein molecules 
located near the glass wall can be continually exposed to room light or daylight during the entire 
process [Kerwin et al., 2007]. Furthermore, light exposure might occur during bulk storage, 
when the storage container is transparent for light, during fill and finish operations, and visual 
inspections. Finally, the intravenously administration of therapeutic proteins requires the use of 
IV bags, enabling the exposure to light irradiation while delivery [Kerwin et al., 2007; Roy et al., 
2009]. The expression of recombinant proteins by mammalian cell lines often implicates viral 
contamination. This entails requirements by FDA dealing with viral reduction. One excellent 
option is the inactivation of viruses by ultraviolet C (UV-C) light, though its application to 
biopharmaceuticals is controversial, due to photodegradation of proteins [Lorenz et al., 2009]. 
The most prominent amino acids for photodegradation are Phenylalanine, Tryptophan, and 
Tyrosine. The different pathways of photoreactions in proteins were reported in numerous 
publications and shall not be discussed in more detail [Davies et al., 2001; Hovorka et al., 2001; 
Kerwin et al., 2007; Parker et al., 2007; Prompers et al., 1999; Roy et al., 2009; Vanhooren et 
al., 2002]. The regulatory agencies are aware of the potentially occurring degradation of 
proteins by light exposure and published guidelines on photostability testing of new active 
substances at the International Conference on Harmonization (ICH) [ICH Q1B, 1998]. The 
consequences of light absorbance by proteins vary from conformational changes, aggregation, 
to loss of efficacy and biological activity. Light induced degradation of proteins is a well-known 
phenomenon in vivo. The damage of proteins in the skin and in the eyes is of great concern in 
aging [Mizdrak et al., 2008; Parker et al., 2007]. This study omits the implications on chemical 
stability, but investigates the physical stability of monoclonal antibodies by light exposure. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Materials  
3.2.1.1 Human IgG1 antibody (huAb) 
A recombinant human monoclonal IgG1 antibody (huAb) was kindly provided by Abbott 
GmbH & Co. KG and used as a model protein for these separation studies. The antibody 
solution applied in the experiments was diluted to a concentration of 4 mg/mL in a formulation 
buffer containing 1.2 mM citrate, 14 mM phosphate, 105 mM sodium chloride and 66 mM 
mannitol at pH 5.2. The IgG1 stock solution had an initial concentration of 70 mg/mL and was 
stored at -80 °C in the deep freezer. Prior to use, the formulation buffer was filtrated using a 
0.2 µm sterile syringe filter made of cellulose acetate (VWR International, Darmstadt, 
Germany). 3 mL of the antibody solution was filled into cleaned and sterilized 6 R vials made 
from glass type 1 (Schott AG, Mainz, Germany), sealed with Teflon
®
-faced rubber stoppers 
(West Pharmaceuticals Services, Eschweiler, Germany) and crimped. All antibody samples 
were prepared under aseptic conditions. Highly purified water generated in-house was used for 
the preparation of samples and buffers (PURELAB Plus instrument (USF Elga, Celle, 
Germany)). All substances used were of analytical grade.  
3.2.2 Methods to provoke protein instability  
3.2.2.1 Stirring stress 
Stirring stress of the huAb was performed in 6 R glass vials filled with 3 mL of a 
4 mg/mL antibody solution. A 6 x 3 mm sized Teflon
®
 (PTFE)-coated stir bar (VWR 
International, Darmstadt, Germany) was used on a Variomag Telesystem 60.07 multipoint 
stirrer (Thermo Fisher Scientific, Schwerte, Germany). Speed was set to 240 rounds per minute 
(rpm) and a temperature of 25°C was fixed by stirring in a cabinet dryer. For control 
experiments, the pure buffer solution was stirred under the same conditions as well.  
3.2.2.2 Shaking stress 
Shaking stress of the antibodies was performed in 6 R glass vials filled with 3 mL of a 
4 mg/mL antibody solution. A VWR Microplate Shaker (VWR International, Darmstadt, 
Germany) was used for shaking the vials at 240 rpm. Therefore, the vials were arranged upright 
in a non-transparent box and the shaker moves in horizontal circles and with an orbit size of 
3 mm.  
3.2.2.3 Freeze-thaw stress 
Freeze-thaw stress was conducted in 6 R glass vials filled with 3 mL of a 4 mg/mL 
antibody solution. The vials were placed in the deep freezer at -80°C for 2 hours and 
subsequently thawed at 25°C in a cabinet dryer for 2 hours. The cycle was repeated up to eight 
times.  
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3.2.2.4 Light exposure 
A Suntest CPS radiation chamber (Heraeus Holding, Hanau, Germany) was used to 
expose the samples to light. Radiation intensity was set to 55 ± 5 W/m². The light source was a 
xenon lamp emitting light of the whole sunlight spectrum. A filter made of sheet glass was 
incorporated to obtain a radiation spectrum close to that to which an antibody formulation might 
be exposed to during storage and handling. 3 mL of the samples containing 4 mg/mL of protein 
were filled in 6 R glass vials and placed in the center of the radiation chamber in an upright 
position. Sampling was performed after 1 day, 4 days, 6 days and 7 days by withdrawal of three 
vials. Additionally, the formulation buffer was exposed to light as well and sampled at the same 
time points. For control experiments, a triplicate of vials completely shielded with aluminum foil 
was included in the study, serving as control on final sampling date for the slight temperature 
increase (35 ± 2°C) during radiation.  
3.2.2.5 Temperature stress 
Heating was performed 6 R glass vials filled with 3 mL of a 4 mg/mL antibody solution. 
The vials were incubated in cabinet dryers of a fixed temperature of 50°C for up to 4 weeks. 
Sampling was performed weekly. The melting temperature (Tm) of the human IgG1 was 75°C, 
thus several degrees above the incubation temperature.  
3.2.3 Methods to determine protein stability 
3.2.3.1 Light obscuration 
Light obscuration (LO) measurements were conducted with a PAMAS-SVSS-C Sensor 
HCB-LD 25/25 (Partikelmess- und Analysensysteme GmbH, Rutesheim, Germany) to quantify 
subvisible particles between 1 and 200 μm. Three aliquots of 0.3 mL of each sample were 
analyzed. Before each measurement, 0.3 mL of the sample was flushed through the system 
and discarded. Between the sample measurements the system was rinsed with highly purified 
water until the system was free of particles. The results of the particle counts were calculate as 
mean value out of three measurements, referring to a sample volume of 1.0 mL. If necessary 
the samples were diluted with highly purified water to reach the linear range of the instrument. 
3.2.3.2 Dynamic light scattering  
Dynamic light scattering on a Malvern Zetasizer Nano ZS (Malvern, Herrenberg, 
Germany) was used to investigate the size distribution of particles and molecules in the protein 
samples in the sub-visible range between 1 nm and 1 µm. Non-invasive backscattering at an 
angle of 173° was performed at 25°C using a Helium-Neon-Laser at 633 nm. Each sample was 
analyzed twice. The refractive index for aqueous protein solution was set to 1.45. 700 µL of the 
undiluted protein samples were measured in half-micro cuvettes made of polystyrene (Fisher 
Scientific, Schwerte, Germany). Each sample was measured in triplicate. Using the Dispersion 
Technology Software (version 6.1, Malvern) the polydispersity index (PDI) and the Z-average 
diameter (Zave) were calculated from the correlation function. 
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3.2.3.3 Turbidity  
The turbidity was measured by 90° light scattering at λ = 860 nm using a NEPHLA 
turbidimeter (Dr. Lange, Düsseldorf, Germany). Approximately 1.8 ml of the final samples were 
analyzed according to the European Pharmacopoeia and the results are reported in formazine 
nephelometric units (FNU) [PhEur 2.9.19., 2011]. 
3.2.3.4 Size exclusion chromatography 
Concentrations of soluble aggregates, fragments, and monomeric protein were 
measured by size exclusion chromatography on an Agilent system with RI and UV detection 
(Agilent Technologies, Palo Alto, USA). A Superdex 200 10/300 GL column (GE Healthcare, 
Little Chalfont, UK) was used as the solid phase. Phosphate buffered saline (PBS) at pH 7.4 
(12 mM phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride) with a flow rate of 
0.5 ml/min was used as a mobile phase. Before injection the samples were centrifuged at 
5000 x g for 10 minutes to remove insoluble species, probably clogging the column. Each 
sample was analyzed in duplicate, using an injection volume of 50 µl. The protein recovery was 
calculated using either the refractive index signal or the UV absorbance signal at 280 nm. The 
area under the curve (AUC) of the unstressed sample was defined as 100%.  
3.2.3.5 Intrinsic protein fluorescence spectroscopy 
A Varian Cary Eclipse fluorescence spectrometer (Varian, Inc., Darmstadt, Germany) 
was used to monitor intrinsic protein fluorescence and thus to analyze the tertiary structure of 
the protein. The temperature was set to 20°C for all measurements. Samples were centrifuged 
and supernatant was measured in triplicate in white 96-well plates (Nunc, Roskilde, Denmark) 
using a volume of 200 µL for each well. Excitation wavelength was set to 295 nm and the 
excitation slit was fixed at 5 nm. Emission was recorded from 300 to 500 nm using a 5 nm 
emission slit. The sample concentration was 0.5 mg/mL, unless otherwise mentioned. The 
scanning rate was set to 20 nm/min and the voltage of the photomultiplier was set to 800 V. The 
“Scan application” of the Cary Eclipse Software (version 1.0, Varian, Inc., Darmstadt, Germany) 
was utilized to record the spectra. The mean spectrum of each triplicate was calculated after 
recording. All samples were buffer corrected. Smoothing was performed by OriginLab 8.0 
DataAnalysis Software (OriginLab Corporation, Northampton, USA) on 99 points according to 
the Savitzky-Golay algorithm. 
3.2.3.6 Extrinsic protein fluorescence spectroscopy 
A Varian Cary Eclipse fluorescence spectrometer (Varian, Inc., Darmstadt, Germany) 
was used to monitor extrinsic protein fluorescence and thus to analyze the conformational 
structure of the protein. ANS (1-Anilinonaphthalene-8-sulfonic acid) at 20 µM concentration was 
used as fluorescent dye. ANS is hardly fluorescent in a polar, aqueous environment, but in a 
non-polar, hydrophobic environment it becomes highly fluorescent [Weber et al., 1954]. 
However, ANS itself might induce structural alterations of proteins due to electrostatic 
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interactions [Ali et al., 1999]. Besides electrostatic interactions between protein and ANS, 
hydrophobic interactions are discussed to be involved in the binding mechanisms between both 
[Laurence, 1952]. Several studies reported the ability of ANS to interact with hydrophobic sites 
of proteins accompanied with an increase of fluorescence intensity and an blue shift of the 
emission maximum [De Filippis et al., 1996; Stryer, 1965].  
The temperature was set to 20°C for all ANS fluorescence measurements. Samples 
were measured in triplicate in white 96-well plates (Nunc, Roskilde, Denmark) using a volume 
of 200 µL for each well. Excitation wavelength was set to 350 nm and the excitation slit was 
fixed at 5 nm. Emission was recorded from 360 to 600 nm using a 5 nm emission slit. The 
sample concentration was 0.5 mg/mL, unless otherwise mentioned. The scanning rate was set 
to 20 nm/min and the voltage of the photomultiplier was set to 800 V. The “Scan application” of 
the Cary Eclipse Software (version 1.0, Varian, Inc., Darmstadt, Germany) was utilized to 
record the spectra. The mean spectrum of each triplicate was calculated and buffer corrected 
after recording. Smoothing was performed by OriginLab 8.0 DataAnalysis Software (OriginLab 
Corporation, Northampton, USA) on 99 points according to the Savitzky-Golay algorithm. 
3.2.3.7 Fourier transform infrared spectroscopy (FTIR) 
For the determination of changes in secondary structure of proteins, native and 
aggregated formulation samples were analyzed at 1 mg/mL by FTIR in ATR mode, unless 
otherwise mentioned. The temperature of the Bio-ATR II unit of a Tensor 27 spectrometer 
(Bruker Optics GmbH, Ettlingen, Germany) was set to 20°C. Spectra were collected from 
4000 cm
-1
 to 850 cm
-1
 with a resolution of 4 cm
-1
. 120 scans were averaged for each sample 
measurement. Each spectrum was background corrected and vector normalized on the amide I 
band using the Opus software (version 6.5, Bruker Optics, Ettlingen, Germany). Finally, the 
second derivatives of the spectra were calculated and smoothened on 17 points (according to 
the Savitzky-Golay algorithm).  
3.2.3.8 High resolution UV absorbance spectroscopy  
The tertiary structure of the samples was analyzed by high-resolution UV absorbance 
spectroscopy in a quartz cuvette at 25°C using an Agilent 8453 UV-visible spectrophotometer 
(Agilent Technologies, Waldbronn, Germany). Spectra were recorded from 190 to 400 nm at a 
resolution of 1 nm and a protein concentration of 0.5 mg/mL. Finally, the second derivatives of 
the spectra were calculated and fitted to a cubic function with 99 interpolated points per raw 
data point [Kueltzo et al., 2003]. The final resolution resulting from this procedure was 0.01 nm. 
The a/b ratio was calculated from the peak to peak distances between the minimum around 
283 nm and the maximum around 287 nm (referring to a), as well as the peak to peak distance 
between the minimum around 290 nm and the maximum around 295 nm (referring to b). The 
determination of peaks and a/b ratios was performed by OriginLab 8.0 Data Analysis Software 
(OriginLab Corporation, Northampton, USA).  
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3.3 RESULTS 
 
3.3.1 Mechanical stability of Human IgG1 antibody (huAb) 
The formation of particles in the huAb formulation in the micrometer range was 
determined by light obscuration. Stirring and shaking at 240 rpm quickly lead to the formation of 
numerous particles larger than 1 µm and an increase in turbidity (see Table 3-1).  
Table 3-1 – Results of light obscuration and turbidity measurements of huAb after agitation stress. 
Stirring 240 rpm   huAb  buffer 
Duration 0 h 4 h 24h 72h 72h 
# of particles ≥ 1 µm 1479 263,041 272,490 329,476 16,234 
# of particles ≥ 10 µm 20 327 16,557 15,284 150 
# of particles ≥ 25 µm 2 1 7 403 13 
Turbidity [FNU] 1.5 28.8 191.1 > 1300 0.9 
Shaking 240 rpm   huAb  buffer 
Duration 0 h 4 h 24h 72h 72h 
# of particles ≥ 1 µm 1479 16,346 43,852 75,574 8549 
# of particles ≥ 10 µm 20 216 228 3,223 107 
# of particles ≥ 25 µm 2 9 15 87 32 
Turbidity [FNU] 1.5 4.9 9.1 12.2 0.8 
 
These results indicate that especially prolonged stirring of several hours results in the 
formation of numerous aggregates in the upper µm-range. A particle growth on the cost of low 
µm sized initial species, generated within the first hours of stirring is suggested. 72 h of stirring 
of the buffer solution was additionally performed to verify that the enhanced particle loading 
originates from protein. The total particle counts within the formulation buffer increased due to 
stirring, though particle numbers far below those in protein containing solutions were detected. 
About 16,200 particles ≥ 1 µm per mL were detected in the buffer sample. Thus, a minor 
fraction (~1-5%) of generated particles can at least partially consist of abrasive PTFE (Teflon
®
) 
particles. 
Another valuable and simple method to detect insoluble aggregates in protein solutions 
is turbidity measurement [Wang, John et al., 1996]. Using a laser wavelength of 860 nm 
especially large particles will impact the results, since large particles more effectively scatter 
light of long wavelengths than light of short wavelengths [Mahler et al., 2005]. Turbidity 
measurements using the nephelometric set-up resulted in significantly increasing formazine 
nephelometric unit (FNU) values during stirring. Already after 4 h of stirring the samples were 
visually observed to be turbid, represented by a value of 28.8 FNU. After one day, 191.1 FNU 
were measured within the stirred samples. Finally, the turbidity of the samples exceeded the 
limitations of the turbidimeter after 72 h of stirring. These elevated turbidity values indicate the 
existence of large particles/aggregates and precipitation.  For control, the buffer formulation 
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was stirred under the same conditions for 72 h as well. The resulting turbidity was 0.9 FNU, 
which is considered to be a clear solution, according to the PhEur [PhEur 2.2.1., 2011]. 
Dynamic light scattering measurements resulted in the determination of two peaks of 
different size after 4 hours. The main peak exhibited a diameter of 9.2 nm, and a second minor 
peak arises around 1000 nm (data not shown). After 72 hours, one peak around 1000 nm was 
detected. The dynamic light scattering results were heavily influenced by precipitation 
appearing already after 4 hours of stirring. Thus the parameters characterizing the size 
distribution in the nanometer range are not evaluated for the stirred samples. 
Shaking the protein samples also induces particle formation in micrometer range. 
Furthermore, a constantly increasing turbidity was measured referring to shaking time. In the 
end, 12.2 FNU were determined in the antibody samples shaken for three days. After 24 hours 
of shaking the samples started to visibly appear turbid as well, whereas the buffer remained 
clear after shaking up to 72 hours. After 4 hours of shaking the sample appeared still 
monodispers (PDI 0.09) in DLS measurements, with one peak around 9.4 nm (diameter). 
Increasing shaking time to 72 h resulted in two species and a PDI of ~0.3. The major peak 
appeared at a diameter of 10.9 nm and a minor one around 950 nm (data not shown). The 
shaken samples slightly started to precipitate after 72 h. The elevated PDI indicates the 
formation of species of different sizes within the samples. Additionally the Z-average diameter 
increased with shaking duration too, suggesting that especially larger species/ aggregates are 
formed. Table 3-2 summarizes the Zave and PDI results of the shaken samples. 
Table 3-2 – Results of Z-average diameter and polydispersity index of huAb samples after shaking. 
Shaking 240 rpm 0 h 4 h 24 h 72 h 
Zave 11.5 11.3 17.8 30.6 
PDI 0.04 0.09 0.31 0.29 
 
Size exclusion chromatography (SEC) was performed after centrifugation of the 
mechanically stressed samples. The insoluble species that obviously appeared within the 
samples were separated and the size distribution of soluble protein species was determined by 
UV-detection at 280 nm. After 4 hours of stirring 96 ± 1.9 % of total protein content compared to 
the unstressed sample was recovered. The total recovery further decreases to 94 ± 2.5 % after 
24 hours and finally after 72 hours of stirring merely 80.3 ± 4.5 % of the original protein content 
were found. These data confirm the results from the previous experiments, showing that stirring 
induces a strong formation of insoluble aggregates, expressed by the significant reduction of 
total protein recovery. The huAb samples that were shaken revealed a decreasing protein 
recovery within the three days of investigation too. After 72 hours 89.8 ± 2.6 % of the protein 
content were recovered, compared to the unstressed sample. All chromatograms of shaken and 
stirred samples consisted of only one peak eluting around 66 minutes representing the 
monomeric protein. No additional soluble species like fragments or aggregates were detected 
by SEC (data not shown).  
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To determine alterations in the tertiary structure of the human IgG1 samples intrinsic 
protein fluorescence was utilized. The emission spectra of the samples after stirring are shown 
in Figure 3-1, A. The position of the maximum fluorescence intensity around 340 nm did not 
change in any of the stirred samples. But the intensity of emitting fluorescence decreases about 
17 % (from 690 arbitrary units (a.u.) of the unstressed sample to 570 a.u. after 72 h of stirring) 
with prolonged stirring time. Similar results were obtained of the samples after shaking (see 
Figure 3-1, B). No wavelength shift of the emission maxima was detected (data not shown). A 
reduction of fluorescence intensity was first detected after 24 hours of shaking. It finally 
decreases about 9 % while 72 h of shaking.  
Intrinsic fluorescence of a protein is provoked by the aromatic amino acids 
phenylalanine, tryptophan and tyrosine [Jiskoot et al., 2005]. The emission spectra shown in 
Figure 3-1 solely represent the emission of tryptophan (Trp), due to the excitation at 295 nm. 
The fluorescence of the hydrophobic amino acid tryptophan is especially dependent on the 
environmental conditions surrounding the protein. Thus, changes in the local environment of 
Trp can be investigated by intrinsic fluorescence. Depending on the characteristics of the 
original surrounding, alterations can either lead to decreases or increases of the fluorescence 
intensity. For example, polar conditions can decrease fluorescence intensity by quenching 
[Jiskoot et al., 2005]. When quenching amino acids will be removed from the micro-environment 
of Trp due to unfolding, intensity might also increase [Hawe et al., 2008]. As a typical 
application area unfolding processes of proteins should be mentioned, which might expose the 
hydrophobic core of a protein to the aqueous solvent. Thus, the aromatic amino acids will 
change their interaction with neighboring amino acids leading to changes in the fluorescence 
intensity [Chen et al., 1998]. If the maximum of the fluorescence intensity changes its 
wavelength position as well, a pronounced alteration of the environment of tryptophan can be 
assumed. 
The maxima of all emission spectra arise around 340 nm thereby indicating that the 
tertiary structure of the IgG1 did not considerably change while stirring. A complete unfolding 
would entail contact of tryptophan to water molecules in the aqueous surrounding and is 
reported to shift the emission maximum to 350 nm [Ladokhin, 2006]. However, both stress 
methods reduced the fluorescence intensity, indicating that unfolding processes occurred in the 
non-precipitated protein species and the fluorescence of Trp is quenched. Comparing both 
agitation methods at the same duration, stirring leads to stronger alterations in the 
neighborhood of Trp than shaking. 
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Figure 3-1 – Intrinsic protein fluorescence emission spectra of 0.5 mg/mL human IgG1 after 
excitation at 295 nm.  A) Spectra of stirred samples B) spectra of shaken samples 
The sold black lines represent the spectra of the unstressed huAb sample. The dashed red lines represent 
the spectra after 4 hours of stirring/shaking, the dashed blue lines after 24 h of stirring/shaking and the 
dashed green lines after 72 hours of stirring/shaking.  
 
Another spectroscopic method to investigate the tertiary structure of proteins is UV/Vis 
absorbance spectroscopy. It was additionally utilized to assess the conformational stability of 
the human IgG1 antibody. The zero-order spectra are typically consisting of the overlapping 
absorbance of phenylalanine (between 245 and 270 nm), tryptophan (between 265 and 295 
nm), and tyrosine (between 265 and 285 nm). The second derivative of UV absorbance is 
commonly used to enhance the resolution compared to the zero-order spectra [Kueltzo et al., 
2003]. The resulting spectra obtain peaks whose positions are sensitive to the polarity of the 
environment of the absorbing amino acids. A peak shift to shorter wavelengths generally 
indicates an increase in polarity of the amino acid`s environment [Mach et al., 1994]. The 
A) 
B) 
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a/b ratio is often used to determine the exposure of tyrosine and tryptophane residues to the 
surrounding environment [Kueltzo et al., 2005]. 
 
 
Figure 3-2 – UV 2
nd
 derivative spectra of 0.5 mg/mL human IgG1.               
A) Spectra of stirred samples B) spectra of shaken samples 
The solid black lines represent the spectra of the unstressed huAb sample. The dashed red lines 
represent the spectra after 4 hours of stirring/shaking, the dashed blue lines after 24 h of stirring/shaking 
and the dashed green lines after 72 hours of stirring/shaking.  
 
The 2
nd
 derivative spectra recorded between 260 and 310 nm after stirring and shaking 
procedures are displayed in Figure 3-2. The spectra showed no significant peak shift, neither 
after stirring, nor after shaking the human IgG1 formulation. The mean values of the triplicate 
measurements of the a/b ratios determined in the 2
nd
 derivative spectra are summarized in 
Table 3-3. Stirring slightly increases the a/b ratio, whereas shaking does not affect the ratio at 
all. Thus, UV absorbance spectroscopy enabled the detection of slight changes in the 
environment of tyrosine and tryptophane of soluble species after stirring, but not after shaking. 
But these unfolding processes are suggested to be weak.  
B) 
A) 
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Table 3-3 – Results of a/b ratio determination from UV 2
nd
 derivative spectroscopy of huAb. 
Agitation Unstressed Stirred 72 h Shaken 72 h 
a/b ratio 1.516 1.535 1.516 
 
The conformational state of the human IgG1 after agitation was further analyzed by 
extrinsic fluorescence spectroscopy and ATR-FTIR spectroscopy. 1-Anilinonaphthalene-8-
sulfonic acid (ANS) in 20 µM concentration was used as fluorescent dye for the determination of 
the extrinsic fluorescence of the protein. Significant increases of ANS-fluorescence intensity 
were determined after stirring as well as after shaking.  
 
 
Figure 3-3 – Extrinsic fluorescence emission spectra of 0.5 mg/mL human IgG1 and 20 µM ANS 
after excitation at 350 nm.  A) Spectra of stirred samples B) spectra of shaken samples 
The solid black lines represent the spectra of the unstressed huAb sample. The dashed red lines 
represent the spectra after 4 hours of stirring/shaking, the dashed blue lines after 24 h of stirring/shaking 
and the dashed green lines after 72 hours of stirring/shaking.  
 
B) 
A) 
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The emission spectra of huAb after agitation stress after background subtraction are 
shown in Figure 3-3. The intensity of the emitting light is continuously increasing with prolonged 
stirring time. Starting with a weak ANS fluorescence intensity of ~18 a.u. for the native protein 
sample, a nearly four times higher intensity of more than 70 a.u. is finally emitted after 72 h of 
stirring. Shaking resulted in only minor increases in ANS fluorescence intensity. After the same 
duration of agitation the peak maximum possessed an intensity of 32 a.u.. It can be suggested 
that during shaking and stirring unfolding the protein underwent processes that enabled an 
enhanced interaction with ANS. The peak maxima are summarized in Table 3-4. The 
determined wavelength shifts are weak. A red shift to higher wavelengths of 3 nm was 
determined after 72 h of shaking. After the same duration of shaking, instead, a blue shift of 
nearly 2 nm was found. The shaken and the stirred samples showed an increased capability to 
bind ANS, indicating that unfolding occurred [Hawe et al., 2008; Jiskoot et al., 2005]. But the 
characteristics of the secondary structure of shaken and stirred huAb and their interaction with 
ANS differ. 
Table 3-4 – Results of peak position from ANS fluorescence emission spectra of 0.5 mg/mL huAb. 
Agitation Unstressed Stirring 72 h Shaking 72 h 
Peak position 462.98 nm 465.97 nm 461.04 nm 
 
FTIR spectroscopy was consulted to assess the influence of mechanical stress on the 
secondary structure of the human antibody. The 2
nd
 derivative spectra of the samples (after 
removal of particles) before and after agitation are shown in Figure 3-4. The spectra are 
dominated by the strong valley at 1638 cm
-1
, associated with the typical intramolecular β-sheet 
structure of antibodies [Byler et al., 1998; Costantino et al., 1997]. Figure 3-4, A depicts the 
effect of stirring on the secondary structure of huAb. Slight decreases of the intramolecular 
β-sheet band were detected, coming along with minor changes at band positions around 
1622 - 1615 cm
-1
, representing intermolecular β-sheets. The weak alterations in the spectra 
suggest that minor unfolding and aggregation was induced by stirring. However, the 
predominant β-sheet structure of the IgG1 was maintained in the soluble species. No 
substantial difference in second derivative ATR-FTIR spectra was detectable between the 
soluble fraction of the shaken and non-shaken antibody formulations (Figure 3-4, B). These 
data indicate that the secondary structure did not change in the non-particulate fraction after 
shaking.  
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Figure 3-4 – Second derivative ATR-FTIR spectra of amide I band of 1 mg/mL human IgG1            
A) Spectra of stirred samples B) spectra of shaken samples 
The solid black lines represent the spectra of the unstressed huAb sample. The dashed red lines 
represent the spectra after 4 hours of stirring/shaking, the dashed blue lines after 24 h of stirring/shaking 
and the dashed green lines after 72 hours of stirring/shaking.  
 
3.3.2 Stability of huAb against freeze-thawing  
Most therapeutic proteins undergo freeze-thaw processes during production or storage, 
either in bulk formulation, or in the final formulation for lyophilization or final storage. The 
influence of up to eight freeze-thaw cycles alternating between -80°C and +25°C were 
investigated with the human IgG1 antibody. Light obscuration detected no significant increasing 
numbers of particles ≥ 1 µm per mL (data not shown). The numbers of particles larger than 
10 µm slightly increased within 8 freeze-thaw cycles. The unstressed material obtained 37 
particles of this size per mL, and after eight times freezing and thawing 149 particles per mL 
were counted. Turbidity measurements resulted in 1.9 FNU after eight freeze-thaw cycles and 
A) 
B) 
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dynamic light scattering determined one single peak obtaining a diameter of 11.5 nm (data not 
shown). The data suggest that no substantial formation of subvisible particles was induced by 
freeze-thawing. 
To detect potentially generated soluble protein aggregates or fragments, the samples 
were investigated by size exclusion chromatography. The chromatograms revealed a total 
protein recovery of 107.8 ± 13.2 %, indicating that no precipitation occurred while freeze-
thawing. The distribution of soluble protein species in the chromatograms detected by UV 
absorbance showed no increase in fragmented or aggregated species (data not shown). 
Neither soluble nor insoluble aggregates were generated by freeze-thawing of huAb.  
 
Figure 3-5 – Intrinsic protein fluorescence emission spectra of 0.5 mg/mL human IgG1 after 
excitation at 295 nm. 
The solid black line represents the mean spectrum of the unstressed huAb sample. The dashed red line 
represents the mean spectrum after 4 freeze-thaw cycles and the dashed blue line after 8 freeze-thaw 
cycles.  
 
The tertiary structure of huAb after freeze-thawing was monitored by intrinsic protein 
fluorescence measurements (see Figure 3-5). Neither a significant change in fluorescence 
intensity nor a peak shift was determined in the emission spectra. Each spectrum represents 
the mean of three measurements.  
As orthogonal methods for the determination of changes in tertiary structure UV/Vis 
absorbance spectroscopy and extrinsic fluorescence spectroscopy were utilized. The 2
nd
 
derivative spectra of UV absorbance between 260 and 310 nm revealed no differences of either 
peak position or a/b ratio between the unstressed antibody formulation and that after eight 
freeze-thaw cycles (data not shown). Analyses of potential conformational changes using 20 
µM ANS as fluorescent dye confirmed these results. The emission spectra obtained from the 
human IgG1 antibody samples before and after freeze-thaw stress showed no differences in 
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ANS fluorescence intensity or peak position (data not shown). Repetitive freeze-thawing did not 
alter the conformational state of the human monoclonal antibody. 
Finally, the investigations on alterations of the secondary structure were performed by 
ATR-FTIR spectroscopy. The unmodified spectra of the amide I band revealed neither a 
difference in absorbance nor in the wavenumbers of the peaks. Furthermore, no differences 
between the spectra after vector normalization and the 2
nd
 derivative spectra were distinguished 
(data not shown). Freeze-thawing also does not influence the secondary structure of the human 
IgG1 antibody. 
3.3.3 Stability of huAb against light exposure 
Light exposure was included as stress condition potentially inducing chemical 
modifications of the protein, followed by aggregation [Schoeneich, 2010]. The used light source 
emitted a spectrum ranging from 200 to 1000 nm, thus consequences on protein stability 
cannot be referred to a certain wavelength or the range of UV light.  
Particle formation soared after day 4 (see Figure 3-6). The total numbers of particles in 
the µm-range exponentially increased from approximately 3 x 10
3
 to 2 x 10
5
 between day 4 and 
day 6.  
 
Figure 3-6 – Particle counts of light exposed huAb by light obscuration. 
Cumulative particle numbers ≥ diameter per mL of unstressed sample (   ), 1 day light exposed 
sample (      ), 4 days light exposed sample (      ), 6 days light exposed sample (      ), 7 days light exposed 
sample (    ), and control sample shielded from light after 7 days (     ). Error bars represent standard 
deviation of at least two measurements.  
 
Turbidity measurements confirmed these observations. The formazine nephelometric 
units (FNU) of the irradiated samples slightly increased until day 4. The turbidity of 3.7 FNU on 
day 4 exceeded the benchmark of 3.2 FNU of the PhEur, below which samples are considered 
to be clear [PhEur 2.2.1., 2011]. This slightly increased turbidity is not caused by particles 
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≤ 10 µm, since the counts of these larger particles were not significantly increased after 4 days 
of light exposure. Prolonging the radiation time leads to visible precipitation, enhanced 
formation of particles ≥ 10 µm and ≥ 25 µm and thus an escalation of turbidity. It immediately 
reaches the limit of detection of the method at 1300 FNU (see Figure 3-7).  
 
 
 
Figure 3-7 – Results of turbidity measurements of human IgG1 after light exposure. 
The graph shows the formazine nephelometric units of the light exposed samples (black squares) and the 
shielded control samples (red triangles). The error bars represent the standard deviation of three samples 
per time point. Within the first 4 days of irradiation turbidity slightly increased, but later on the samples on 
day 6 and 7 got extremely turbid. The turbidity of the control samples slightly increased within 7 days. 
 
The total particle counts of the shielded control samples showed an increase of the 
species ≥ 1.0 µm, which exceeded the particle load after 4 days of light exposure, but no 
enhanced formation of larger particles. Therefore, the sample appeared to be clear after 7 d 
incubation in the radiation chamber and resulted in a slightly increased turbidity of 2.9 FNU.  
The buffer formulations stressed under the same conditions showed no significant 
increase in total particle numbers and turbidity over 7 days of light exposure (data not shown). 
The generation of particles is therefore related to the light exposure of the protein.  
Dynamic light scattering of the light exposed samples showed similar results. Until 4 
days of light exposure small and medium sized subvisible species were detected. The occurring 
heavy precipitation hindered the dynamic light scattering measurements of the samples 
exposed to light for 6 or 7 days. Therefore, Figure 3-8 shows only the mean particle size 
distribution in the nanometer range of the samples up to four days of light exposure.  
The particle size distribution determined by DLS show constantly increasing Zave and 
PDI values over radiation time. The native huAb sample initially revealed a monodispers 
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distribution with a Zave value of 11.48 nm, and a polydispersity index (PDI) of 0.042. After four 
days of light exposure Zave resulted in 49.31 nm and the mean PDI was 0.208. The enhanced 
polydispersity of these samples is represented by the additional peaks rising between 20 and 
100 nm in Figure 3-8. A slight increase was also observed measuring the turbidity of these 
samples. 3.7 FNU were detected after 4 days of light exposure, implying that the samples are 
considered not to be clear anymore [PhEur 2.2.1., 2011]. 
 
Figure 3-8 – Particle size distribution of light exposed huAb samples determined by DLS. 
The scattering intensity of the irradiated IgG1 samples and their diameter in nm is plotted. Each line 
represents the mean out of three samples, each measured in duplicate. The black solid line represents the 
native human IgG1 sample, the grey solid line represents the shielded control sample after 7 days, the red 
dashed line represents the sample after 1 day of light exposure and the blue dashed line represents the 
sample after 4 days of light exposure. 
 
Within the control sample, shielded from light, a mean Zave of 47.61 nm and a PDI of 
0.186 were determined after 7 days. The control samples show the formation of new particles of 
diameters between 30 and 400 nm with weak scattering intensities, which contribute to the 
slightly increase turbidity. The original peak around 11 nm represents still the main compound 
in this sample, maintaining more than 27 % of scattering intensity.  
Besides particle formation of sub-visible and visible size range, smaller protein species 
like fragments or aggregates might be induced by light exposure too. Size exclusion 
chromatography is the most important method to detect soluble protein species and separate 
them concerning to their size. The results of UV detection after SEC separation of the light 
exposed samples of the human IgG1 antibody are summarized in Figure 3-9. The total recovery 
of all detected species dramatically starts to decrease on day 6 of radiation, and ends at 
approximately 32 % at day 7. This reduction is accompanied by the enhanced precipitation 
mentioned above. The recovery of monomeric species starts to decrease already on day 1, 
accompanied by an enhanced formation of fragments and small aggregates. On day 4, before 
strong formation of insoluble particles begins, 61 % of the total recovered species is composed 
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of monomeric protein species, followed by 19.7 % of intermediate molecular weight species. 
The relative majority of soluble high molecular weight aggregates appeared on day 6. Further 
radiation of the samples resulted in only half of the total recovery. Decreases in the relative 
amounts of all three differentiated soluble aggregate species accompanied by a constant 
amount of monomeric species and a slightly increasing relative amount of fragments were 
detected. The control samples shielded from light, maintained 97 % of total recovery over the 
whole study and no generation of soluble aggregates or fragments. Only an increase in 
subvisible particles in the size range > 1 µm < 10 µm was detected. Anyway, the tremendous 
formation of fragments as well as aggregates is attributed to the light exposure and not to the 
side effect of a slightly elevated temperature during incubation. The resulting distribution of 
fragments, monomeric species and the various aggregates is time dependent. Generally, with 
prolonged duration of irradiation, the amount and size of aggregates increases. A growth of 
aggregated species is suggested which sometime between day 4 and day 6 exceeds a critical 
size of several µm and subsequently start to precipitate. Besides aggregation, fragmentation 
was detected too, indicating that light exposure is also able to cleave the IgG1 molecules.  
 
Figure 3-9 – Distribution of soluble protein species in samples after light exposure determined by 
UV detection after SEC. 
The content of the species is ranked on the left y-axis. The white bars represent the amount of fragments, 
the light grey bars represent the amount of dimers/trimers, the grey bars represent the amount of 
intermediate molecular weight aggregates (IMW) and the dark grey bars represent the high molecular 
weight aggregates (HMW). The right y-axis ranks the total recovery (black squares) and the monomer 
recovery (red dots). The error bars represent the standard deviation of at least two samples. 
 
The appearance of aggregation and fragmentation potentially implicates changes in the 
conformation of the protein, detectable by spectroscopic methods analyzing the secondary and 
tertiary structure of a protein. The tertiary structure describes the steric constitution of the 
protein`s amino acid chain [Lottspeich, 2006]. Fluorescence spectroscopy and UV absorbance 
spectroscopy were utilized to investigate changes in the steric organization of the protein after 
light exposure. Intrinsic protein fluorescence was measured at 0.25 mg/mL protein 
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concentration for the light exposed samples, since huge amounts of protein precipitated after 
6 days of radiation and the concentration in the supernatant was too low for all intended 
analytical investigations. The intrinsic protein fluorescence is reduced with increasing duration 
of light exposure (see Figure 3-10a). After 1 day of light exposure, the fluorescence intensity 
slightly dropped. Further irradiation led to strong attenuation of the emission intensities. 
However, no significant wavelength shift of the maximum emission peak around 337 nm was 
detected at any time point. The reduced intensities imply a quenching of Trp residues within the 
samples due to the exposure to more polar conditions, i.e. unfolding occurred. 
 
Figure 3-10a – Intrinsic protein fluorescence of human IgG1 at 0.25 mg/mL after light exposure and 
excitation at 295 nm. 
The black solid line represents the unstressed huAb sample, the grey solid line represents the shielded 
control sample and the dashed lines represent the light exposed sample after 1 d (red), 4 d (blue), 6 d 
(green), and 7 d (yellow). Each line represents the mean of at least two spectra recordings.  
 
Differences were additionally detected in the section of the spectra displaying 
wavelengths higher than 380 nm. The emitting fluorescence intensities of samples radiated 
4 days or longer increased in this section. This new emerging peak indicates the enhanced 
formation of dityrosine due to oxidation caused by light irradiation [Malencik et al., 1991; 
Malencik et al., 1996]. Even more, a pronounced blue shift in wavelength of the dityrosine peak 
was monitored, proving that considerable changes in the polarity of the environment appeared 
additionally. The evident formation of novel species like dityrosine accompanied by the shift of 
peak position, emphasize that oxidation processes were induced by light exposure. The intrinsic 
protein fluorescence spectra also reveal that substantial structural changes started to appear at 
day 4 of light exposure, proceeding on days 6 and 7. The positions of dityrosine peak 
determined within the samples after several days light exposure are listed in Table 3-5. 
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Table 3-5 – Results of secondary peak position from intrinsic protein fluorescence emission 
spectra of 0.25 mg/mL huAb after light exposure. 
Light exposure Unstressed 4 d 6 d 7 d Control 
Peak position 411.5 nm 423.9 nm 419.1 nm 411.1 nm 410.5 nm 
  
The second derivative UV absorbance spectra were additionally monitored to 
investigate the tertiary structure after light exposure. The resulting spectra showed no shift in 
the wavelengths of any minimum or maximum peak between 280 and 300 nm (data not shown). 
Differences were measured in the absorbance units of these minima and maxima. The 
a/b ratios calculated for the mean spectra are listed in Table 3-6. They show a significant trend 
to higher values with increasing duration of light exposure, suggesting that tyrosine residues are 
more and more exposed to the solvent [Ragone et al., 1984]. This increased exposure to the 
solvent indicates the unfolding of the human antibody. 
Table 3-6 – Results of a/b ratio determination from UV 2
nd
 derivative spectroscopy of huAb after 
light exposure. 
Light exposure Unstressed 1 d 4 d 6 d 7 d Control 
a/b ratio 1.4937 1.5771 1.8611 1.9301 2.0499 1.5152 
 
Alterations in the conformational structure of the human antibody after light exposure 
were also detected by extrinsic fluorescence spectroscopy using 20 µM ANS and a protein 
concentration of 0.5 mg/mL. The emission spectra recorded of the supernatant of centrifuged 
samples are shown in Figure 3-10b.  
 
Figure 3-10b – ANS fluorescence emission spectra of light exposed huAb samples at 0.25 mg/mL 
after excitation at 350 nm. 
The solid black line represents the unstressed huAb sample, and the solid grey line represents the control 
samples, shielded from light. The light exposed samples are shown in dashed lines: in red (1 d), in blue 
(4 d), in green (6 d) and in yellow (7 d).   
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Already after one day of light exposure the ANS fluorescence intensity is significantly 
enhanced. Between day 1 and day 4 the major enhancement of intensity was detected, 
whereas the further increases induced by the samples that were radiated even longer are 
relatively small. The positions of the ANS emission peaks are listed in Table 3-7. Ignoring the 
maximum intensity determined for the unstressed sample, a blue shift of the ANS-fluorescence 
maxima was detected. Between day 1 and day 7 a shift of nearly 10 nm was detected. The 
maximum detected in the unstressed sample might be imprecise due to the broad peak shape. 
The strong increase in intensity as well as the detected shift of the maximum peak to lower 
wavelengths indicates pronounced alterations in the protein structure and unfolding processes 
induced by light irradiation. Within the control samples shielded from light a marginal increase 
of ANS-fluorescence intensity was detected. The determination of the peak maximum of this 
sample was imprecise as well, due to the peak shape, and thus it is not mentioned in Table 3-7. 
 
Table 3-7 – Results of peak position from extrinsic ANS fluorescence emission spectra of 
0.5 mg/mL huAb after light exposure and excitation at 350 nm. 
Light exposure Unstressed 1 d 4 d 6 d 7 d Control 
Peak position 475.5 nm 486.6 nm 478.9 nm 478.5 nm 477.0 nm 481.9 nm 
 
Potential changes in the secondary structure were analyzed by FTIR spectroscopy of 
the amide I band. The second derivate spectra of the normalized zero-order spectra are shown 
in Figure 3-11. The dominating valley at 1638 cm
-1
 representing intramolecular β-sheets 
decreases with increasing light exposure. The decrease is first detectable on day 4 and 
accompanied by an increase in the range of 1650 – 1660 cm
-1
, an area that represents α-helical 
structures [Mahler et al., 2010a]. Even more, a second valley starts to form around 1634 cm
-1
, 
and the small dent at 1614 cm
-1
 is deepened and shifted to lower wavenumbers. These 
alterations indicate the formation of intermolecular β-sheet structures [Van De Weert et al., 
2005]. The section of high wavenumbers (between 1660 and 1690 cm
-1
) within the second 
derivative spectra heavily changes due to light exposure, but also in the control sample 
shielded from light radiation. These regions are assigned to various secondary structures like 
loops, β-turns, and unordered structures [Mahler et al., 2010a; Van De Weert et al., 2005]. The 
control samples show also the beginning formation of an additional band between 1620 and 
1630 cm
-1
, which is attributed to the formation of intermolecular β-sheets.  
Light exposure has a strong influence on the secondary structure of a protein leading to 
numerous alterations. In summary, the predominant β-sheet structures of the investigated 
monoclonal antibody are disturbed and accompanied by an increase in α-helical structures 
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Figure 3-11 – Second derivative ATR-FTIR spectra of light exposed huAb samples at 0.5 mg/mL. 
The spectrum of the native huAb is plotted in the black solid line. The grey solid line represents the control 
samples after 7 days of incubation. The light exposed samples are plotted in dashed lines. Red = 1 d of 
light exposure, blue = 4 d of light exposure, green = 6 d of light exposure, and yellow = 7 d of light 
exposure. 
 
3.3.4 Stability of huAb against storage at elevated temperatures 
To evaluate the influence of elevated temperatures on the stability of the human 
monoclonal antibody the samples were stored in drying a chamber at 50°C for up to 4 weeks. 
The particle numbers counted by light obscuration and the turbidity measurements are 
summarized in Table 3-8.  
Table 3-8 – Results of particle counts by light obscuration and turbidity measurements of huAb 
after storage at 50°C. 
Storage at 50°C Unstressed 7 d 14 d 21 d 28 d 
≥ 1 µm 1479 1037 863 1619 18,320 
≥ 10 µm 20 56 16 30 313 
≥ 25 µm 2 4 2 3 18 
Turbidity [FNU] 1.5 1.8 1.6 1.2 4.3 
 
Within the first three weeks of storage at 50°C, no consistent influence on the particle 
numbers of micron-sized species was detected by light obscuration. The predefined 
benchmarks of 1 µm, 10 µm, and 25 µm resulted in no significant increase. The generation of 
additional particles of those sizes was firstly detected after 28 days. Turbidity measurements 
confirmed these observations, since the turbidity remained on a nearly constant level of 1.5 ± 
0.3 FNU within 21 days, before increasing to 4.3 after 28 days of storage at 50°C. Buffer 
samples were similarly incubated for 28 days, but neither enhanced particle numbers nor 
enhanced turbidity was detectable (data not shown). In contrast, dynamic light scattering 
indicated the enhanced formation of particles already on day 21, as the results of Z-average 
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diameter and polydispersity index in Table 3-9 show. Both parameters approximately remain on 
the same level within the first 14 days, but show an elevation on day 21. The Zave diameter 
increases to 64.1 nm on day 21 and 68.5 nm on day 28. The PDI increases to 0.19 on day 28. 
Incubation at 50°C does not show enhanced tendencies to formation of subvisible particles 
within the first four weeks of storage.  
Table 3-9 – Results of Z-average diameter and PDI of huAb after storage at 50°C. 
Storage at 50°C Unstressed 7 d 14 d 21 d 28 d 
Zave 11.5 12.1 11.9 64.1 68.5 
PDI 0.04 0.03 0.09 0.18 0.19 
 
The samples were also chromatographically analyzed after centrifugation by SEC to 
determine the distribution of soluble protein species potentially generated during storage at 
50°C. The resulting chromatograms and the distribution of protein species are displayed in 
Figures 3-12 and 3-13.  
 
Figure 3-12 – Refractive index - Size exclusion chromatograms of huAb samples stored at 50°C. 
Chromatograms of huAb samples after incubation at 50°C. The solid black line represents the unstressed 
sample. The stressed sample are displayed in red (after 7 days of storage), in blue (after 14 days of 
storage), in green (after 21 days of storage), and in yellow (after 28 days of storage). 
 
The most obvious difference between the samples which can bet detected from the 
chromatograms (Figure 3-12) is the constantly decreasing height of the monomer peak eluting 
around 66 minutes. At the same time, the amount of species eluting subsequent to the 
monomer being of smaller size increases. A shoulder coupled to the monomer peak rises 
around 70 minutes and the already existing fragment peak (eluting ~76 minutes) grows. The 
marginal amounts of aggregates can hardly be detected in this Figure, but became verifiable by 
increasing the resolution (data not shown). Figure 3-13 summarizes the results from RI 
detection including all soluble species that were unambiguously detectable. In the unstressed 
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samples of huAb > 96% or monomer were detected, accompanied by 2.5% of fragments and 
negligible amounts of aggregates (< 1% in total). After 7 and 14 days of storage the total 
recovery did not significantly change. The recovery of the monomer slightly decreased to ~ 93% 
after 14 days. At the same time the amount of fragments in the samples doubled to 5% (see 
green trend line). Furthermore, a minute increase of high molecular weight (HMW) aggregates 
was detected. After 14 days 1.6% of the soluble protein fraction was HMW aggregates. 
 
Figure 3-13 – Distribution of soluble protein species in huAb samples stored at 50°C determined 
by RI detection after SEC.  
The content of the species is ranked on the left y-axis: the amount of fragments (     ), the amount of 
dimers/trimers (     ) and the high molecular weight aggregates (HMW,      ). The right y-axis ranks the 
total recovery (black squares) and the monomer recovery (red dots). The error bars represent the 
standard deviation of 3 samples. 
 
Numerous reports have shown that storage at elevated temperatures and heating 
triggers conformational changes of proteins [Carpenter, John F. et al., 1999; Vermeer et al., 
2000]. Temperature is probably the most important factor which impacts protein stability, though 
there is no general mechanism to describe the influence of temperature on protein structure 
[Wang, W., 1999]. Potential structural changes of the investigated human IgG1 antibody due to 
storage at 50°C were monitored over 4 weeks by several spectroscopic techniques. Intrinsic 
protein fluorescence resulted in marginal decreases of the emission intensity (see Figure 3-14) 
but no wavelength shift (data not shown). The main reduction of intensity was achieved 
between day 21 and day 28. The magnitudes of intensity decrease monitored at the other 
sampling time points are rather small and inconsistent. Especially between day 14 and day 21 
no substantial reduction of the emission intensity was detected. These observations suggest 
that significant unfolding processes might have started not until the last week of investigation, 
but for distinct assessment the incubation time was too short. However, 4 weeks at 50°C did not 
lead to substantial unfolding of the antibody, but slight quenching of Trp residues due to 
increasing polarity in the Trp surrounding was detected.  
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Figure 3-14 – Intrinsic protein fluorescence of human IgG1 at 0.5 mg/mL after storage at 50°C and 
excitation at 295 nm. 
The black solid line represents the unstressed huAb sample. The dashed lines represent the heated 
sample after 7 d (red), 14 d (blue), 21 d (green), and 28 d (yellow). Each line represents the mean of at 
least two spectra recordings.  
 
The 2
nd
 derivative UV absorbance spectra point in the same direction as the results 
from intrinsic protein fluorescence. Marginal differences in the spectra and the decisive 
parameters were detected until day 21. After 4 weeks of incubation at 50°C the spectra featured 
significant differences compared to the spectra of native huAb. Figure 3-15 shows the 2
nd
 
derivative spectra between 260 and 310 nm.  
 
Figure 3-15 – UV 2
nd
 derivative spectra of 0.5 mg/mL human IgG1 after storage at 50°C.                   
The solid black line represents the spectra of the unstressed huAb sample. The dashed red line 
represents the spectra after 7 days of storage at 50°C, the dashed blue line after 14 d, the dashed green 
line after 21 d, and the dashed yellow line after 28 d of storage at 50°C. 
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Slight variations in the peak height were observable and resulted in substantial 
differences in the a/b ratio, which are summarized in Table 3-10. The discrepancies between 
the a/b ratios of the unstressed sample and those samples incubated at 50°C up to 3 weeks are 
negligible, but follow the trend of reduced a/b ratios with prolonged storage. They range from 
1.5305 for the unstressed material to 1.5232 for the material after 3 weeks of storage. On top of 
that, a distinctly diminished a/b ratio of 1.3562 was determined after 4 weeks of incubation.  
Table 3-10 – Results of a/b ratio determination from UV 2
nd
 derivative spectroscopy of huAb after 
storage at 50°C. 
Storage @ 50°C Unstressed 7d 14 d 21 d 28 d 
a/b ratio 1.5306 1.5258 1.5253 1.5232 1.3562 
 
Changes of this value of tyrosine/tryptophane mixtures indicate alterations in solvent 
polarity, which are presumably induced by unfolding of the protein [Kueltzo et al., 2005]. The 
high resolution of the UV absorbance spectroscopy method enables the determination of tiny 
peak shifts of up to 0.02 nm. The sensitivity of shifts on the wavelengths of derivative peaks to 
the environmental conditions of a protein and thus to conformational changes, was observed 
decades ago [Beaven et al., 1952; Ichikawa et al., 1979]. The two minima around 285 and 
292 nm as well as the two maxima around 289 and 296 nm representing aromatic amino acids 
are typically considered. Storage at 50°C resulted in slight peak shifts to shorter wavelengths 
after 28 d of incubation (Table 3-11). A shift of up to 0.06 nm was detected potentially indicating 
a starting increase in the polarity of the environment of Tyr and Trp [Mach et al., 1994]. 
However, a prolonged incubation would have been needed to confirm these findings. 
Table 3-11 – Results of wavelength shift of peaks from UV 2
nd
 derivative spectroscopy of huAb 
after storage at 50°C. 
Storage @ 50°C Unstressed 7d 14 d 21 d 28 d 
Minimum 1 [nm] 284.58 284.56 284.56 284.56 284.50 
Maximum 1 [nm] 288.53 288.52 288.52 288.52 288.49 
Minimum 2 [nm] 292.15 292.14 292.14 292.13 292.08 
Maximum 2 [nm] 296.24 296.25 296.25 296.25 296.24 
 
Structural changes after several weeks of storing at elevated temperatures were also 
detected by ANS-fluorescence. The spectra displayed in Figure 3-16 show a constant increase 
of fluorescence intensity at the emission peak maximum. The highest magnitude of intensity 
elevation was detected between 21 and 28 days of incubation, confirming the results obtained 
from intrinsic fluorescence and 2
nd
 derivative UV absorbance.  
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Figure 3-16 – ANS fluorescence emission spectra of huAb samples stored at 50°C at 0.5 mg/mL 
after excitation at 350 nm. 
The solid black line represents the spectra of the unstressed huAb sample. The dashed red line 
represents the spectra after 7 days of storage at 50°C, the dashed blue line after 14 d, the dashed green 
line after 21 d, and the dashed yellow line after 28 d of storage at 50°C. 
 
The emission peak maxima additionally revealed a slight peak shift to longer 
wavelengths with enhanced incubation time. The detected peak positions are summarized in 
Table 3-12. The peak did not show a wavelength shift within the first week of storage at 50°C, 
but starts to move to longer wavelengths after two weeks. A maximum red shift of 4.6 nm was 
detected after 3 weeks. The emission peak detected after 4 weeks was 4.0 nm red shifted from 
the unstressed sample.  
Table 3-12 – Results of peak position from extrinsic ANS fluorescence emission spectra of 
0.5 mg/mL huAb after storage at 50°C and excitation at 350 nm. 
Storage @ 50°C Unstressed 7d 14 d 21 d 28 d 
Peak position 466.9 nm 466.9 nm 467.9 nm 470.5 nm 469.9 nm 
 
The investigations on the tertiary structure of samples of the human IgG1 antibody after 
storage at 50°C for several weeks indicated that unfolding and structural alterations of the 
protein`s conformation started. Analyzing the 2
nd
 derivative spectra of ATR-FTIR spectroscopy 
no substantial alteration of the secondary structure of the immunoglobulin was detected during 
the first three weeks of storage (data not shown). A slight change in the intermolecular β-sheet 
band around 1622 cm
-1
 was discovered after 4 weeks, suggesting structural changes in the 
molecule due to the unfolding processes determined e.g. also by fluorescence spectroscopy. 
However, the antibody revealed to be stable to storage at elevated temperatures, at least for 
several days. 
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3.4 DISCUSSION 
 
The aim of this chapter was to investigate the effect of several extrinsic stress factors 
on folding and aggregation of a human monoclonal antibody (huAb), serving as a model 
protein. Agitation, freeze-thawing, light exposure and storage at elevated temperatures were 
chosen to evaluate the stability of huAb. Multiple methods were applied to the protein to gain 
deep insight in the influence of these factors on its structure. The formation of particles due to 
the stress methods was investigated by measurements of light obscuration, turbidity and 
dynamic light scattering. No subvisible particle formation at all was detected in the IgG1 
samples after repetitive freeze-thawing. The by far fastest particle formation resulting in 
extreme numbers of subvisible particles was discovered after stirring using LO and turbidity 
measurements. The particles generated were too large for detection in dynamic light scattering 
since they precipitated and would entail miscalculation because of interfering with the Brownian 
movement. The control sample of stirred formulation buffer proved that the majority of 
generated particles were composed of protein, though abrasion of the PTFE-coated stir bar has 
to be considered a particle source as well. A slower but constant increase in particle numbers of 
nm- and µm-size was observed after shaking. All three methods to determine subvisible 
species showed consistent results, i.e. an increase in particle numbers and size. The light 
exposed samples initially do not include an enhanced subvisible particle numbers in the µm-
range, but dramatically precipitate after 6 days of irradiation. Storage at 50°C possessed 
comparable characteristics of sustained particle formation, since the loading of subvisible 
particles remains on a low level within 3 weeks and subsequently starts to increase. However, 
during the predefined incubation time no precipitation occurred, indicating that the majority of 
induced particles were much smaller than those generated by prolonged light exposure. After 6 
days of light exposure several thousand particles of ≥ 10 µm and even ≥ 25 µm were counted 
and turbidity reaches the upper limit of detection, whereas after 28 d storage at 50°C the 
numbers of two digit micrometer sized particles and turbidity are much less.  
Based on the varying observations on particle formation it is suggested, that diverging 
mechanisms can be distinguished behind the stress methods. The particle growth after light 
exposure partly follows a nucleation controlled process. Within the first 4 days no enhanced 
loading of subvisible particles in µm-range was detectable. The slightly increasing turbidity of 
the sample is accompanied by enhanced values of Zave diameter and PDI, suggesting that 
these medium sized particles between 20 and 100 nm are attributed to the minor increases in 
turbidity [Mahler et al., 2005]. Further continuation of irradiation provides numerous particles of 
several µm in size and heavy precipitation. These large and partly visible structures account for 
the tremendous turbidity increase detected in those samples. Initially, species in nm-range 
serving as nuclei are generated that become bigger and finally reach a size where precipitation 
occurs. This process of particle growth is often accelerated when the nucleus achieved a critical 
size [Philo et al., 2009]. In the light exposed samples of human IgG1 this critical size is gained 
between day 4 and day 6. The increase in subvisible particles ≥ 1 µm (but < 10 µm) proves the 
accompanying influence of the slightly enhanced temperature (35 ± 2°C) on the particle 
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formation. Unexpectedly, the impact of 7 d incubation at this temperature on particle formation 
is higher than that of 4 d incubation at this temperature plus the strong light exposure. However, 
after 7 d the particle numbers in the light exposed sample outreach the numbers in the control 
sample, indicating the additional influence of light radiation accompanied by strong 
conformational changes on the generation of particles. Furthermore, in the shielded sample 
only minor alterations in the secondary structure of the huAb and no formation of fragments or 
soluble aggregates have been detected. These results suggest that the entire vast 
modifications detected in the huAb samples after light exposure are mainly triggered by light 
irradiation. Though, a minor impact of the slightly elevated temperature in the radiation chamber 
has to be taken into consideration when evaluating the aggregation mechanisms behind.  
Accessory phenomena of the particle formation are the structural changes detected 
after light irradiation. All spectroscopic methods employed to determine alterations in secondary 
or tertiary structure of huAb yielded in substantial changes in the spectra already after 1 day of 
light exposure, thus before mentionable subvisible particle formation was detected. It is 
suggested that light exposure induces the formation of growing particles in the human IgG1 
model antibody formulation upon certain modification of the conformation of the model protein. 
Besides the conformationally modifications, chemical modifications induced by light exposure, 
such as oxidations, are conceivable as well. The detection of the dityrosine peak in intrinsic 
protein fluorescence proves this indication. However, chemical alterations were not in detail 
investigated throughout this study. It is therefore speculative on what kind of initial modification 
in the monomer the subsequent particle growth is based on. In summary: besides nucleation, a 
second mechanism is suggested to be involved in the aggregation process after light exposure. 
The strong aggregation appearing after several days of irradiation could also result from the 
chemical and physical alterations in the initial structure of the protein [Philo et al., 2009; Wang, 
2005]. 
The mechanism considered to be involved in the aggregation process elicited by 
4 weeks storage at elevated temperatures also requires conformational changes of the 
monomer. According to Philo et al. heat is a well-known stress that can promote the initial 
conformational change or partial unfolding of the monomer [Philo et al., 2009]. No increase in 
the subvisible particle content was detected during the first 21 days of incubation at 50°C, but 
slight incremental alterations of the conformational structure were discovered. Reaching a 
certain level subvisible particles arose, firstly detectable on day 21 by an enhanced Zave and 
PDI, thus representing species in nm-range. These enhancements were not accompanied by 
increases in turbidity, indicating that the generated subvisible species were rather small and 
their content in the sample is low. At the next sampling time point also µm-sized species were 
detected and came along with an elevated turbidity, attributed to the increase in size and 
numbers of particles. Concomitantly to the beginning formation of subvisible particles the 
strongest alteration in tertiary structure of the antibody was detected in the supernatant. 
However, the unfolding is rather slow and no denaturation was observed. The melting 
temperature Tm, which is the temperature at which half of the protein molecules are unfolded 
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during a thermal transition [Mahler et al., 2009], of the model antibody was beforehand 
determined by temperature dependent turbidity measurements using a UV-visible absorbance 
spectrophotometer (Agilent Technologies, Waldbronn, Germany) to be approximately 75°C 
(data not shown). Hence, the incubation was performed far below Tm of the human IgG1 and 
complete denaturation was not intended. However, partial unfolding and enhanced aggregation 
can occur to a protein when exposed to a temperature close to Tm [Chi et al., 2003a]. McCarthy 
and Drake detected aggregates by light scattering after heating an IgG to 50°C [McCarthy et al., 
1989]. They furthermore stated that heating leads to unfolding especially in the Fab parts of 
immunoglobulines enabling aggregation. Instead, the Fc parts will be exposed to the hydrophilic 
environment [McCarthy et al., 1989]. Heat might also enhance chemical degradation of proteins 
which can distort the protein conformation and amplify aggregation [Wang, 2005]. The most 
pronounced protein species that appeared from huAb after storage at 50°C were fragments. 
During this 4-week study the amount of antibody-fragments detected by SEC increased up to 
13 %, indicating the degradation of the huAb molecule by temperature. Fragmentation by heat 
treatment is also a well-known phenomenon occurring in immunoglobulins [Harpel et al., 1979; 
Lee, 2000]. Especially the IgG1 subclass has recently been shown to be more prone to 
fragmentation than other IgG subclasses [Ishikawa et al., 2010].  
Shaking and stirring are two mechanical stress conditions that were often reported to 
elicit aggregation in proteins [Kiese, 2008; Wang, W., 1999]. Comparing both agitation methods 
concerning protein stability, it was found that stirring can be much more harmful [Mahler et al., 
2005]. The resulting aggregate species generated by shaking and stirring vary substantially in 
terms of amount and size [Kiese, 2008]. Stirring and shaking of the huAb in this study provided 
similar results. The total particle numbers counted by light obscuration as well as the turbidity 
measurements indicate that shaking with a comparable agitation speed leads to weaker 
formation of particles than stirring. The size of the particles differs as well. Stirring results in 
larger particles, easily detectable by eye and by an elevated turbidity. The major step in protein 
aggregation caused by agitation is considered to be the collision of the protein molecules. Thus, 
it appears clear that especially the agitation speed and time influence the aggregation rate 
[Colombie et al., 2001]. Though theoretically agitated at the same speed substantial differences 
between shaking and stirring were discovered. The overall mechanism behind both agitation 
methods is aggregation on new emerging surfaces [Philo et al., 2009]. In case of shaking and 
stirring with Teflon
®
 stir bars, the surface is hydrophobic. Therefore, the interaction of the 
protein with the new interface is mostly driven by hydrophobic binding and leads to partial 
unfolding. Accordingly, the subsequent aggregation is again based on modifications in protein 
structure [Philo et al., 2009]. However, the detected variations in aggregate pattern after 
shaking and stirring are suggested to result on the one hand from the differences in 
hydrophobicity of the surfaces [Vermeer et al., 1998], which is considered to be much higher in 
Teflon
®
. On the other hand, slight abrasion of particles from the surface of the stir bar might 
provide nuclei and thus amplify aggregation as well. Additional stress conditions which can be 
provoked by stirring as local heat and cavitation should also be taken into consideration. Thus, 
the detrimental effects on protein stability observed by stirring are caused by a combination of 
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occurring phenomena and various underlying mechanisms are conceivable. Instead, during 
shaking a constantly renewal of air/water interfaces was created in the vials and air bubbles 
were entrained into the solution. The protein potentially can adsorb or partially unfold at these 
interfaces and the modified molecules might be transported into the solution [Henson et al., 
1970; Maa et al., 1997]. The air/water interface formation depends on the fill volume of the vial 
and aggregation caused by shaking can be heavily reduced by filling the container to the 
maximum diminishing the headspace [Kiese, 2008]. These observation indicate that 
aggregation during shaking solely relies on air/water interfaces and it can be suggested that the 
aggregation rate is therefore reduced, compared to stirring at the same speed. 
Freeze-thawing cycles of the human antibody formulation served no increase in 
subvisible or visible particles and no substantial changes in protein conformation. The most 
critical phenomena that appear during freeze-thawing are concentration of the protein itself and 
osmolytes, resulting pH shifts and the formation of ice/water interfaces [Carpenter, John F. et 
al., 1988; Kueltzo et al., 2008; van den Berg et al., 1959]. The IgG1 can be suggested to be 
very robust and stable to freeze-thawing and the meanwhile appearing stress conditions. The 
formulation buffer of huAb contained mannitol, a polyhydric alcohol and isomer of sorbitol. 
Polyhydric alcohols are well-known cryoprotective substances [Arakawa et al., 1991; Carpenter, 
John F. et al., 1988]. They were shown to preferentially being excluded from the protein`s 
surface in aqueous solution [Timasheff, 1995]. This phenomenon accounts for their 
cryoprotective capacity [Carpenter, John F. et al., 1988].  
A summarizing overview of all stress methods and the resulting alterations in the 
amount of particles, aggregates and fragments as well as the conformational changes is 
provided in Table 3-13. 
Table 3-13 – Overview of resulting physico-chemical alterations in huAb after stress studies.  
Stress 
method 
Enhanced 
number of 
particles 
Formation of 
soluble 
aggregates 
Formation of 
fragments 
Altered 
secondary 
structure 
Altered tertiary 
structure / 
unfolding 
Stirring ++ - - - + 
Shaking + - - - - 
Freeze-
Thawing - - - - - 
Heat + - + + + 
Light ++ + + ++ ++ 
   -  No substantial alterations detected 
  +  Moderate alterations detected 
++  Strong alterations detected 
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3.5 CONCLUSION 
 
A variety of stress conditions was investigated and found to induce structural 
modifications and the formation of aggregates in the human antibody. In perspective of the 
planned in vivo studies investigating the immunogenicity of protein aggregates, a huge 
spectrum of aggregates of different sizes and different conformational structures of a 
monoclonal antibody was requested. Stress conditions found to be capable to reproducibly 
generate a substantial amount of aggregates within a short time will now be transferred to a 
murine antibody.  
The chosen stress conditions are all considered to be relevant for protein 
manufacturing processes. The aggregate pattern within the stress samples strongly differs 
according to applied conditions and time. Except repetitive freeze-thawing, all other stress 
methods were found to increase the number of subvisible particles in the antibody formulation 
and lead to structural changes of the protein. Therefore, freeze-thawing was decided to be 
omitted in the follow-up studies with the murine protein. 
 Subvisible particles are currently heavily discussed to be related to immunogenicity 
[Carpenter et al., 2009; Cromwell et al., 2006; Hermeling et al., 2004; Rosenberg, 2006]. 
Stirring was found to be the fastest method to solely generate particles. In comparison to 
shaking, the numbers and sizes of particles generated were larger after stirring. Both agitation 
methods were found to result solely in the formation of insoluble species, without formation of 
smaller soluble aggregates detectable by SEC. However, stirring as well as shaking were 
decided to be valuable methods to generate aggregates for immunogenicity studies and thus 
should be transferred to the murine antibody. 
Besides particle formation, during light exposure and storage at 50°C soluble species, 
were generated and discovered by size exclusion chromatography. Whereas in the heated 
samples the monomer was only accompanied by fragments, the light exposed samples 
contained soluble aggregates as well. Therefore light exposure of only a few days was the only 
stress condition to induce soluble aggregates. Furthermore, the most impressive modifications 
of secondary and tertiary structure were detected after light exposure, including oxidation 
products. Mass spectrometry as for example reported by Schöneich et al. potentially could 
provide detailed information about the primary structure of the resulting products [Schoeneich, 
Christian et al., 2006]. Since protein aggregates induced by light oxidation are discussed to be 
immunogenic as well [Schoeneich, 2010], this method should also be transferred to the murine 
antibody. Though storage at elevated temperatures for 4 weeks did not reveal huge amounts of 
aggregates, heating should also be a method tested with the murine antibody. As for all other 
methods, the stress conditions might then be adapted.  
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4  AGGREGATION STUDIES ON A MURINE 
MONOCLONAL ANTIBODY 
 
 
4.1 INTRODUCTION 
 
The structural diversity within the category of monoclonal antibodies is huge. Two major 
features of antibody structure should be mentioned: (i) The isotype of monoclonal antibodies, 
which depends on the glycosylation pattern of the Fc part of the molecule [Janeway et al., 
2004], varies between the market products. So far, all mAb products on the market belong to 
the immunoglobuline G subclass [Roskos et al., 2004; Wang, W. et al., 2006]. Most therapeutic 
mAbs are of IgG1 isotype, but IgG2 (Muromonab, Denosumab) and IgG4 (Natalizumab) 
subclasses are used as drug molecules as well [Datamonitor, 2010]. (ii) The structures of the 
monoclonal antibodies can also be classified according to the content of mouse protein in the 
molecules. Depending on the percentage of murine protein mAbs are classified in murine, 
chimeric, humanized and fully human antibodies. These two classifications provide only an 
extract of the manifold discriminative structures of mAbs. The discrepancies within the class of 
antibodies indicate that variations in the stability of the molecules, in their tendencies to 
aggregate, and finally in the resulting immunogenicity could appear. 
It is the overall objective of this thesis to elucidate the immunogenicity of aggregates 
from a murine monoclonal antibody in mice. In this part of the work, the detailed aggregation 
studies on the human model antibody discussed in Chapter 3 will be transferred to the 
corresponding murine monoclonal antibody. Slight differences in aggregation between both 
molecules might be expected, since the fully human model antibody is of IgG1 subclass, 
whereas the murine antibody employed is of IgG2c subclass. However, the overall aggregation 
behaviors of both antibodies are expected to be rather similar. Thus, this chapter additionally 
aims to ensure similar aggregation patterns of both antibodies, confirming an appropriate 
transferability and prediction of immunogenicity results to a human antibody in human.  
Another objective of this chapter is to implement methods to generate aggregates of 
the mouse muAb, which in the next step will be used in the preparation of an in vivo study on 
immunogenicity. A sufficient amount of aggregates reproducibly generated in a proper time 
were defined to be key parameters for the methods.  
 
 
 
 
 
 
  ANGELIKA FREITAG        DISSERTATION       AGGREGATION STUDIES ON MURINE MAB 
 
72 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Materials  
4.2.1.1 Murine IgG2c antibody (muAb) samples 
A murine monoclonal IgG2c antibody (muAb) was kindly provided by Abbott GmbH & 
Co. KG. The antibody solution applied in the experiments was diluted to a concentration of 
10 mg/mL in a 20 mM histidine formulation buffer at pH 6.0. Compared to the aggregation 
studies on the human model antibody in Chapter 3, the concentration was enhanced from 4 to 
10 mg/mL aiming to generate higher total amounts of aggregates sufficient for preparative 
separation from accompanying protein species. At the same time the sample volume was 
reduced from 3 mL in 6 R vials to 1 mL in 2 R vials. Both conditions should have comparable 
filling volume to head space volume ratios, that otherwise can strongly impact the aggregation 
behavior of the antibody at the air/water interface. The IgG2c stock solution had an initial 
concentration of 24 mg/mL and was stored at -80 °C in the deep freezer. Prior to use, the 
formulation buffer was filtrated using a 0.2 µm sterile syringe filter made of cellulose acetate 
(VWR International, Darmstadt, Germany). 1 mL of the antibody solution was filled into cleaned 
and sterilized 2 R vials made from glass type 1 (Schott AG, Mainz, Germany), sealed with 
Teflon
®
-faced rubber stoppers (West Pharmaceuticals Services, Eschweiler, Germany) and 
crimped. All antibody samples were prepared under aseptic conditions. Highly purified water 
generated in-house was used for the preparation of samples and buffers (PURELAB Plus 
instrument (USF Elga, Celle, Germany)). All substances used were of analytical grade. 
4.2.2 Methods to provoke protein instability  
4.2.2.1 Stirring stress 
Stirring stress of the muAb was performed in 2 R glass vials filled with 1 mL of a 
10 mg/mL antibody solution. The same stirrer, stir bars and incubation temperature as in 
Chapter 3 were used to conduct this study. To accelerate the formation of particles speed was 
set to 400 rpm (instead of 240 rpm in huAb studies) and the final sampling time point was set to 
24 hours of stirring. One vial was selected and removed after 4 h and another one after 6h of 
stirring. After the entire incubation time a triplicate of samples was left and used for more 
comprehensive analytics. For control experiments, the pure buffer solution was stirred for 24 h 
under the same conditions as well. 
4.2.2.2 Shaking stress 
Shaking stress of the antibodies was performed in 2 R glass vials filled with 1 mL of a 
10 mg/mL antibody solution. A VWR Microplate Shaker (VWR International, Darmstadt, 
Germany) was used for shaking the vials up to 48 hours. One sample was additionally 
investigated after 24 h, whereas a triplicate of vials was analyzed after 48 hours. Like in the 
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stirring experiments the agitation was accelerated to 400 rpm, compared to the previous huAb 
studies. The arrangement of the vials on the shaker was identical to the huAb samples. For 
control experiments, the pure buffer solution was shaken for 48 h under the same conditions as 
well. 
4.2.2.3 Light exposure 
The same settings of the Suntest CPS radiation chamber (Heraeus Holding, Hanau, 
Germany) as in the previous study were used for irradiation. 1 mL of the samples containing 10 
mg/mL of protein were filled in 2 R glass vials and placed in the center of the radiation chamber 
in an upright position. Sampling of the vials was performed after 24 h and 48 h (n=1) and finally 
after 72 h (n=3). These time points were selected to focus the investigation on conformational 
alterations and the formation of soluble aggregates and fragments, since the huAb started to 
precipitate after 4 d (96 h) of light exposure. For size exclusion chromatography analysis 10 µL 
of light exposed sample were withdrawn of the remaining three vials after 65 hours. 
Additionally, the formulation buffer was exposed to light as well and sampled at the same time 
points. For control experiments, a triplicate of vials completely shielded with aluminum foil was 
included in the study, serving as control for the slight temperature increase (35 ± 3°C) during 
radiation and was sampled after 72 h of incubation.  
4.2.2.4 Temperature stress 
Heating was performed in 2 R glass vials filled with 1 mL of a 10 mg/mL antibody 
solution. The vials were incubated in cabinet dryers of a fixed temperature of 50°C for up to 27 
days. Every other week one vial was removed (after 7, 14, 21 days). Finally, a triplicate of vials 
was incubated 27 days. The melting temperature (Tm) of the murine IgG2c was 65.9°C 
determined by micro differential scanning calorimetry (µ-DSC) (data not shown) thus several 
degrees above the predefined incubation temperature. For control experiments, the pure buffer 
solution was incubated 27 days at 50°C as well. 
4.2.3 Methods to determine protein stability 
4.2.3.1 Light obscuration 
Light obscuration (LO) measurements were conducted with a PAMAS-SVSS-C Sensor 
HCB-LD 25/25 (Partikelmess- und Analysensysteme GmbH, Rutesheim, Germany) to quantify 
subvisible particles between 1 and 200 μm. Due to limited volume, the muAb samples were 
diluted 1:5 using placebo formulation prior to analysis. Please refer to section 3.2.3.1 for 
detailed parameters of the LO measurements.  
4.2.3.2 Turbidity  
The settings for turbidity measurements are described in section 3.2.3.3. 
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4.2.3.3 Size exclusion chromatography 
Concentrations of soluble aggregates, fragments, and monomeric protein were 
measured by size exclusion chromatography on an Agilent system equipped with RI and UV 
detection (Agilent Technologies, Palo Alto, USA) as well as a multi angle laser light scattering 
detector (MALLS) (DAWN EOS, Wyatt Technology Europe GmbH, Dernbach, Germany). A 
Superose 6 10/300 GL column (GE Healthcare, Little Chalfont, UK) was used as solid phase. 
Further settings to conduct SEC measurements are equal to those described in section 3.2.3.4 
for the huAb studies. 
4.2.3.4 Intrinsic protein fluorescence spectroscopy 
The settings for intrinsic protein fluorescence spectroscopy measurements are 
described in section 3.2.3.5. The sample concentration was changed to 0.1 mg/ml for muAb 
samples, unless otherwise mentioned. 
4.2.3.5 Extrinsic protein fluorescence spectroscopy 
The settings for extrinsic protein fluorescence spectroscopy measurements with ANS 
are described in section 3.2.3.6.  
4.2.3.6 Fourier transform infrared spectroscopy (FTIR) 
The settings for Fourier transform infrared spectroscopy measurements are described 
in section 3.2.3.7.  
4.2.3.7 High resolution UV absorbance spectroscopy  
The settings for high resolution UV absorbance spectroscopy measurements are 
described in section 3.2.3.8.  
 
4.3 RESULTS        
  
 
4.3.1 Formation of subvisible particles of the murine IgG2c antibody (muAb) 
The formation of particles in the muAb formulation in the micrometer range was 
determined by light obscuration. One sample of each stress condition was measured after the 
entire incubation time. The highest numbers of subvisible particles ≥ 1 µm were generated by 
stirring. The total particle numbers counted were three times higher than after shaking, and ten 
times higher than after heating. The overall increase in particle loading after stirring was 
accompanied by numerous particles larger than 10 µm and 25 µm. After 72 h of light exposure 
the detected total numbers of subvisible particles were on a comparable level to the total 
numbers after 48 h of shaking. However, the numbers of particles ≥ 10 µm and ≥ 25 µm 
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exceeded those generated by shaking. Table 4-1 and Figure 4-1 summarize the cumulative 
particle counts in muAb samples. The particle numbers counted in the corresponding control 
samples containing the formulation buffer are not included. None of the stressed buffer samples 
resulted in a substantial increase in subvisible particles or turbidity. 
Table 4-1 – Numbers of subvisible particles in murine IgG2c samples counted by light obscuration. 
Sample 
Number of Particles 
≥ 1 µm 
Number of Particles 
≥ 10 µm 
Number of Particles 
≥ 25 µm 
Unstressed 2,786 29 7 
Stirring 24h 234,341 50,014 1,267 
Shaking 48h 78,456 1,143 57 
Light exposure 72h 61,617 1,650 372 
Heat 27d 21,493 326 24 
 
 
 
Figure 4-1 – Particle size distribution of murine IgG2c samples detected by LO. 
                   A) Particles ≥ 1 µm      B) Particles ≥ 10 µm     C) Particles ≥ 25 µm 
The unstressed samples are shown in black (     ), the heated samples are shown striped (      ), the light 
exposed samples are shown in light grey (     ), the shaken samples are shown in grey (     ) and the stirred 
samples are shown in dark grey (     ). The error bars represent the standard deviation of 3 measurements. 
 
An overview of the determination of the turbidity of the samples is provided in Table 4-
2. Confirming the results from light obscuration, the stirred samples were detected to be most 
turbid. After 24 hours of shaking the cloudiness of the samples slightly increased and a turbidity 
of 7.55 ± 2.86 FNU was detected. 27 days of storage at 50°C did not increase the turbidity of 
the murine IgG2c antibody formulation and according to the European Pharmacopoeia the 
samples appeared clear [PhEur 2.2.1., 2011].  
 
 
A) B) C) 
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Table 4-2 – Turbidity measurements of muAb samples after stressing. 
 
Unstressed Stirring 24h Shaking 48h 
Light 
exposure 72h 
Heat 27d 
Turbidity 
[FNU] 
1.20 ± 0.12 87.62 ± 31.48 7.55 ± 2.86 4.40 ± 2.31 1.27 ± 0.30 
 
4.3.2 Formation of soluble aggregates of the murine IgG2c antibody (muAb) 
Size exclusion chromatography was used to identify and quantify non-particulate 
protein species accompanying the monomeric antibody, such as fragments and aggregates. 
Repeated samplings were performed for each chosen stress condition and hence the progress 
in size distribution of soluble species was monitored. Figure 4-2 provides an overview of the 
total recoveries after all stress conditions determined by SEC.  
  
Figure 4-2 – Recoveries of soluble protein species after stressing muAb – determined by SEC. 
The total recoveries after stirring (red), shaking (black), light exposure (blue) and heating (green) are 
shown compared to the incubation time (time axis not true to scale). A triplicate of samples was analyzed 
and the error bars represent the standard deviation of n=3. 
 
Stirring the murine antibody with 400 rpm initiated a considerable loss of total protein 
recovery in SEC. After 24 hours of stirring 43 ± 19 % of the original protein content was 
detected yet. Reviewing the tremendous increase in subvisible particles and turbidity in these 
samples, the formation of insoluble protein species is suggested. The centrifugation of the 
samples prior to injection to the SEC column separated these species from the solution finally 
injected.  
The aggregation studies with the human IgG1 antibody previously described also 
revealed a formation of insoluble protein species from shaking, though not as incisive as from 
stirring. Shaking the murine antibody with 400 rpm also initiated a steady loss of total protein 
recovery in SEC. After 48 hours of shaking 84 ± 4 % of the injected protein mass was detected 
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by UV absorption at 280 nm. Similarly to stirring, the formation of subvisible particles 
discovered by LO and turbidity measurements confirm the findings. Both methods, shaking and 
stirring, did not initiate the formation of fragments or soluble aggregates feasible to be 
separated by SEC. The UV 280 nm chromatograms did not show any new emerging peaks 
(data not shown).  
During storage of the antibody at an elevated temperature of 50°C the total protein 
recovery decreased within the first week to 77 ± 4 % (see Figure 4-2). Subsequently, it 
approximately remains on this level during the next two weeks, and further drops until day 27 
reaching 59 ± 1 % of total recovery.  
The total recoveries determined in the light exposed samples revealed a constantly 
decreasing profile up to the final incubation time of 72 h.  
Comparing the kinetics in the loss of total recovery between all stress conditions 
obviously stirring appears to be the fastest method to generate huge amounts of insoluble 
species which cannot be detected by SEC anymore. A drastic but slower loss of total recovery 
was determined after light exposure as well, whereas shaking and storage at 50°C revealed a 
very slow reduction of total recovery within the first days.  
 
Figure 4-3 – Distribution of soluble protein species in muAb samples stored at 50°C determined by 
UV detection after SEC separation. 
The UV chromatograms of the native muAb (red line) and the muAb after 27d of storage at 50°C (black 
line) are scaled on the left y-axis. The molar masses determined are scaled on the right axis. 
 
The incubation at 50°C additionally led to the formation of additional species of lower 
and higher molecular weight detected by UV 280 nm. The molar mass determination of this 
peak indicated it to be formed by fragments (~42 kDa). The main peak comprised 85 % of the in 
total recovered soluble protein and represented the monomeric muAb approved by a molar 
mass determination of ~138 kDa. Furthermore, two species of higher molecular weight could be 
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differentiated due to retention time (see Figure 4-3). A small fraction eluting around 27 – 28 
minutes was detected in UV and supposed to be dimers and/or trimers, though for molar mass 
determination by MALLS the peak was undersized. Besides, oligomers were detected, eluting 
in a broad peak prior to the dimers/trimers and the monomer. A molar mass of ~2 MDa was 
determined in a narrow section in the center of the peak. A broad size distribution of species is 
suggested to form this peak. Figure 4-4 provides the overview of the different species formed 
during storage at 50°C. The maximum of soluble aggregates was detected after 2 weeks of 
storage, subsequently dropping simultaneous to the loss of total recovery. 
 
Figure 4-4 – Distribution of soluble protein species after heating muAb – determined by SEC. 
The total recovery of soluble species is shown by the red squares, scaled on the right y-axis. The white 
bars represent the amount of species of lower molecular weight (fragments), the striped bars represent 
the monomer, the checkered bars represent small aggregates and the black bars represent oligomers. 
The error bars show the standard deviations of n=3 samples.  
 
Soluble aggregates of the murine IgG2c antibody were as well generated by light 
exposure. The samples irradiated by light feature the quick formation of soluble species of both 
lower and higher molecular weight. The histidine containing formulation buffer implied the rising 
of a variety of peaks eluting between 38 and 52 minutes that are also seen in control samples 
of light exposed buffer. Figure 4-5 exemplarily displays the chromatogram after 72 h of light 
exposure overlaid to the native muAb sample and the shielded control sample. The formulation 
buffer degraded by light exposure is shown as well. 
The majority of the total area under the curve after 72 h of light exposure eluted prior to 
the monomer peak. These larger molecular weight species are separated in a sharp peak 
eluting after 15 minutes and a broad peak eluting between 17 and 28 minutes. The molar mass 
within these peaks revealed approximations of 1.5 to 3 MDa (see Table 4-3). Besides the 
generation of huge amounts of aggregates, the originally detected peak representing fragments 
of muAb raised as well. Within the control samples (shielded from light but exposed to the 
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elevated temperature of ~35°C) 2.5 % lower molecular weight species but no species of higher 
molecular weight (aggregates) were detected.  
 
  
Figure 4-5 – Distribution of soluble protein species of muAb samples after light exposure 
determined by UV detection after SEC separation. 
The UV 280 nm chromatograms represent the native murine antibody (black line), the control samples 
shielded from light but incubated 72h (blue line), and the sample after 72h of light exposure (red line). The 
grey line shows the chromatogram of light exposed formulation buffer (not true to scale). 
 
Table 4-3 – SEC: Molecular weight approximations and area percentages (UV) of muAb samples. 
Sample LMW (Fragments) Monomer HMW 1 HMW 2 
MW % MW % MW % MW % 
Native muAb 50 kDa 1.2 % 124 kDa 98.8 % - - - - 
Control shielded 
from light 
38 kDa 2.5 % 123 kDa 97.5 % - - - - 
72 h light 
exposure 
n/a 4.0 % n/a 9.2 % 2.7 MDa 50.4 % 1.6 MDa 36.4 % 
 
The distribution of soluble protein species as a function of incubation time is shown in 
Figure 4-6. Throughout the investigated 72h of light exposure the majority of remaining soluble 
protein species is represented by higher molecular weight species (aggregates) which were not 
detectable before irradiation. After the entire time of light exposure, 88.5 ± 0.2 % of aggregates 
were detected within the 24.3 ± 0.7 % of total protein that could be recovered. The rest was 
already precipitated into particles. The percentage of aggregates steadily increased during 
irradiation, whereas the monomer content coincidentally decreased. At the same time the 
amount of fragments in the samples remains more or less constant between 5.6 and 8.8 %.  
HMW 1 HMW 2 LMW Buffer degradation products 
Monomer 
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Figure 4-6 – Time dependent distribution of soluble muAb species determined by SEC after light 
exposure. 
The left y-axis scales the recovery of the different species: fragments (white bars), monomer (striped bars) 
and aggregates (black bars). The right y-axis scales the total recovery displayed by the red triangles. The 
error bars represent the standard deviation of triplicate measurements. 
 
4.3.3 Modifications in the structure of the murine IgG2c antibody (muAb) 
In this section the structural investigations on muAb using spectroscopic methods such 
as 2
nd
 derivative UV absorbance, intrinsic and extrinsic (ANS) fluorescence and FTIR 
spectroscopy are briefly described. Table 4-4 provides a short summary of the results from 
spectroscopic methods.  
Table 4-4 – Overview of results of spectroscopic investigations of stressed muAb.  
Stress method 2
nd
 derivative UV Intrinsic 
fluorescence 
ANS 
fluorescence 
FTIR 
Stirring - ++ ++ + 
Shaking - + - + 
Heat + ++ ++ ++ 
Light ++ n/a n/a ++ 
   -  No substantial alterations detected   
  +  Moderate alterations detected 
++  Strong alterations detected 
 
4.3.3.1 Structural modifications of muAb after stirring and shaking 
The detected alterations in the structure of muAb after stirring involve three categories:  
(i) Minor changes in the tertiary structure of muAb were detected after 24h of stirring by reduced 
intrinsic fluorescence intensities but at the same time no remarkable changes in 2
nd
 derivative 
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UV absorbance spectroscopy were detected. (ii) A significantly enhanced probability of 
hydrophobic interactions with ANS after stirring was shown by extrinsic fluorescence. (iii) The 
susceptibility of the secondary structure of muAb to stirring was indicated by a decrease of 
intramolecular β-sheet structures in FTIR spectroscopy data. 
In comparison, after shaking also a slightly decreased intensity of intrinsic fluorescence 
and changes in the 2
nd
 derivative FTIR spectra were detected, but no increase in ANS 
fluorescence spectroscopy. Thus, the conformational changes and unfolding procedures after 
stirring of muAb are more pronounced than after shaking muAb. However, both stress methods 
entail modifications in the secondary and tertiary structure of the antibody.  
4.3.3.2 Structural modifications of muAb after storage at 50°C 
Several weeks of storage at 50°C led to enhanced changes in the structure of the 
murine antibody. The impact of heat on the tertiary structure was detected by a reduced 
intrinsic protein fluorescence as well as by changes in the a/b ratio of the 2
nd
 derivative UV 
absorbance spectra. These changes in tertiary structure were accompanied by an increase in 
ANS fluorescence with a minute blue shift of the peak maximum, that indicate unfolding of the 
antibody and hydrophobic surface. By FTIR spectroscopy distinct changes in the secondary 
structure of the muAb were shown.  
4.3.3.3 Structural modifications of muAb after light exposure 
The exposure of the murine antibody formulated in 20 mM histidine to light entailed an 
increasing yellow staining of the samples. The staining derived from the placebo formulation, 
since the control samples of placebo solution exposed to light were equally colored. With 
prolonged incubation time the intensity of the staining increased. Since this phenomenon was 
not observed in the human antibody samples that were formulated in a citrate-phosphate buffer 
with mannitol, it can be assumed that the coloring is related to oxidation of the histidine in the 
placebo formulation. This side effect of the irradiation interfered with several analytical methods, 
like fluorescence and UV absorbance spectroscopy measurements. Fluorescence 
measurements could not be conducted at all, whereas 2
nd
 derivative UV absorbance 
spectroscopy was possible for the samples after 24 h and 48 h of light exposure. Already within 
this incubation time a tremendous alteration in the a/b ratio was detected suggesting a distinct 
modification in tertiary structure of light exposed muAb. Furthermore, 2
nd
 derivative FTIR 
spectroscopy revealed significant changes in the secondary structure such as the formation of 
α-helices in the antibody.  
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4.4 DISCUSSION 
 
Four different stress methods aiming to generate aggregates of a murine IgG2c 
antibody were investigated. All methods elicited aggregation of the antibody and thus are 
evaluated to be suitable for preparative generation of larger amounts of aggregates.  
Table 4-5 provides an overview of the classification of physico-chemical changes on 
the muAb molecule caused by the stress conditions. 
Table 4-5 – Overview of resulting physico-chemical alterations in muAb after stress studies.  
Stress 
method 
Enhanced 
number of 
particles 
Formation of 
soluble 
aggregates 
Formation of 
fragments 
Altered 
secondary 
structure 
Altered tertiary 
structure / 
unfolding 
Stirring ++ - - + + 
Shaking + - - + + 
Heat + + + ++ ++ 
Light + ++ + ++ ++ 
   -  No substantial alterations detected 
  +  Moderate alterations detected 
++  Strong alterations detected 
 
Agitation of muAb by stirring and shaking particularly induces the generation of 
particulate protein aggregates. At a similar agitation speed stirring with PTFE – coated stir bars 
was found to be more efficient in aggregation than shaking, resulting in faster formation of 
higher particle numbers, accompanied by a loss of soluble protein content. Furthermore, no 
increased particle loading was detected in the buffer formulation (either stirred or shaken). 
Therefore, it can be concluded that the majority of particles is composed of protein. Though no 
soluble aggregates were detected by SEC in either sample after agitation modifications in the 
protein`s secondary and tertiary structure were indicated. Again the stirred samples revealed 
stronger changes after 24 hours than the shaken samples after 48 hours of incubation. After 
stirring the most severe disparities in the parameters for protein conformation were discovered 
in the ANS fluorescence spectra. Already after 4 h of stirring a considerable increase in ANS 
fluorescence was detectable, suggesting the exposure of hydrophobic moieties and thus 
unfolding of the antibody. At the same time it was found from the 2
nd
 derivative FTIR spectra 
that the unfolding is accompanied by alterations in secondary structure. Interestingly, the 
shaken muAb samples show similar changes in 2
nd
 derivative FTIR spectra, but no differences 
in ANS fluorescence and 2
nd
 derivative UV absorbance spectra were detected at all. Therefore, 
it can be assumed, that shaking the protein for up to 48 h does not imply substantial unfolding 
expressed by the enhanced exposure of hydrophobic patches. However, a minor quenching of 
the tryptophane fluorescence was found which might be considered as precursor for unfolding 
when shaking is prolonged. Regarding the five aggregation mechanisms widely accepted in 
biopharmaceutical research [Philo et al., 2009], both stress methods, shaking and stirring, are 
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assumed to be at least partly based on the interaction between the protein and surfaces. The 
air-water interface enables an enrichment of protein molecules that potentially can involve 
unfolding [Chi et al., 2003a; Manning et al., 1995]. During stirring the PTFE surface of the stir 
bars might additionally serve as areas of protein enrichment. Such resulting assemblings of 
mostly native antibody molecules in literature are assumed to be weak and might be resolvable. 
Kiese et al. reported that insoluble aggregates of a monoclonal antibody vanished during 
storage, indicating the reversibility of the assembling [Kiese et al., 2010].   
The storage of the murine IgG2c antibody at an elevated temperature of 50°C entails 
the formation of soluble as well as insoluble aggregates. The distribution of protein species 
detected by SEC indicates the growth of aggregates gaining an intermediate size of soluble 
oligomers before exceeding the benchmark and forming insoluble oligomers. Since the 
monomer content is only slightly reduced during 27 d of incubation, it is suggested that the 
formation of conformationally altered structures leads to aggregation and later on small 
oligomers tend assemble to large aggregates. The protein`s structure was found to be 
considerably altered to an increasing extent during storage at 50°C. The characteristic 
secondary structure of the antibody changed and substantial unfolding including the exposure 
of hydrophobic moieties to the surface was proven. Hence, the aggregation mechanism based 
on conformationally altered structures is definitely involved in the formation of aggregates 
during storage at 50°C [Kendrick et al., 1998; Krishnamurthy et al., 2002; Krishnan et al., 2002; 
Wang, 2005]. However, the generation of remarkable amounts of aggregates took several 
weeks which is disadvantageous for the aimed repeated preparation of aggregate samples for 
in vivo studies.  
Similar to the human model antibody (see previous Chapter 3) light exposure induces 
vast structural modifications and strong aggregation in the murine antibody as well. Huge 
percentages of the total amount of protein were incorporated in aggregates during light 
exposure. Size exclusion chromatograms showed a strong reduction of monomeric species 
coincidental with a steady elevation of the amount of soluble oligomers. At the same time the 
total recovery of soluble protein species drastically decreased. Besides, the exposure to light 
results in alterations of the histidine containing formulation buffer as well. Presumably the 
histidine is oxidized by light. The distribution of protein species after light exposure is different to 
the muAb samples stored at 50°C, where the oligomer content in the soluble fraction is reduced 
with increasing formation of insoluble species and the monomer content remains rather stable. 
Therefore, the mechanisms behind differ as well. The nucleation theory reported in literature 
[Chi et al., 2003b; Philo et al., 2009] is assumed to be part of the underlying aggregation 
mechanism during light exposure. The soluble oligomers are assumed to serve as nuclei 
interacting with monomeric antibody. This interaction leads to growth and subsequently the 
formation of particulate aggregates. At the same time, the amount of oligomers in the remaining 
soluble fraction does not drop but slightly increase, indicating that no association between 
oligomers occurred. However, the immense structural modifications proven by spectroscopic 
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methods indicate the involvement of altered conformations in aggregation too. A combination of 
several aggregation mechanisms has to be assumed.  
Regarding the previous study performed with the model antibody (see Chapter 3), the 
behavior of both immunoglobulines under similar stress conditions is concluded to be very 
much comparable. The human IgG1 as well as the murine IgG2c are prone to the formation of 
subvisible particles by stirring. Both agitation procedures performed during these studies, 
stirring and shaking, had only minor impact on the conformation of the IgG`s, whereas heating 
and light exposure resulted in significant alterations of their secondary and tertiary structures 
and unfolding. The most impressive formation of soluble protein aggregates was triggered by 
light exposure in both cases. However, some substantial differences between both antibodies 
have to be mentioned as well. Storage at 50°C for several weeks resulted in strong 
fragmentation of the human antibody but not in the murine antibody. This finding can be 
explained by the higher susceptibility of the IgG1 isotype to fragmentation as described by 
Ishikawa et al. [Ishikawa et al., 2010]. Instead, in the murine antibody higher amounts of soluble 
aggregates were detected after storage at 50°C. These discrepancies can be assumed to 
depend on the different Tm and thus the unfolding of the proteins. The different formulation 
buffers also have to be taken into consideration when comparing the aggregation behaviors of 
both IgG`s. It can be concluded that the histidine in muAb formulation is oxidized during light 
exposure [Huvaere et al., 2009]. The degradation products of histidine have a major impact on 
the analytical methods to evaluate the modifications appearing in muAb samples during light 
exposure. 
 
4.5 CONCLUSION 
 
A variety of methods to reproducibly generate aggregates in a human model IgG1 
antibody was successfully transferred to a murine IgG2c antibody. Furthermore, the analytical 
tools to detect changes in protein structure were transferred as well.  
Comparing the results of the murine IgG2c antibody to the aggregation studies on the 
model human IgG1 antibody in chapter 3, it can be concluded that the characteristics of the 
formulations after stressing are very similar. Both molecules form more or less only insoluble 
aggregates during agitation stress, with stirring being much more efficient than shaking. Both 
molecules are prone to conformational alterations by light exposure, forming huge amounts of 
soluble oligomers amongst others. After storage at 50°C some differences can be discriminated 
between huAb and muAb. The murine antibody seems to be more susceptible for the elevated 
temperature and revealed more distinct changes. This can be explained by the lower Tm of the 
murine molecule.  
In the murine antibody formulation, which is aimed to be used in subsequent in vivo 
studies, all investigated stress procedures induced the formation of aggregates. After certain 
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incubation time all four methods led to the formation of insoluble aggregates, namely subvisible 
particles. Besides, heavy modifications of protein structure were detected after storage at 50°C 
and after light exposure. The latter was also found to be the only procedure leading to high 
amounts of soluble aggregates. The next chapters will deal with the preparative separation of 
these species from monomer and fragments.  
Regarding all analytical results characterizing the muAb samples, tremendous 
discrepancies between the stress methods were discovered, which was strongly desired 
concerning the planned in vivo studies. However, separation of the aggregated species and an 
affiliated characterization of these aggregate need to be done prior to animal studies.  
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5  FRACTIONATION OF PROTEIN AGGREGATES OF 
A HUMAN MONOCLONAL ANTIBODY BY AF4 
 
 
5.1 INTRODUCTION 
 
The aim of this study was to develop a preparative AF4 method to separate soluble 
aggregates of a monoclonal antibody from the concurrently existing monomeric species and 
fragments in preparation of an in vivo study. A human monoclonal antibody of IgG1 isotype 
(huAb) should first be utilized for method development and optimization. This step aims to 
achieve a suitable concentration of a certain protein aggregate that is stable during several 
days of storage. The final concentration of the protein aggregates after fractionation should at 
least exceed 250 µg/mL, due to limited volumes that can be administered subcutaneously. The 
separated fractions were characterized as far as possible. Furthermore, it was checked whether 
those aggregates separated from concomitant protein species show a tendency to dissociate 
during storage. Later on, the entire procedure was transferred and reassigned to a mouse 
monoclonal antibody (muAb) and the immunogenicity of these aggregates was evaluated in an 
animal study. -80°C and 2-8°C storage were chosen as appropriate conditions for the 
preparation of in vivo studies. 
Due to the investigations on various methods capable of inducing aggregation in the 
model huAb (see chapter 3 of this thesis), light exposure was utilized to provide a suitable 
distribution of soluble aggregates for this study. It was shown that the conditions of irradiation 
resulted in abundant amounts of huAb-oligomers that were differentiable by SEC. Therefore, a 
separation via asymmetrical flow field-flow fractionation seemed to be feasible as well.  
5.1.1 The use of asymmetrical flow field-flow fractionation (AF4) to separate 
protein aggregates 
Recently, AF4 is increasingly used as analytical tool to separate different species of 
various materials according to their size. A major benefit of the technique is the broad size 
range that can be covered. The field of application starts in the low nanometer range, covers 
the complete colloidal size range and ends up in the two-digit micrometer range [Giddings, 
1993]. Therefore, one feature of this separation technology that is worth it to be highlighted is its 
great versatility [Fraunhofer et al., 2004; Schimpf, 2000]. It is capable of separating 
macromolecules such as polysaccharides or proteins [Leeman et al., 2006; Liu et al., 2006] as 
well as assemblies like viruses, virus-like particles and liposomes [Hupfeld et al., 2006; 
Kowalkowski et al., 2006; Lang et al., 2009; Sweeney et al., 2010].  
AF4 is a valuable analytical method for sizing and quantification of different aggregate 
species within protein samples [Fraunhofer et al., 2004]. It is distinguished from size exclusion 
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chromatography (SEC) and reversed phase high performance liquid chromatography (RP-
HPLC) by lower pressures, much lower shear forces and very small surface areas, interfering 
with the analytes. Out of these, the major benefit of AF4 when using to separate and 
characterize protein aggregates is its separation principle involving no matrices that might 
absorb or interact with protein aggregates, potentially altering the proteins features. In SEC, the 
non-specific binding to the column material can even lead to a loss of aggregates [Stulik et al., 
2003]. Instead, the field-flow fractionation principle is based on differences in diffusion 
coefficients, respectively the hydrodynamic radii of the analytes [Giddings et al., 1976]. 
However, at harsh cross flow conditions, a membrane-protein interaction can still exist. Using a 
membrane made from regenerated cellulose, these interactions can strongly be reduced, since 
the material is known to be hydrophilic and non-protein adsorptive. For prevention of enhanced 
particle – wall interactions and particle – particle interactions due to high concentration in a 
small area, the cross flow always should be fixed at low values for analyzing protein aggregates 
[Liu et al., 2006]. A high cross flow implies an enhanced pressure in the separation channel and 
concentration effects at the membrane which can impact for example the conformation of 
aggregates. However, a fair separation of different size species strongly depends on a sufficient 
cross flow and usually there is only little scope of varying this parameter. 
Like in SEC, the AF4 system can be connected to refractive index (RI) and ultraviolet 
(UV) detectors that enable a quantification of the protein species [Reschiglian et al., 2001]. 
Furthermore light scattering detectors are used to determine the molecular weight of the 
analytes [Thielking et al., 1995; Wyatt, 1991]. Due to the separation principle in AF4 based on 
the perpendicular directed flows, the sample is usually diluted in much higher volumes of mobile 
phase than in SEC. The removal of buffer by the cross flow through the ultrafiltration membrane 
over the whole channel length finally results in sufficient protein concentrations reaching the 
detector. To increase the final concentration improvements of the channel were implemented by 
Postnova Analytics (Salt Lake City, USA). The upper portion of the laminar flow can be 
discharged by an additional port incorporated close to the detector outlet. This fraction of mobile 
phase should be free of protein. Therefore, the previous dilution of the sample can be reduced 
and the sensitivity of the detector can be enhanced. Increasing the loading of the protein can 
raise the yield only to a limited amount. Overloading can be recognized by loss of resolution, 
peak broadening and peak skewness [Litzen et al., 1991]. To overcome this, the channel height 
can easily be increased by using spacers of various thicknesses. However, an increased 
channel height concurrently entails a higher volume of mobile phase and thus dilution, as well 
as an altered peak resolution. Alternatively, the channel width can be broadened to improve the 
sample loading. But again the volume of the mobile phase and hence dilution increase. 
Furthermore, broadening of the channel can lead to trouble with tightness of the channel. 
AF4 can be utilized with various buffers, in many cases allowing the use of the buffer 
the protein is formulated in. Like in SEC, a separation in a mobile phase substantially differing 
from the formulation buffer potentially can alter the distribution of weakly associated protein 
species like non-covalent aggregates [Arakawa et al., 2007]. A fractionation in the formulation 
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buffer is furthermore advantageous if subsequent in vivo studies are planned. No buffer 
exchange has to be performed before administration to the animals when the formulation buffer 
can be maintained while fractionation takes place. The typically utilized high salt concentrations 
in SEC [Wen et al., 1996], would interfere with the adjustment of tonicity for parenteral 
administration.  
 
5.2 MATERIALS AND METHODS  
 
5.2.1 Sample preparation 
A recombinant human monoclonal IgG1 antibody (huAb) was kindly provided by Abbott 
GmbH & Co. KG and used as a model protein for these separation studies. The antibody 
solution applied in the experiments was diluted to a concentration of 10 mg/mL in a 
citrate/phosphate formulation buffer at pH 5.2. The IgG1 stock solution had an initial 
concentration of 70 mg/mL and was stored at -80 °C in the deep freezer. Prior to use, the 
formulation buffer was filtrated using a 0.2 µm sterile syringe filter made of cellulose acetate 
(VWR International, Darmstadt, Germany). The antibody solution was filled into cleaned and 
sterilized 6 R vials made from glass type 1 (Schott AG, Mainz, Germany), sealed with Teflon-
faced rubber stoppers (West Pharmaceuticals Services, Eschweiler, Germany) and crimped. All 
antibody samples were prepared under aseptic conditions. Highly purified water generated in-
house was used for the preparation of samples and buffers (PURELAB Plus instrument (USF 
Elga, Celle, Germany)). All substances used were of analytical grade.  
The generation of aggregates was triggered by 48 h of light exposure, using a Suntest 
CPS instrument (Heraeus, Hanau, Germany) using the same conditions as in chapters 3 and 4 
(see section 3.2.2.4).  
5.2.2 Asymmetrical flow field-flow fractionation 
AF4 was employed to separate the soluble oligomers generated by 48 h of light 
exposure from other protein species. The separation was conducted with an Eclipse 2.0 system 
(Wyatt Technology Europe GmbH, Dernbach, Germany) combined with an auto sampler and an 
in-line degasser of the Agilent 1100 series (Agilent Technologies, Palo Alto, USA). The system 
was additionally connected to detectors for refractive index, for ultraviolet spectroscopy (both 
from Agilent Technologies, Palo Alto, USA) and to a DAWN EOS (Wyatt Technology Europe 
GmbH, Dernbach, Germany) multi angle laser light scattering detector. For molar mass 
determination of all proteins, the refractive index increment dn/dc was set at 0.185 mL/g. A 
novel semi-preparative channel (SP1, Wyatt Technology Europe GmbH, Dernbach, Germany) 
of 245 mm length and 350 µm height and equipped with a membrane made of regenerated 
cellulose with a 10 kDa molecular weight cut off (MWCO) was used for separation. The 
samples were collected in glass tubes by a Gilson FC 203B Fraction Collector (Gilson Inc., 
Middleton, USA).  The delay of time between UV detector and fraction collector was previously 
determined using dextrane blue and transparent tubing between detector and collector. The 
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time between the rising UV absorbance and the visually detected arriving at the fraction 
collector amounted to 1 minute and 40 seconds. As carrier liquid a phosphate buffered saline 
(PBS) consisting of 50 mM phosphate and 400 mM sodium chloride at pH 7.0 was employed. 
The buffer was filtrated through a 0.1 µm cellulose nitrate filter with a diameter of 50 mm 
(Whatman GmbH, Dassel, Germany) prior to connection the system. The detector flow was set 
to 1 mL/min, whereas the cross flow was appointed at 3 mL/min for 5 minutes followed by a 
linear reduction to 0 mL/min over a period of 20 min. Finally, 30 minutes of elution without any 
cross flow (VX) were added. 100 μL of stressed antibody sample were injected per run, 
equaling a total amount of 1 mg of protein injected to the channel. The injection volume used for 
the native huAb was 50 µL, equaling 0.5 mg of protein. The distribution of the species was 
calculated from the AUC using Astra 5.3 software (Wyatt Technology Europe GmbH, Dernbach, 
Germany).  
 
 
Table 5-1 – Separation methods of AF4 applied to the recombinant human IgG1 antibody (huAb) 
using the semi-preparative channel SP1 with a constant detector flow of 1.0 mL/min. 
A) Separation method applied to the native huAb   B) Separation method applied to huAb after light 
exposure 
Time 
[min] 
Mode 
VX start 
[mL/min] 
VX end 
[mL/min] 
Focus flow 
[mL/min] 
2 Elution 5.0 5.0  
1 Focus   3.0 
2 Focus + Injection   3.0 
1 Focus   3.0 
20 Elution 2.0 2.0  
10 Elution 2.0 0.0  
17 Elution 0.0 0.0  
Σ = 53     
              
Time 
[min] 
Mode 
VX start 
[mL/min] 
VX end 
[mL/min] 
Focus flow 
[mL/min] 
2 Elution 5.0 5.0  
1 Focus   3.0 
2 Focus + Injection   3.0 
1 Focus   3.0 
5 Elution 3.0 3.0  
20 Elution 3.0 0.0  
32 Elution 0.0 0.0  
Σ = 63     
 
Both methods described in Table 5-1 could be divided into three major steps. Each run 
starts with the injection of the sample, followed by a focusing step and the final elution and 
separation. The detector flow was set to 1 mL/min for all methods. Depending on the volume of 
A) 
B) 
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the sample injected, the analytes might diffuse all over the channel, resulting in broad peaks 
and a very poor resolution. Therefore, a focusing step is carried out prior to separation by the 
cross flow. This step entails the accumulation of the complete sample within a narrow band 
inside the channel. Ideally, this band is formed approximately 5 mm downstream from the 
injection port [Fraunhofer et al., 2004].  
5.2.3 Protein concentration by centrifugation 
The oligomer fractions of several injections were collected in glass tubes and 
concentrated by centrifugation using disposable centrifugal protein concentration devices. 
Three different types of protein concentrators were tested and compared. Vivaspin 6 (2 – 6 mL, 
5 kDa MWCO, membrane made of polyethersulfone, Sartorius Stedim Biotech S.A., Aubagne 
Cedex, France) and Vivaspin 15R centrifugal concentrators (2 – 15 mL, 5 kDa MWCO, 
membrane made of cellulose derivate Hydrosart
®
, Sartorius Stedim Biotech S.A., Aubagne 
Cedex, France) as well as Protein Concentrators (7 mL, 9 kDa MWCO, membrane made of 
regenerated cellulose, Pierce Biotechnology, Rockford, USA) were employed to test whether 
concentration of the probes was actually possible. Hence, 100 µL of stressed antibody sample 
were injected to AF4 three times in a row, the aggregate peaks collected pooled and loaded 
onto either type of the Vivaspin concentrators or Protein Concentrator tubes, respectively. Pre-
rinsing was carried out according to the manufacturer’s instructions by adding 2 mL of AF4 
mobile phase to the tubes, followed by a centrifugation step for 5 min at 4000 x g in order to 
allow equilibrium and to remove traces of glycerine or sodium azide from the production 
process that could possibly influence the results. Once the pooled protein solution had been 
placed in the upper chamber of the concentrators, the tubes were put into swinging buckets and 
centrifuged at 4000 x g and a temperature of 4 °C for 30 min using a Megafuge 1.0R and the 
corresponding 7570F rotor (Heraeus Instruments, Santa Clara, USA). The concentration of the 
resulting fractions was determined via UV absorbance at an excitation wavelength of 280 nm as 
well as with a Micro BCA Assay according to the manufacturer`s instructions (Pierce 
Biotechnology, Rockford, USA). UV absorbance spectroscopy measurements were performed 
at 25°C with a Fluostar Omega spectrophotometer (BMG Labtech, Offenburg, Germany) and 
the Omega Software Version 1.01 together with MARS data analysis, Version 1.01. 200 µL 
aliquots of native samples were measured in a quartz 96-well plate.  
5.2.4 Micro BCA™ Protein Assay Kit 
To determine very low protein concentrations a Micro BCA assay (µ-BCA) was used 
from Pierce Biotechnology (Rockford, USA). Bicinchoninic acid reacts with Cu
+
, which 
originates from a stoichiometric reduction of Cu
2+
, mediated by peptide bonds. Finally, the 
absorbance of the resulting coloration is measured at 562 nm in a 96 well plate made of quartz 
(Hellma, Müllheim, Germany). 
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5.2.5 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
Non-reducing denaturing sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
(SDS-PAGE) was used to additionally investigate the distribution of protein species, such as 
aggregates and fragments, after light exposure. The electrophoresis was performed in a XCell II 
Mini cell system (Novex, San Diego, USA). The samples were diluted to a final concentration of 
0.05 mg/mL in a Tris-buffer pH 6.8 including 2 % glycerin and 2 % SDS. For reducing 
conditions dithiothreitol (DTT) was added to the sample buffer. Denaturation was performed by 
heating at 95°C for 20 minutes. Finally, 20 µl of each sample were loaded into the precast wells 
in the gel. Electrophoresis was carried out with NuPAGE© Pre-Cast 10 % Bis-Tris gels 1 mm, 
12 wells and NuPAGE® MES running buffer (Life Technologies, Grand Island, USA). 
Separation was accomplished with 40 mA and running time was approximately 45 minutes. 
After electrophoretic separation the gels were stained with SilverXPress© Silver Staining Kit 
(Life Technologies, Grand Island, USA). A molecular weight standard was analyzed on each gel 
as well, to determine the molecular weight of the detected protein species (HiMark™ Unstained 
Standard, Life Technologies, Grand Island, USA).  
5.2.6 Size exclusion chromatography 
Size exclusion chromatography (SEC) was employed as orthogonal method to AF4 to 
monitor the distribution of protein species after light exposure. A Superose 6 10/300 GL column 
(GE Healthcare, Little Chalfont, Great Britain) was utilized as solid phase on a Postnova 
AF2000 FOCUS system (Postnova Analytics GmbH, Landsberg, Germany). As mobile phase 
PBS pH 7.4 (12 mM phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride) with a 
flow rate of 0.5 mL/min was used. The protein recovery was calculated using UV absorbance 
signal at 280 nm. The area under the curve (AUC) of the unstressed sample was defined 100%.  
 
5.3 RESULTS 
 
5.3.1 Characterization of the samples 
Non-reduced SDS-PAGE showed no bands originated from aggregates in the native 
protein sample. The height of the most prominent band in line 2 of the gel (Figure 5-1, A) is 
around 160 kDa and thus originates from the monomer. No species larger than the monomer 
and its isoforms are detected in SDS-PAGE. Two light bands referring to species smaller than 
100 kDa are detected in the native sample as well. They resemble fragments of the antibody 
that were generated by the harsh conditions of denaturing SDS-PAGE. Comparing the resulting 
pattern of native and light exposed sample, they look similar in the majority of bands, though 
the intensity of the bands differs. However, after light exposure additional stains above the 160 
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kDa band arise. These weak areas probably derived from covalently aggregates within the 
sample, though no clear band can be detected.  
  
Figure 5-1 – Silver-stained SDS-PAGE gels of huAb. 
A) SDS-PAGE under non-reducing conditions  B) SDS-PAGE under reducing conditions 
In line 1 the resulting bands of the HiMark™ Unstained Protein Standard are shown and some dedicated 
molecular weight values are labelled on the left side. Line 2 represents the native huAb molecule and line 
3 represent the huAb after 48 h of light exposure. 
 
Under reducing conditions (Figure 5-1, B) the native huAb sample is completely cut in 
pieces through disulfide-cleavage, resulting in one intense band around 50 kDa. Instead, the 
light exposed sample reveals three additional bands of larger molar mass, that derived from 
new formed species within the sample and that are not linked by disulfide bonds.  
To confirm the formation of aggregates the sample were analyzed by SEC as well. The 
chromatograms obtained of a single run of the native or stressed sample by SEC are shown in 
Figure 5-2. 200 µg of each material were injected into the system. For better comparison of the 
distribution of the species, the chromatogram of the native huAb is displayed in another scale. 
The area under the curve (AUC) of the UV 280 nm chromatogram was used to calculate the 
percentage of the different species separated by SEC. The native huAb (see Figure 5-2, black 
line) results in one sharp peak eluting after 32 minutes. The recovery determined by Astra 
software was 97.0 % and the molecular weight determined by a 3-angle MALLS detector was 
166 kDa. The red line depicts the chromatogram of the stressed huAb sample, with a total 
recovery of 79.2 % compared to the unstressed sample. The separation resulted in 3 different 
species eluting prior to the monomer at 32 minutes. Referring to the molecular weight behind 
these peaks (see Table 5-2), they are defined as high molecular weight aggregates (HMW) 
eluting at 15 minutes, intermediate molecular weight aggregates (IMW) eluting between 17 and 
25 minutes and dimers/trimers eluting at 27.5 minutes.  
 
A) B) 
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Figure 5-2 – SEC separation of the human IgG1 before and after light exposure. 
Time dependent UV detector voltage at 280 nm and molar mass detection by MALLS after SEC 
separation of light exposed huAb (red line) and native huAb (black line). The UV chromatograms are 
scaled on the y-axes on the left side. The red y-axis refers to the stressed sample and the black y-axis 
refers to the native sample. The right y-axis represents the molar mass scale for both samples. 
 
The samples of the recombinant human IgG1 antibody after 48 h of light exposure 
showed four different peaks in UV 280 nm detection after field-flow fractionation (see 
Figure 5-3).  
 
Figure 5-3 – AF4 separation of the human IgG1 before and after light exposure. 
Time dependent UV detector voltage at 280 nm and molar mass detection by MALLS of light exposed 
huAb (red line) and native huAb (black line) after separation by Eclipse 2.0.  
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The area under the curve (AUC) of the UV 280 nm fractogram was used to calculate 
the percentage of the different species separated by AF4. The native huAb (see Figure 5-3, 
black line) results in one single peak eluting between 17 and 27 minutes, with a peak maximum 
at ~23.5 minutes. The determination of the molecular weight light scattering of the overall peak 
yielded in 131 kDa, which is reasonable for the expected molecular weight of ~ 144 kDa for this 
specific antibody. Due to the nearly monodispers composition of that sample only a limited 
amount of 500 µg protein was injected into the channel, since overloading would result in a poor 
peak shape and fronting or tailing effects. However, the slightly elevated baseline prior to the 
main peak is attributed to the high injection mass. The calculated total recovery was 96.8 %. To 
maximize the amount of protein aggregates fractionated and collected after elution, 100 µl of 
the sample after light exposure was injected into the system. The concentration of the sample 
was 10 mg/mL, thus a maximum recovery of 1 mg protein was procurable. The total recovery 
detected by UV spectroscopy at 280 nm was 88.4 % of protein, compared to the unstressed 
sample. The fractogram was subdivided into four different peaks and one shoulder shown in 
Figure 5-3. Using the 18-angle MALLS detector the molecular weights (MW) of these species 
were determined. The three major eluting peaks represent fragments of the IgG1 (elution 
maximum at 15.5 minutes), the monomeric protein (elution maximum at 22 minutes), and 
oligomeric structures (elution maximum at 33 minutes). Furthermore, a shoulder eluted directly 
after the monomeric species between 24.5 and 27.5 minutes. Additionally a void peak arose 
when analyzing this sample. The elution time of this novel peak was at 7 – 7.5 minutes. 
Determination of the MW of this void peak with Astra 5.3 software was not possible. This peak 
most likely represents large aggregates that elute prior to all other species due to the so called 
steric mode of flied-flow fractionation (see Chapter 2). 
The results of both orthogonal methods are summarized in Table 5-2. 
Table 5-2 – Comparison of SEC and AF4 analysis of huAb after light exposure. 
Overview of molecular weight determination as well as the content of the separated protein species in 
SEC (MWSEC, Content SEC) and in AF4 (MWAF4, Content AF4) measurements. 
 
Protein species MW SEC MW AF4 Content SEC Content AF4 
Fragments n/a 37 kDa 8.6 % 6.7 % 
Monomer 162 kDa 166 kDa 35.2 % 25.4 % 
Dimer / Trimer 415 kDa 295 kDa 15.6 % 9.5 % 
Oligomers 
1867 kDa (IMW) 
6620 kDa (HMW) 
2771 kDa 
30.0 % (IMW) 
10.6 % (HMW) 
54.7 % 
Total recovery --- --- 79.2 % 88.4 % 
 
The overall recovery is pretty much comparable within both methods. After separation 
with AF4, 88.4 % of the original protein content was detected, whereas the analysis by SEC 
resulted in only 79.2 %. The difference is at least in part due to the missing void peak in SEC, 
representing large aggregates. However, the AUC of this peak in AF4 amounted only 3.7 %, not 
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completing the entire difference of 9 %. Since the total recovery in both methods is not 100 %, 
the formation of large insoluble species that precipitated prior to injection is expected. The 
percentages of the various protein species differ as well. Using SEC the content of fragments, 
monomer and small aggregates like dimers/trimers is higher than in AF4, in exchange the 
recovery of oligomers is lower. Comparing the determination of the molecular weights of the 
species very similar results were determined for the monomer peak. For the fragment peak in 
AF4 37 kDa were found, whereas no value was available in SEC. The comparison of molecular 
weight of species larger than the monomer is flawed, because of the totally differing distribution. 
For example small aggregates like dimers and trimers are separated well in SEC, forming a 
peak. Instead, the separation by AF4 shows only a shoulder representing these species, 
compromising a distinct determination of MW and AUC. Anyway, the resolution in both methods 
is poor and does not reach the baseline within the peaks. Therefore, all values are only 
approximations. 
5.3.2 Collection of protein species after field-flow fractionation 
The fractions separated by AF4 were collected by elution time using a Gilson fraction 
collector. Directly after fractionation the protein concentration of each fraction was determined 
by Micro BCA assay (µ-BCA assay). Before injecting the light exposed sample to the field-flow 
fractionation channel, the sample concentration of 10 mg/mL was confirmed by this assay too. 
After injection of 100 µL, fractionation and collection of one sample over the entire elution time 
an amount of 1.053 mg total protein was determined using the µ-BCA assay as well.  
All protein species incorporated in the stressed sample except the shoulder resembling 
the dimer were gathered in glass tubes. The collection times comprised only the peak maxima 
and are shown in Table 5-3. The collected fractions covered only portions of the eluting peaks 
to achieve the highest possible protein concentrations.  
Table 5-3 – Elution times and collection times of protein species in huAb sample after light 
exposure. 
The collection times were always defined narrower than the elution to reduce potential cross-
contamination of two fractions. A collection time of 1 minute implies a volume of 1 mL, since the detector 
flow was set to 1 mL/min. 
 
Protein species Elution time Collection time 
Void Peak / Large aggregates 7.0 – 7.5 minutes 7.0 – 7.5 minutes 
Fragments 12.0 – 17.5 minutes 13.0 – 17.0 minutes 
Monomers 18.0 – 24.0 minutes 18.5 – 23.5 minutes 
Oligomers 28.0 – 40.0 minutes 31.0 – 38.0 minutes 
 
The single void peak fraction covered only 7.2 ± 0.33 µg/mL and the fractions 
containing fragments covered 20.2 ± 1.3 µg/mL. The recovery of the monomer was 
42.1 ± 4.4 µg/mL of total protein, whereas 58.8 ± 3.9 µg/mL of soluble oligomers were 
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determined in the fraction. Due to the remarkable dilution effect occurring in AF4 
measurements, these concentrations are far below the expected 1 mg/mL. However, regarding 
the volumes of the collected fractions, 707 µg of protein were recovered in the fractions 
comprising only the peak maxima. That means, approximately 30 % of the injected amount of 
protein was not collected and got lost.  
To make sure that the aggregates did not disintegrate after collection due to dilution 
within the AF4 buffer or other side effects, 100 µL of the collected aggregate fraction were re-
injected using the same separation mode again. Proving that aggregates were still present in 
the sample, a peak was observed in light scattering signal as well as in UV absorbance at the 
same retention time found before for the aggregate peak in the stressed sample between 28 
and 36 minutes. However, the low concentration of the sample accounts for the very small peak 
in UV absorbance (see Figure 5-4). The other collected fractions were not re-injected, since the 
concentrations were even less and the study focused on the large oligomer peak. 
 
Figure 5-4 – AF4 fractogram of re-injected oligomeric fraction of huAb after 48 h of light exposure. 
After collection of the fraction containing the oligomeric species, 100 µl of that sample were re-injected. 
The black line displays the UV absorbance at 280 nm. The grey line displays the light scattering signal at 
90°. 
 
The stability of the samples after fractionation was investigated after storage at 2 – 8 °C 
since it is already known that protein species like aggregates tend to change their size 
distribution during storage [Kiese et al., 2010]. The fractionation by AF4 implicates a new buffer 
composition the protein species exist in, which might have an impact on the stability of the 
species as well. Two consecutive runs injecting 100 µL of the stressed sample were 
fractionated by AF4 as described above. The collection of both runs was pooled in clean and 
sterilized 6 R glass vials (Schott AG, Mainz, Germany). Concentration was measured at day 0, 
day 3, day 7, day 14 and after three weeks by µ-BCA. For each time point a separate vial was 
utilized. The samples were centrifuged for 5 min at 4000 x g before analysis, and Figure 5-5 
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displays the determined protein concentrations over time. The fractions containing fragments, 
monomers or oligomers maintain their total protein concentrations over 21 days of storage at 
2 – 8 °C. Precipitation was neither visually detected nor did the concentration in the 
supernatants decrease over time. Only the fraction containing the void peak shows a constant 
decrease in protein concentration. Due to the marginal protein concentration < 10 µg/mL only a 
slight precipitation was detected visually after 21 days.  
 
Figure 5-5 – Fractions collected during AF4 analysis of the huAb after 48 h of light exposure. 
Stability investigated over a period of three weeks storage at  2 – 8 °C by determination of protein 
concentration via a Micro BCA assay. 
 
Parts of the samples were also stored in the deep freezer at -80 °C, gently thawed over 
night at 2 – 8 °C and subsequently the concentration was analyzed by µ-BCA assay as well. 
The concentration of soluble species remained stable when thawed after three weeks and no 
precipitation was apparent (data not shown).  
5.3.3 Increasing protein concentration within the fractions 
As the aggregates collected after the separation via asymmetrical flow field-flow 
fractionation were supposed to be administered to mice and a significant dilution occurred 
during fractionation, samples had to be concentrated and adjusted to a certain protein 
concentration. Disposable ultracentrifugation centrifugal devices appeared to be the most 
applicable and time-effective means to achieve satisfactory protein concentrations. The 
membranes inserted into the centrifugal tubes consisted of hydrophilic substances such as 
high-performance regenerated cellulose, polyethersulfone or Hydrosart
® 
which guarantee low 
protein binding and could retain molecules bigger than the molecular weight cut off claimed by 
the manufacturer. Besides the membrane material, precipitation, aggregation and adsorption to 
the filter material could have a strong impact on concentration efficiency and can entail sample 
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loss. Those interactions to some extent are based on the surface characteristics of the protein 
which again are highly dependent on its aggregation state. 
Using the collection schedule shown in Table 5-3 the aggregate peak of each run 
comprises 7 mL. Hence, 21 mL of AF4 mobile phase including ~1260 µg aggregated protein 
were collected within three runs. The fractions of three runs first were pooled. Then, the volume 
was split into thirds of 7.0 mL and each was loaded onto a Vivaspin 6, Vivaspin 15 R or a 
Protein Concentrator tube and centrifuged for 30 min at 4000 x g and a temperature of 4 °C. 
Afterwards, protein content was determined and compared as shown in Table 5-4. The whole 
procedure was carried out twice. 
Table 5-4 – Concentration of oligomeric fractions separated by AF4. 
Comparison of the effectiveness of three different types of centrifugal protein concentration devices, 
concerning the resulting concentration after 30 minutes of spinning at 4000 x g and 4 °C. Protein content 
was determined via a Micro BCA assay. 
 
Type of disposable 
concentrator 
Concentration before (c0) and 
after centrifugation (cconc) 
1 2 
Vivaspin 6 c0 59.0  µg/mL 55.1  µg/mL 
 cconc 111.0  µg/mL 102.3  µg/mL 
Vivaspin 15 R c0 59.0  µg/mL 55.1  µg/mL 
 cconc 140.5 µg/mL 138.8 µg/mL 
Protein Concentrator c0 59.0  µg/mL 55.1  µg/mL 
 cconc 197.7  µg/mL 198.2  µg/mL 
 
Protein Concentrators from Pierce Biotechnology were assumed to be best suited for 
enriching the concentration of the aggregates. The concentration process using those devices 
was subsequently further improved and the efficiency was evaluated. Promising protein 
contents of more than 1 mg/mL for the aggregate fraction could be achieved (data not shown). 
The reproducibility and reliability of the process was ensured by the repetitive 
fractionation and concentration of three consecutive runs. Each repetition based on two 
injections of 100 µL of the stressed huAb sample to the AF4 system. Both collected fractions 
were pooled before the total volume and the initial protein content were determined. Then the 
pooled sample was divided in two halves and applied to two Protein Concentrators. 
Centrifugation was carried out as described above and a µ-BCA assay was performed and the 
remaining volume was recorded too (see Table 5-5).  
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Table 5-5 - Results of reproducibility study. 
Protein concentrations at various intermediate steps during fractionation and concentration. The 
concentration was determined in AF4 mobile phase by µ-BCA assay.  
 
Preparation step 1 2 3 
Collection of aggregate peak    
Protein mass at injection 2000 µg 2000 µg 2000 µg 
Concentration of collected aggregate peak 63.2 µg/mL 63.0 µg/mL 55.3 µg/mL 
Volume of collected aggregate peak 14.5 mL 14.5 mL 14.5 mL 
Protein mass in collected aggregate peak 916.4 µg 913.5 µg 801.9 µg 
Total amount of aggregates in the sample 45.8 % 45.7 % 40.1 % 
Concentration step    
Volume prior to concentration 14.0 mL 14.0 mL 14.0 mL 
Protein mass prior to concentration 884.8 µg 882.0 µg 774.2 µg 
Concentration after 30 min centrifugation 328.6 µg/mL 330.5 µg/mL 391.6 µg/mL 
Volume after 30 min centrifugation 2.0 mL 2.0 mL 1.7 mL 
Protein mass after 30 min centrifugation 657.2 µg 661.0 µg 665.72 µg 
Total recovery of protein 74.3 % 74.9 % 86.0 % 
 
The collection of the aggregate peak provided an aggregate content varying between 
800 and 916 µg, implying that 40 to 46 % of the total protein in the stressed sample could be 
collected. During the concentration step, the protein content of the samples was increased by a 
factor of 5.2 for the first two runs. A higher factor was found for the third run, reaching a 7.0 fold 
increase in protein concentration. Furthermore, the total recoveries of protein achieved by the 
concentrating procedure were approximately 74 % for runs 1 and 2, and 86 % in the more 
effective third run. The filtrate was checked by µ-BCA assay for accidental passing of protein 
through the membrane. No significant amount of protein appeared in the filtrate. Hence, the low 
recoveries indicate a loss of protein by adsorption to the membrane material.   
The stability of the concentrated aggregate samples was investigated as described 
above in section 5.3.2. New samples were prepared and stored at 2 – 8 °C and –80 °C in clean 
and sterilized 6 R glass vials (Schott AG, Mainz, Germany) for 21 days. Before performing a 
  ANGELIKA FREITAG        DISSERTATION       FRACTIONATION OF PROTEIN AGGREGATES 
 
101 
 
µ-BCA assay, potentially generated precipitates were separated by centrifugation. The protein 
concentration over storage time at 2 – 8 °C is shown in Figure 5-6.  
 
Figure 5-6 – Protein content in concentrated aggregate peak. 
Stability of the concentrated aggregate fraction in AF4 mobile phase investigated over a period of three 
weeks storage at 2 - 8 °C by determination of protein concentration via a Micro BCA assay. 
 
No important loss of protein concentration was determined over 21 days of storage at           
2 – 8 °C. For -80°C storage the concentration of soluble species remained stable over three 
weeks of time and including one freeze-thaw cycle and no precipitation was apparent (data not 
shown). Besides the overall protein content in solution, the stability of the aggregates was 
checked by re-injection to the AF4 system and detection at 214 nm. 100 µL of sample were 
injected to AF4 system either directly after concentration or after 21 days of storing. Both 
storage conditions of 2 – 8 °C and –80 °C were tested. The resulting fractograms are displayed 
in Figure 5-7. Directly after concentration the fractogram shows mainly the peak representing 
the aggregates, eluting around 30 minutes. After storage at -80 °C for three weeks and 
subsequent thawing at 2 – 8 °C overnight, slight fronting effects were found in peak shape, and 
a growth of peaks that can be assumed to consist of fragments and monomer due to their 
elution times. This instability of the aggregates is dramatically higher when storing several days 
at 2 – 8 °C. After 21 days storage in the refrigerator, nearly no aggregates are found anymore, 
though the amount of species eluting early significantly increased. The molar mass 
determination of this shifted elution profile revealed 155 kDa in the main peak and confirmed 
the assumption of the presence of monomeric antibody species. The distribution of the species 
cannot clearly be defined, because of the poor resolution between the peaks. The storage at 
2 - 8 °C leads to dissociation of the aggregates in fragments and monomeric species.  
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Figure 5-7 – UV 214 nm AF4 fractograms after re-injection of aggregate fractions. 
The concentrated aggregate fraction was re-injected directly after concentration (red line), after 21 days 
storage at 2 – 8 °C (blue line) and after 21 days storage at -80 °C (green line). The UV 280 nm fractogram 
of the original sample of huAb after 48 h of light exposure is shown in grey. 
 
Identical samples were also analyzed by size exclusion chromatography and revealed 
similar results (see Figure 5-8). Directly after finishing the concentration using the disposable 
devices, the sample consists of mostly aggregates. These aggregates can be subdivided in two 
species with SEC. During storage at 2 – 8 °C the aggregate content drastically decreases and 
the chromatogram shows monomer and fragments again. In comparison, storage at -80 °C 
leads only to a slight dissociation of the aggregates represented by a slight increase in height of 
the monomer peak. 
 
Figure 5-8 – UV 214 nm SEC chromatograms after re-injection of aggregate fractions. 
The concentrated aggregate fraction was re-injected directly after concentration (red line), after 21 days 
storage at 2 – 8 °C (blue line) and after 21 days storage at -80 °C (green line). The UV 280 nm fractogram 
of the original sample of huAb after 48 h of light exposure is shown in grey. 
void peak fragments monomers oligomers 
oligomers dimers monomer fragments 
dimers 
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These results were furthermore confirmed by non-reducing SDS-PAGE, showing weak 
bands representing fragments as well as monomeric species, besides diffuse stains 
representing aggregates (data not shown). 
 
5.4 DISCUSSION 
 
Light exposure can occur to biopharmaceuticals during multiple stages in formulation 
and subsequent inspection as long as the primary containers are not yet packaged and labeled. 
Furthermore, many recently developed therapeutic proteins are aimed for self-administration to 
improve the compliance of the patient. The advancement involves increasing possibility of 
undesigned exposure to room light or even sun light. Thus light exposure has to be considered 
as relevant extrinsic stress condition a protein therapeutic can encounter. 
The high amount of soluble protein species generated by light exposure was in the 
focus of this study. Asymmetrical flow field-flow fractionation served as analytical method for the 
separation and fractionation of the distinct protein species and was first of all compared to the 
separation by the “gold-standard” size exclusion chromatography. Discrepancies in the 
distribution of the protein species within identical samples either analyzed by SEC or analyzed 
by AF4 were found.  
In SEC a lower amount of protein was recovered in total. Besides, the pattern of huAb 
protein species displayed in the chromatograms and fractograms of this study differ a lot. In 
AF4 but not in SEC a void peak eluting before any other protein species was detected. The 
resolution between the monomer and small aggregates is much better in SEC, whereas the 
AF4 fractogram shows only a shoulder following the monomer peak impeding an accurate area 
definition. Therefore, also the MW determination is affected and influenced by the overlay with 
monomeric species. In SEC a MW of 415 kDa was determined for these small aggregates, 
representing dimers and trimers. However, an improvement of resolution in the AF4 method 
was not the ambition of this study. Another obvious difference is the elution of oligomers. In AF4 
only one oligomeric species, eluting after all other protein species was detected. Instead, the 
size exclusion chromatograms revealed two species of higher molecular weight eluting several 
minutes prior to the small aggregates: a sharp peak eluting very early, representing high 
molecular weight (HMW) aggregates, and a broad peak that represents intermediate molecular 
weight (IMW) aggregates.  
As described in literature, these differences are first and foremost related to the varying 
separation principles [Litzen et al., 1993]. In general, during the focusing step in AF4, the 
protein sample is pushed towards the ultrafiltration membrane and concentrated in a narrow 
band within the channel. This might alter the conformation and structure of the species and an 
artificial aggregation can be triggered, potentially leading to higher recoveries of soluble 
aggregates [Liu et al., 2006]. The incidence of interaction to a solid phase is much higher in 
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SEC, which first and foremost induces protein losses and might modify the aggregate 
distribution as well.  
Another reason for the reduced protein recovery in SEC is the separation range of the 
Superose 6 column, which is narrower than the range of molar masses AF4 is capable to 
separate. 5 x 10
3
 to 5 x 10
6
 Da is the designated molar mass range the Superose column can 
cope with, whereas AF4 was shown to separate also large protein complexes in the higher 
Mega-Dalton range [Veesler, 2010]. Considering the extended separation range, it can be 
concluded, that the void peak detected by AF4 comprises large protein species or even 
insoluble aggregates which elude from separation by the cross flow due to their size. This 
inverse elution profile, the so called steric operation mode of AF4, has been reported in 
literature several times [Gottschalk et al., 2006; Litzen et al., 1993]. This void peak, which only 
appears in the fractogram, also contributes to the higher total protein recovery in AF4 compared 
to SEC. 
The detected HMW species in SEC found to be larger than 6 x 10
6
 Da in size already 
exceeded the limit of detection of the column and thus eluted very early in a very sharp peak. 
However, they are clearly separated from IMW species that resulted in a broad peak, probably 
representing numerous different aggregates of similar size. The oligomer peak in AF4 
fractogram also represents aggregates of different sizes, which obtain similar hydrodynamic 
radii and thus diffuse in close areas in the channel and elute simultaneously. Since the recovery 
of this peak was 54.7 % it can be assumed, that both, the peak representing HMW aggregates 
and the peak representing IMW aggregates in SEC with a total recovery of 40.6 % are 
incorporated in that single peak in AF4. The MW determination supports this hypothesis, since 
the value found in AF4 (2771 kDa) is in between the MW values of the peaks found in SEC 
(1867 kDa and 6620 kDa).  
Both methods entail a significant dilution to the sample, which potentially leads to the 
dissociation of weak, non-covalently linked aggregates [Liu et al., 2006]. In addition, the 
utilization of different mobile phases can also bias the mass distribution of the protein species. 
Furthermore, differences in shear force and adsorption the protein encounters in AF4 and SEC 
could have an impact on aggregates [Demeule et al., 2009].  
The AF4 studies described, for the first time used a semi-preparative channel, a 
prototype that was kindly provided by Wyatt Technology Europe. However, the final 
concentration of the collected aggregate peak was quite low. Challenges in construction 
accompanied with leakage are problems involved in the enlargement of the separation channel. 
Besides, protein loading is limited, due to poor resolution and thus overlapping of the various 
species, and the dilution of the sample is still very high. Hence, an aggregate fraction containing 
approximately 60 µg/mL of protein was achieved.  
A variety of disposable centrifugal devices were tested for their ability to concentrate 
these aggregate samples. All three tested tools were feasible to concentrate the sample. 
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However, the efficiency differed and the Protein concentrators
® 
turned out to be best suited. 
The molecular weight cut off of 9 kDa, compared to 5 kDa within the both Vivaspin tubes, might 
account for the more effective enhancement of the protein concentration. Slight differences in 
membrane materials where not investigated and can play a role as well. An up to seven-fold 
increase of the protein content was achieved, though further improvement of the method could 
provide even higher concentrations. 
By re-injection of this fraction the composition and size of the concentrated fractions of 
aggregates was confirmed. The stability studies conducted with the aggregates after 
fractionation indicate the formation of weakly linked, reversible aggregates that tend to 
re-dissociate when separated from monomer and fragments. Non-reducing as well as reducing 
SDS-PAGE showed the formation of covalently linked aggregates. However, the harsh 
conditions of denaturing at 90 °C can tamper with the original aggregation and fragmentation 
pattern in the sample [Hunt et al., 1999]. But, since non-covalent aggregates are not detectable 
with denaturing SDS-PAGE, it can be concluded that the light exposed sample consists of a 
versatile mixture of fragments and covalently linked aggregates. Interestingly, the aggregation 
process is not stopped when turning of the light, but proceeds in the sample. Removing the 
smaller species within the mixture destabilizes the aggregates and leads to dissociation of the 
aggregates. During storage of the entire huAb sample in formulation buffer at the same 
conditions directly after light exposure, no dissociation of the oligomers back to fragments and 
monomers was detected (data not shown). Thus, a stabilizing effect of the smaller species, 
such as monomer and fragments, on the cohesion of the aggregates can be concluded. The 
resulting species exist in a balance, though influences of the buffer composition cannot be 
excluded. Kiese et al. already showed that protein aggregates of a monoclonal IgG1 antibody 
tend to gain equilibrium during storage [Kiese et al., 2010]. When storing the collected 
aggregate fraction of huAb at –80°C almost complete absence of other peaks, e.g. fragment or 
monomer, was found, confirming that the soluble aggregates remained stable. Disintegration 
occurred only to a negligible extinct, which might emerge during thawing overnight at 2 – 8 °C 
and the time in the auto sampler at 4 °C prior to injection to SEC or AF4.  
Looking at these results, it was shown that acceptable concentration of separated 
soluble aggregates of the applied human IgG1 antibody can be achieved by the AF4 technique. 
For the first time, the stability of antibody oligomers after separation from accompanying protein 
species and concentration was shown. Thus, the field-flow fractionation is a promising tool for 
preparation of samples for the prospective in vivo studies.  
 
 
 
 
 
 
 
  ANGELIKA FREITAG        DISSERTATION       FRACTIONATION OF PROTEIN AGGREGATES 
 
106 
 
5.5 CONCLUSIONS 
 
AF4 is a valuable method to analyze and characterize protein aggregates. Using the 
new semi-preparative channel and combining it with a fraction collector, FFF is now applicable 
as a semi-preparative system as well, maintaining its advantages compared with SEC. The 
major benefit of AF4 is the separation principle, which is independent of a packed stationary 
phase. That implicates minor shear stress and marginal interactions of the analytes with solid 
phases. The semi-preparative channel enables separation of protein in the upper µg/mL range 
and no complex upgrading of the instrumentation for standard AF4 is necessary for this 
approach. The described procedure of light exposure, fractionation by semi-preparative AF4 
and concentration by disposable concentration devices is suitable to generate large amounts of 
a pure aggregate fraction. Storage at –80 °C in combination with gentle thawing and short-term 
storage at 2 – 8 °C is recommended to maintain the aggregated structure of the monoclonal 
antibody. The good reproducibility and reliability of the method guarantee for consistent 
amounts of aggregates and are promising results for the planned transfer to a mouse antibody. 
The aggregates formed by light exposure definitely need to be further characterized to 
understand the mechanisms behind the disintegration behavior. The reversibility of even 
covalent linked aggregates should be investigated in more detail by, for example, experts in 
mass spectrometry and peptide mapping. Furthermore, it would also be of interest to 
investigate the secondary and tertiary structure of the separated fractions.  
The studies described in this chapter are only dealing with the separation of the most 
abundant oligomer peak of one monoclonal antibody by light exposure. Further investigations 
are useful to transfer the method to other proteins and other aggregate species as well, 
generated under varying stress conditions. Since for an in vivo study a certain buffer 
composition is required, the fractionation by AF4 should be performed within the final buffer to 
avoid destabilizing dialysis prior to administration. 
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6  THE PREPARATIVE USE OF AF4 TO OBTAIN 
ENDOTOXIN-FREE PROTEIN SPECIES 
 
 
6.1 INTRODUCTION 
 
The immunogenic potential of therapeutic proteins is a serious problem for their 
application. The formation of antibodies against the drug depends on numerous factors such as 
the route of administration, formulation properties, and patient characteristics [Schellekens, 
2002]. Several studies showed that aggregates present in a biopharmaceutical formulation 
enhance the immunogenicity of the therapeutic protein [Hermeling et al., 2006; Moore et al., 
1980; Palleroni et al., 1997; Schernthaner, 1993]. Since proven methods for the prediction of 
immunogenicity are not available, in vivo studies have to be conducted for detailed 
investigations. Two general approaches, usually conducted in mice, can be pursued. 
Transgenic mice are immune tolerant to a certain human protein, closely resembling the 
therapeutic situation. However, the immune system of these animals is artificially altered, which 
might bias its response. Wild-type mice, instead, will recognize all human proteins as foreign 
molecules and induce a classical immune response. The use of wild-type mice is only 
reasonable when a protein generated in mice is investigated. Due to the versatile potential 
immunogenic stimuli mentioned above, a proper implementation is crucial for all 
immunogenicity studies in vivo, to eliminate all potentially biasing factors, such as endotoxins.  
Endotoxins are toxic molecules that typically can be found in the membrane of gram-
negative bacteria and are capable of being recognized by the immune system [Magalhães et 
al., 2007]. The most common endotoxins are lipopolysaccharides (LPS) consisting of a lipid and 
a polysaccharide chain [Williams, 2007]. Since the existence of even small amounts of 
endotoxins within a parenteral drug product can induce inflammation in patients or even septic 
shock, they must be removed from formulations and containers [Hurley, 1995]. Sterilization 
does not sufficiently destroy endotoxins, because they are released during bacterial cell lysis. 
Depyrogenation processes have to be performed to remove endotoxins from containers and 
formulations. Glass containers can easily be exposed to temperatures above 250 °C for at least 
30 minutes to inactivate LPS [USP/NF, 2008]. Sodium hydroxide can as well be used to 
inactivate endotoxins, for example for container materials susceptible to heat like plastics. Ion 
exchange chromatography is one method utilized to remove endotoxins from protein samples 
[Dembinski et al., 1986]. 
Because of the severe effects of endotoxins inadvertently administered to patients the 
European Pharmacopoeia strictly limits the endotoxin levels for parenteral formulations to 
0.25 EU/mL, for “Water for injections”, which usually represents the main “excipient” in all 
parenteral products [PhEur 0169, 2011]. The maximum endotoxin level for a product depends 
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on the delivered volume and body weight of the patient and is specified in the individual 
monographs. A benchmark of 5 EU/kg body weight is mentioned in USP <85> to be the limit for 
intravenous application [USP/NF, 2008]. According to the pharmacopoeias all parenterals have 
to be tested with regards to bacterial endotoxins. The Limulus Amebocyte Lysate (LAL) test is 
the most prominent method to quantify endotoxins. It is based on the blood of horseshoe crabs, 
Limulus polyphemus, clotting when exposed to endotoxins. Detection can either be performed 
by measuring turbidity, coloration or by gel formation [Bang, 1956]. The currently available and 
approved test kits have a limit of detection of 0.005 EU/mL and quickly provide the results 
within 30 minutes.  
In preparation of an in vivo study to investigate the immunogenicity of protein 
aggregates, the benchmark of 0.25 EU/ml was predefined and should not be exceeded. 
Therefore, the formulations have to be checked for their endotoxin levels. Hence, utilizing 
asymmetrical flow field-flow fractionation (AF4) as preparative tool to separate protein 
aggregates (see Chapter 5) requires the separation of fractions with low endotoxin levels. The 
aim of this study was to use the AF4 instrument for fractionation of aggregates of a mouse 
monoclonal antibody in preparation of an in vivo study and thus to establish a protocol to clean 
the entire instrument from microbial and endotoxin contaminants. The fractionation and 
concentration procedures established before using a human monoclonal IgG1 antibody had to 
be transferred to a mouse monoclonal IgG2c antibody and final endotoxin concentrations below 
0.25 EU/mL had to be guaranteed.  
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Sample preparation 
A mouse monoclonal IgG2c antibody (muAb) was kindly provided by Abbott GmbH & 
Co. KG. The antibody solution applied in the experiments was diluted to a concentration of 
10 mg/mL in a 20 mM histidine formulation buffer at pH 6.0. The IgG2c stock solution had an 
initial concentration of 33 mg/mL and was stored at -80 °C in the deep freezer. Prior to use, the 
formulation buffer was filtrated using a 0.2 µm sterile syringe filter out of cellulose acetate (VWR 
International, Darmstadt, Germany). The antibody solution was filled into cleaned and sterilized 
2 R vials made from glass type 1 (Schott AG, Mainz, Germany), sealed with Teflon
®
-faced 
rubber stoppers (West Pharmaceuticals Services, Eschweiler, Germany) and crimped. All 
antibody samples were prepared under aseptic conditions. Highly purified water generated in-
house was used for the preparation of samples and buffers (PURELAB Plus instrument (USF 
Elga, Celle, Germany)). All substances used were of analytical grade.  
The generation of aggregates was triggered by light exposure, using a Suntest CPS 
instrument (Heraeus, Hanau, Germany). The light source was a xenon lamp with a wavelength 
spectrum from 200 to 1000 nm. The irradiance was fixed at 55 ± 5 W/m². A filter made of sheet 
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glass was installed, to obtain a radiation close to the real light exposure. The samples were 
exposed to light for 48 h.  
6.2.2 Asymmetrical flow field-flow fractionation 
AF4 was employed to separate the soluble oligomers generated by 48 h of light 
exposure from other protein species. The separation was conducted with an Eclipse 2.0 system 
(Wyatt Technology Europe GmbH, Dernbach, Germany) combined with an auto sampler and an 
in-line degasser of the Agilent 1100 series (Agilent Technologies, Palo Alto, USA). The system 
was additionally connected to detectors for refractive index, for ultraviolet spectroscopy (both 
from Agilent Technologies, Palo Alto, USA) and to a DAWN EOS (Wyatt Technology Europe 
GmbH, Dernbach, Germany) multi angle laser light scattering detector. For molar mass 
determination of all proteins, the refractive index increment dn/dc was set at 0.185 mL/g. A 
semi-preparative channel (SP1, Wyatt Technology Europe GmbH, Dernbach, Germany) of 
245 mm length and 350 µm height and equipped with a membrane made of regenerated 
cellulose with a 10 kDa molecular weight cut off (MWCO) was used for separation. The 
samples were collected in glass tubes by a Gilson FC 203B Fraction Collector (Gilson Inc., 
Middleton, USA).  The delay of time between UV detector and fraction collector was previously 
determined using dextrane blue and transparent tubing between detector and collector. The 
time between the rising UV absorbance and the visually detected arriving at the fraction 
collector amounted to 1 minute and 40 seconds. As carrier liquid the formulation buffer 
consisting of 20 mM histidine buffer at pH 6.0 was employed. The buffer was filtrated through a 
0.1 µm cellulose nitrate filter with a diameter of 50 mm (Whatman GmbH, Dassel, Germany). 
The detector flow was set to 1 mL/min, whereas the cross flow was appointed at 3 mL/min for 
5 minutes followed by a linear reduction to 0 mL/min over a period of 20 min. Finally, 30 
minutes of elution without any cross flow (VX) were added. 100 μL of stressed antibody sample 
were injected per run, equaling a total amount of 1 mg of protein injected to the channel. The 
injection volume of the native muAb was limited to 50 µL, equaling 0.5 mg of protein. The 
distribution of the species was calculated from the AUC using Astra 5.3 software (Wyatt 
Technology Europe GmbH, Dernbach, Germany).  
6.2.3 Protein concentration by centrifugation 
The oligomer fractions of several injections were collected in glass tubes and 
concentrated by centrifugation using Protein Concentrators (7 mL, 9 kDa MWCO, membrane 
made of regenerated cellulose, Pierce Biotechnology, Rockford, USA). Hence, 100 µL of 
stressed antibody sample were injected to AF4 several times in a row, the aggregate peaks 
collected, pooled and loaded onto Protein Concentrator tubes, respectively. Pre-rinsing was 
carried out according to the manufacturer’s instructions by adding 4 mL of 20 mM histidine 
buffer pH 6.0 to the tubes, followed by a centrifugation step for 10 min at 4000 x g in order to 
allow equilibrium and to remove traces of glycerin or sodium azide from the production process 
that could possibly influence the results. Once the pooled protein solution had been placed in 
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the upper chamber of the concentrators, the tubes were put into swinging buckets and 
centrifuged at 4000 x g and a temperature of 4 °C for 90 min using a Megafuge 1.0R and the 
corresponding 7570F rotor (Heraeus Instruments, Santa Clara, USA). The concentration of the 
resulting fractions was determined via UV absorbance at an excitation wavelength of 280 nm. 
UV absorbance spectroscopy measurements were performed at 25°C with a Fluostar Omega 
spectrophotometer (BMG Labtech, Offenburg, Germany) and the Omega Software Version 1.01 
together with MARS data analysis, Version 1.01. Aliquots of 200 µL of the samples were 
measured in a quartz 96-well plate and concentrations between 0.0625 mg/mL and 1 mg/mL 
were used for calibration. 
6.2.4 Determination of endotoxin level 
To assure that the amount of endotoxins in the samples is lower than 0.25 EU/mL as 
required by the European Pharmacopoeia in monograph “water for injections”, a Limulus 
Amebocyte Lysate (LAL) test (Endosafe™-PTS Portable Test System by Charles River 
Laboratories International Inc., Wilmington, USA) was used. The principle of this FDA-licensed 
test bases on an enzyme cascade in which serine proteases are activated by endotoxins. The 
activated enzymes cleave a peptide from the substrate coagulogen that subsequently produces 
gelatin and turbidity. The latter is optically quantified at 395 nm. 4 times 25 μL of the samples of 
interest were added to the disposable cartridge and quantitation results were obtained in 15 
minutes. The sensitivity of the cartridges used was ≥ 0.005 EU/mL.  
 
6.3  RESULTS 
 
6.3.1 Preparation of instrument, samples and buffer solutions 
To assure low endotoxin levels in the final protein fractions a meticulous cleaning and 
disinfection program had to be established for the AF4 instrument and all equipment needed for 
sample preparation. For glass containers, such as vials, collection tubes and buffer reservoirs, 
the depyrogenation at 250 °C for ≥ 30 minutes was chosen. All other container materials like 
stoppers and Teflon
®
-coated stir bars were first of all rinsed with highly purified water and 
subsequently sterilized by hot steam in an autoclave. All samples and the buffer solution were 
prepared under the laminar air flow hood to minimize all new contamination. In addition the 
buffers were sterile filtered using 0.2 µm sterile filters made of cellulose acetate (VWR 
International, Darmstadt, Germany). For the preparation of the protein samples sterile and 
endotoxin-free reaction vessels and pipette tips were utilized (all from Eppendorf Biopur
®
 
quality, Eppendorf AG, Hamburg, Germany).  
The entire AF4 instrument (including all valves, online filter, injection loop and waste 
tubing, and the fraction collector) was first washed with highly purified water (HPW), which was 
shown to be free of endotoxins (data not shown), for at least one hour at 1 mL/min, to remove 
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potential salt residues from previous used buffers. Subsequently the whole procedure was 
repeated with 70 % (v/v) ethanol for disinfection, before again rinsing with highly purified water.  
The SP1 separation channel was treated separately. Steam sterilization of the 
ultrafiltration membrane made of regenerated cellulose lead to shrinkage and thus was not an 
option. Instead the membrane was treated in the same manner as the channel components. All 
single components were stored in 70 % (v/v) ethanol for one hour, except the upper wall. The 
upper wall consists of Plexiglas
®
 and thus is not compatible to organic solvents. Hence, it was 
thoroughly cleaned with Light-Duty tissue wipers (VWR International, Darmstadt, Germany) 
impregnated with 70 % ethanol. All channel components were rinsed with HPW before 
reassembling under the aseptic conditions of the laminar air flow hood.  
After installation of the clean channel to the meticulously rinsed system HPW was 
connected as fluent and the eluate collected in a glass tube was tested for endotoxins. An 
endotoxin level below the limit of detection (LOD) 0.005 EU/mL was detected, proving the 
rinsing protocol was successful. Using 20 mM histidine buffer as fluent, the eluate had to be 
diluted 1:20 for the determination of endotoxins, due to interference of histidine with the test 
principle. On that account the LOD of the test cartridges increased to 0.1 EU/mL and the 
histidine buffer eluting resulted in an endotoxin level below this LOD. After these preliminary 
tests the separation of the mouse antibody started. 
6.3.2 Field-flow fractionation of mouse IgG2c  
The samples of the mouse IgG2c antibody after 48 h of light exposure showed four 
different peaks in UV 280 nm detection after field-flow fractionation (see Figure 6-1). The area 
under the curve (AUC) of the UV 280 nm fractogram was used to calculate the percentage of 
the different species separated by AF4. The native muAb (see Figure 6-1, black line) results in 
one single peak eluting between 16 and 25 minutes, with a peak maximum at ~21.5 minutes. 
The determination of the molecular weight was performed by MALLS and UV absorbance 
detection. The overall monomer peak yielded in 150 kDa, perfectly matching to the expected 
molecular weight for an antibody. The monomer peak is accompanied by a small void peak. A 
limited amount of 500 µg protein was injected into the channel, since overloading would result 
in a poor peak shape and fronting or tailing effects. The total recovery was 93 %. To maximize 
the amount of protein aggregates fractionated and collected after elution, 100 µL of the sample 
after light exposure was injected into the system. The concentration of the sample was 10 
mg/mL, thus a maximum recovery of 1 mg protein was procurable. The total recovery detected 
by UV spectroscopy at 280 nm was 96 ± 2.8 % of protein, subdivided into four different peaks 
shown in Figure 6-1. Using the 18-angle MALLS detector the molecular weights (MW) of these 
species were determined. A huge and sharp void peak elutes first (elution maximum at 7.0 
minutes) and the 5669 kDa of molar mass were detected for this peak. The three following 
eluting peaks represent fragments of the IgG2c (elution maximum at 15.5 minutes), the 
monomeric protein (elution maximum at 21 minutes), and oligomeric structures (elution 
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maximum at 32 minutes). No molecular weight was determined for the fragments portion. The 
monomer peak resulted in 182 kDa and the oligomer peak resulted in 3224 kDa. The 
distribution of the species was calculated by analysis of the area under the curve (AUC). The 
light exposed sample consisted of 19.3 % void peak, 4.8 % fragments, 10.1 % monomers and 
65.9 % oligomers. The resolution between the monomer peak and the oligomer peak is poor. 
Hence there might be some overlay and lack of definition between those species.  
 
Figure 6-1 – AF4 separation of the mouse IgG2c before and after light exposure. 
Time dependent UV detector voltage at 280 nm and molar mass detection by MALLS of light exposed 
muAb (red line) and native muAb (black line) after separation by Eclipse 2.0.  
 
6.3.3 Collection and concentration of protein species after AF4 separation 
The protein fractions separated by AF4 were collected in glass tubes using the Gilson 
fraction collector. In preparation of an in vivo study, facing the immunogenicity of protein 
aggregates, only the void peak and the oligomeric peak were further investigated. Due to earlier 
investigations and the molar mass detection, those fractions are known to represent 
aggregates. For the void peak, collection time was set to 6.5 to 8.0 minutes and that of the large 
oligomer peak was set to 28.0 to 34.0 minutes. The concentrations of the collected fractions 
were subsequently determined by UV absorbance at 280 nm, since the histidine buffer 
interfered with the Micro BCA assay.  
Within three consecutive runs 105.6 ± 3.6 µg/mL of protein were detected in the 
oligomer fractions before pooling them. The duration of the centrifugation using Protein 
concentrators to enhance the concentration in the pooled fraction was prolonged to 90 minutes. 
A final concentration of 593.4 µg/mL protein within the oligomer fraction was achieved. Within 
the void peak fraction very low protein concentrations of approximately 10 µg/mL were 
determined. An accurate determination in that range was not possible by UV 280 nm detection. 
Using Protein concentrators and the extended centrifugation procedure the final concentration 
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could not be significantly increased, though the volume of the sample was slightly narrowed 
(data not shown). However, the investigations were continued only for the oligomer peak eluting 
at the end.  
The stability of the oligomer fraction was confirmed by storage at -80 °C for seven days, 
thawing at 2 – 8 °C overnight and re-injection to the AF4 system. 100 µL of the peak 
representing the oligomers was re-injected to the instrument after concentration and storage. 
Detection was performed by UV absorbance at 214 nm. The distribution in Figure 6-2 shows a 
prominent peak eluting between 25 and 34 minutes, perfectly matching with the original elution 
schedule of the oligomer peak. Besides, a void peak and a very small peak eluting around 20 
minutes were detected. The latter probably represents marginal amounts of monomer within the 
fraction.  
 
Figure 6-2 – UV 214 nm AF4 fractograms after re-injection of aggregate fractions. 
The concentrated aggregate fraction was re-injected directly after concentration and storage at -80 °C 
(green line). The UV 280 nm fractogram of the original sample of muAb after 48 h of light exposure is 
shown in grey. 
 
Directly after collection both fractions were tested for the endotoxin burden in a 1:20 
dilution. Both resulted in < 0.1 EU/mL endotoxin levels after fractionation. Furthermore, the 
endotoxin measurements were repeated after the centrifugation step and again, both 
concentrated fractions showed similar values. The filtrates were tested as well, to detect 
potential contaminations by the cellulose membrane, but they resulted in values below 
0.1 EU/mL as well.  
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6.4 DISCUSSION 
 
 
The separation of a mouse monoclonal IgG2c antibody after 48 h of light exposure was 
performed by utilizing a semi-preparative channel in asymmetrical flow field-flow fractionation. 
The resulting distribution of protein species in the fractogram showed four main portions, which 
is excellently comparable to the results obtained from the human model antibody (see previous 
chapter of this thesis) separated with the same method. The light exposure triggered 
fragmentation of the immunoglobulin as well as the formation of aggregates. The extent of 
aggregate formation within 48 hours of light exposure differs between both antibodies. The 
tremendous peak height of the void peak eluting directly after the focusing step narrowing all 
analytes in a band near the sample inlet, is noticeable in the muAb sample. As the size 
determination by MALLS implies, oligomers larger than 5000 kDa elute within that peak, 
deducing that a steric separation mode existed [Fraunhofer et al., 2004; Qureshi et al., 2011]. 
The total recovery determined by AUC certainly includes the void peak and compared to the 
unstressed muAb sample 96 ± 2.8 % of the overall protein content were retrieved. In reverse, a 
marginal amount of protein formed insoluble species, eluding from AF4 separation. Another 
peak, representing aggregates as well, terminates the separation profile. The average 
molecular weight of those analytes was determined to be around 3000 kDa. The threshold of 
size defining whether an oligomer is eluted in the void peak or regularly after the fragments and 
monomers, presumably lies in between 3000 kDa and 5000 kDa. However, crossovers cannot 
be excluded. Large species that range in areas of high velocity within the laminar channel flow, 
might also entrain other species to pass the channel.  
The determination of the molecular weight by MALLS is proportional to the molar mass 
times the concentration of the species [Larkin et al., 2010]. This implicates that for low molar 
mass species the concentration needs to be very high to achieve a proper determination of the 
molecular weight. The concentration and light scattering signals of the fragment peak were thus 
too low to calculate the molecular weight of this species. The MW of 182 kDa determined for 
the peak representing the monomer of the mouse IgG2c is approximately 20 % higher than the 
expected ~150 kDa for a monoclonal antibody. The overestimation indicates an overlay of 
hidden species like dimers and trimers, though at first sight the peak seems to derive from one 
species. When looking back to chapter 5, a shoulder representing dimers and trimers was 
detected in the human model antibody after light exposure. The formation of small aggregates 
can thus be anticipated as well, since the fractograms in general look very similar. The 
separation of high concentrations in the SP1 channel is not capable of resolving the monomer 
from these small aggregates. However, the overall ambition was the preparative use of AF4 
and thus large amounts of protein are required, though at the cost of resolution.  
Including the void peak, two species of oligomeric aggregates of the mouse antibody 
were generated by light exposure. Both are worth to be investigated in vivo concerning their 
immunogenicity. Unfortunately, it was not possible to obtain satisfactory amounts of the 
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aggregates eluting with the void peak in the collected fractions. The concentration step well 
working for the concomitant aggregate species eluting later, did not significantly increase the 
protein concentration of the species in the void peak. The efficiency of volume reduction was 
quite low. The huge aggregates might have interacted with the ultrafiltration membrane in the 
concentrators and thus clogged the pores. Thus the in vivo study focused on the preparation of 
the slightly smaller oligomers. Nicely comparable to the previous stability study performed with 
the human model antibody, the concentrated fraction of oligomers maintained its composition 
during storage at -80 °C in most parts. Hence, a proper handling of the formulation prior to 
administration to animals is assured and the final distribution within the sample is well-known.  
The overall study was performed in the formulation buffer of the antibody, consisting of 
20 mM histidine buffer at pH 6.0. This consistency implies a simplification of the handling of the 
aggregate fraction prior to animal administration, since the buffer can be maintained and no 
dialysis has to be installed later on which potentially alters the aggregate behavior. Only minor 
adaptations concerning tonicity and pH might be required, but should not have an influence as 
big as a complete buffer exchange.  
The determination of endotoxins within a formulation for parenteral use is of great 
concern, since endotoxins are known to induce severe immune responses or even septic shock 
in patients [Morrison et al., 1979]. The United States Pharmacopoeia and the European 
Pharmacopoeia require endotoxin levels below 0.25 EU/mL in their monographs “water for 
injections”. The planned animal studies will include mice usually having a body weight of 
approximately 20 g. Regarding the 5 EU/kg endotoxin level described in USP <85>, this ends 
up in a tolerable dose of 0.1 EU/mouse per injection. Since the designated injection volume will 
be 200 µl, an endotoxin level of ≤ 0.25 EU/ml will finally entail ≤ 0.05 EU/injection to the mice. 
This benchmark was thus defined to be valid for the preparation of protein formulations for in 
vivo studies. The Endosafe™-PTS Portable Test System by Charles River Laboratories used in 
this study has a high sensitivity of up to 0.005 EU/mL and quickly provides the results. A 
downside of the method is its susceptibility to interference by buffer components. A high dilution 
might be necessary increasing the limit of detection. For example, the 20 mM histidine buffer 
used throughout this study entailed a 1:20 dilution with highly purified water for the endotoxin 
determination. However, the resulting limit of detection of 0.1 EU/mL is still sufficiently below 
the predefined benchmark of 0.25 EU/mL.  
The use of a field-flow fractionation instrument to prepare samples for preclinical 
studies is critical in terms of the endotoxin burden within the separated fractions. For our 
purpose the instrument cannot be placed under sterile conditions and even more the device is 
used for diverging analytical purposes. Hence a reliable method was established to purge the 
instrument and simultaneously clean and disinfect it. The extensive rinsing with highly purified 
water, 70 % (v/v) ethanol and again HPW in combination with the aseptic preparation of 
samples, sterilization of buffers, and heat depyrogenation of containers successfully provided 
fractionation conditions with very low endotoxin levels. The later on required concentration step, 
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using disposable concentrators, did also not contaminate the samples with endotoxins. 
Therefore, the overall procedure of meticulous cleaning, fractionation and concentration turned 
out to be applicable for the generation of protein fractions for preclinical studies.  
 
 
6.5 CONCLUSIONS 
 
Asymmetrical flow field-flow fractionation is a very useful preparative tool to generate 
samples for preclinical in vivo studies. The fractionation of valuable amounts of a certain protein 
species was shown and the concentration protocol established in a previous study worked very 
well for the aggregates of interest of a mouse antibody. The use of the formulation buffer 
instead of PBS for separation was successfully implemented, simplifying the subsequent 
handling of the fraction for the in vivo studies. For the intended animal studies the final fraction 
in formulation buffer can easily be stored at -80 °C, gently thawed prior to use and finally 
administered to the animals. Establishing a meticulous cleaning procedure accompanied by a 
thorough preparation of samples, buffers, and containers under aseptic conditions provides a 
proper possibility to keep the endotoxin levels far below the requested 0.250 EU/mL for 
parenteral administration. The entire cleaning procedure is very simple and thus should easily 
be transferable to similar instruments and different analytes. For regular preparations of 
samples for in vivo studies the entire AF4 system and all steps have to be located and run in a 
sterile facility.  
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7  THE NEED FOR IMMUNE COMPLEX 
DISSOCIATION IN ANTI-DRUG ANTIBODY 
DETECTION 
 
 
7.1 INTRODUCTION 
 
 
When exploring the immunogenic potential of aggregates of a given biopharmaceutical 
three main challenges must be considered. First, representative test aggregates must be 
reproducibly generated in the laboratory. Second, the composition of test aggregates must be 
characterized. Finally, the test aggregates must be tested in a suitable in vivo model.  
The current study investigates for the first time the immunogenicity of aggregates of a 
murine monoclonal antibody in wild-type mice. A murine monoclonal antibody (hereafter 
referred to as muAb) of isotype IgG2c was generated in C57BL/6 mouse cells. Formulations of 
muAb were stressed by exposure to controlled amounts of light or by agitation to produce 
suspensions of aggregated antibody, and these suspensions subsequently were injected 
subcutaneously in C57BL/6 mice. Serum samples were collected from the mice and analyzed 
for antibodies that were cross-reactive with the native muAb molecule. 
At the onset of the study, it was unknown whether administration of aggregates of the 
antibody could provoke an immune response that would be cross-reactive with muAb, but it was 
anticipated that aggregated antibodies might present a variety of epitopes, and that immune 
responses would likely be polyclonal.  As such, one of the challenges in using standard ELISA-
based methods to analyze immune response was the lack of reference standards for positive 
responses. Furthermore, because of their relatively large size (approximately 150 kDa) it was 
anticipated that binding of ADAs to muAb coated on ELISA plates might result in steric overlay 
and hindrance. Depending on the orientation of the ADAs after binding to the capturing antigen, 
other binding sites might then become inaccessible. Finally, monoclonal antibodies have a very 
long half-life (up to several months) as compared to other therapeutic proteins [Carpenter et al., 
2009]. This makes it very challenging to detect anti-drug antibodies in serum samples, because 
immune complexes between the circulating drug and anti-drug antibodies potentially may form. 
Two different ELISA methods were used to test identical serum samples and the results 
were compared. Both set-ups were of sandwich ELISA format, meaning that the antigen of 
interest (anti-drug antibody) is fixed by two antibodies that specifically bind to the antigen. The 
detection mode was varied. One method relied on a bridging over the two Fab fragments of the 
anti-drug antibodies, whereas the other method was based on a bridging over the Fc fragment 
and one Fab fragment of the ADAs [Janeway et al., 2004]. Using the two ELISA set-ups 
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surprisingly lead to completely different results in the detection of ADAs. The limitations and 
results of each method will be discussed and possible advantages and drawbacks of each 
method will be pointed out. 
Subvisible particles are currently under suspicion to be related to enhanced immune 
responses to biopharmaceuticals, though (up to now) for approval only the size classes ≥ 10 
µm and ≥ 25 µm are of concern [PhEur 2.9.19., 2008; Singh et al., 2010; USP/NF, 2008]. These 
specifications entail a huge gap of aggregates below these benchmarks which might impact 
product quality [Carpenter et al., 2009]. However, all conditions that enhanced the loading of 
subvisible particles in the samples were especially found to contain numerous particles smaller 
than 10 µm, accompanied with structural changes. These initial alterations might be missed 
within the current release specifications. 
 
7.2 MATERIALS AND METHODS 
 
7.2.1 Generation of protein aggregate test items 
MuAb, a murine IgG2c antibody directed against murine TNF-α, was kindly provided by 
Abbott Bioresearch Center (Worcester, USA) in a formulation comprising 20 mM histidine, pH 
6.0, and a protein concentration of 33 mg/mL. The initial preparation was diluted under aseptic 
conditions to a protein concentration of 4 mg/mL in 20 mM histidine buffer. The pH was 
adjusted to 5.7 using hydrochloric acid. Three milliliters of the solution were filled in 6 R vials, 
glass type 1 (Schott AG, Mainz, Germany) closed with Teflon
®
-coated rubber stoppers (West 
Pharmaceutical Services, Inc., Lionville, PA, USA). Aliquots were stressed either by stirring at 
400 rpm, 25°C for 48 h using Teflon
®
-coated magnetic stir bars, 6 x 3 mm in size (VWR 
International, Darmstadt, Germany), or by light exposure using a xenon lamp in a Suntest CPS 
(Heraeus Holding, Hanau, Germany) radiation chamber at a radiation intensity of 55 ± 5 W/m² 
for 48 h. Samples were placed horizontally in the irradiation chamber. The xenon lamp emitted 
light of the whole sunlight spectrum including ultraviolet (UV) radiation. The emitted light was 
filtered by sheet glass to obtain a radiation spectrum close to that to which an antibody 
formulation might be exposed to during storage and handling. The light-exposed samples were 
analyzed by size exclusion chromatography and showed a soluble protein concentration of 
about 85% of the muAb initially present. Accordingly, 15 % of the total protein content formed 
insoluble species. Subsequently, the insoluble species in the samples were removed from the 
suspension by centrifugation (10,000 x g, 10 min). The soluble fraction present in the 
supernatant was diluted further to obtain a concentration of 250 µg/mL soluble protein species 
(including ~ 56 % soluble aggregates). To adjust tonicity, 8% (w/v) sucrose was added. If 
necessary, the pH was adjusted to 5.7 with hydrochloric acid or sodium hydroxide. 
Stirring resulted in the formation of visible particles that were subsequently collected by 
centrifugation (10,000 x g, 10 min). The resulting pellet was collected and resuspended in 
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buffer. Particles in the resulting suspension were counted by light obscuration using a Pamas 
SVSS instrument (PAMAS GmbH, Rutesheim, Germany). Each sample was measured in 
triplicate.  
Finally, two different formulations containing either 25 µg/mL or 250 µg/mL protein were 
prepared from the light-exposed samples. These formulations were spiked with ~4000 particles 
(of a size ≥ 1 µm) per ml that previously had been generated by stirring and counted by light 
obscuration. With this approach two dosages of a combination of soluble and insoluble 
aggregates of different kinds and sizes together were used for injection. All reagents used were 
of analytical grade. 
7.2.2 Size exclusion chromatography 
Concentrations of soluble aggregates and monomeric protein were measured by size 
exclusion chromatography (SEC) on an Agilent 1100 system with RI, MALLS and UV detection 
(Agilent Technologies, Palo Alto, USA). A Superose 6 10/300 GL column (GE Healthcare, Little 
Chalfont, UK) was used as the solid phase. Phosphate buffered saline (PBS) at pH 7.4 (12 mM 
phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride) with a flow rate of 0.5 mL/min 
was used as a mobile phase. The protein recovery was calculated using the UV absorbance 
signal at 214 nm. The area under the curve (AUC) of the unstressed sample was defined as 
100%.  
7.2.3 Light obscuration 
Light obscuration (LO) measurements were conducted with a PAMAS-SVSS-C Sensor 
HCB-LD 25/25 (Partikelmess- und Analysensysteme GmbH, Rutesheim, Germany) to quantify 
particles ≥ 1 μm. Three aliquots of 0.3 mL of each sample were analyzed. Between the sample 
measurements the system was rinsed with highly purified water (Millipore Corporation, Billerica, 
USA) until the system was free of particles. Before each measurement, 0.3 mL of the sample 
was flushed through the system and discarded. 
7.2.4 Endotoxin testing 
The samples were checked for endotoxins using a FDA-licensed Endosafe-PTS 
instrument (Charles River Laboratories, Wilmington, USA) with a limit of detection of 
0.005 EU/mL. All samples were diluted 1:50 with endotoxin-free highly purified water, due to 
interference of the buffer with the measurement. All samples were found to be free of 
endotoxins (< 0.25 EU/mL). 
7.2.5 Animals 
Male and female (3 of each per test group) C57BL/6 mice were obtained from Charles 
River Laboratories, Wilmington, USA. All mice were used from approximately 9 weeks of age, 
and had access to tap water (autoclaved, acidified, pH 2.5-2.8) and food (R/M-H pellets rodent 
diet, Ssniff, Soest, Germany) available ad libitum. Mice were allowed at least five days to 
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acclimate before the dosing period commenced. Mice were housed individually in U-Temp
TM 
Type II long cages, barriered conditions with bedding. The environmental conditions were set at 
a room temperature of 22 ± 2°C, humidity of 55 ± 10% and 15 to 18 air changes per hour. 
Rooms were set on a 12-hour daily light cycle (light from 6 a.m. to 6 p.m.) except as required 
for sample collection or other study procedures.  
All animals were observed each day for the duration of the study, and none of the 
animals died or showed abnormalities. Injection sites, body weight and food intake were 
examined for each animal and did not show abnormalities (data not shown). 
All experiments were conducted in the laboratories of Abbott GmbH & Co. KG 
(Ludwigshafen, Germany) in accordance with the following international regulations: 
International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH): Non-Clinical Safety Studies for the Conduct of Human 
Clinical Trials for Pharmaceuticals, ICH M3(M), (CPMP/ICH/286/95, modification), November 
2000 and the Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on 
Repeated Dose Toxicity, CPMP/SWP/1042/99 corr., October 2000. 
7.2.6 Immunization protocol 
200 µL injections of various muAb or placebo formulations were administered 
subcutaneously into the scruff of the neck to male and female C57BL/6 mice. Four different test 
groups were previously defined. Serving as negative control, the first group of animals 
(“Group A”) received a placebo formulation of 20 mM histidine buffer with 8% (w/v) sucrose, pH 
5.7. The verum formulations contained either 250 µg/mL of native muAb (“Group B”), or light 
exposed, aggregate-spiked muAb aggregates at a total concentration of 25 µg/mL of protein 
(“Group C”), light exposed, aggregate-spiked muAb aggregates at a total concentration of 
250 µg/mL of protein (“Group D”).  Injections were carried out on days 1, 2, 4, 6, 13, 20, 27 
followed by a six week recovery period.  
7.2.7 Collection of blood samples 
Blood sampling was performed postmortem during necropsy from the Vena cava on 
day 1 (before any injection), day 15, day 29 or day 71. The whole blood was collected in 
polypropylene tubes without anticoagulant and kept at room temperature for 30 to 60 minutes 
until centrifugation (10000 x g, 5 minutes) at approximately 5°C.  The serum was separated 
from the blood cells and divided in two halves. The aliquots were stored at -80°C before 
analysis.  
7.2.8 Determination of Anti-Drug Antibodies (ADAs) 
Anti-drug antibodies towards muAb were determined from serum samples using 
sandwich enzyme-linked immuno sorbent assays (ELISA’s) in polystyrene MaxiSorp 96-well 
plates (Nunc, Roskilde, Denmark) according to either Method A or Method B below (see Figure 
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7-2). In both methods, 150 µL/well of muAb solution (concentration 750 ng/mL in PBS) were 
used as capture-antibodies for potential anti-muAb antibodies in serum samples. The wells 
were coated with muAb solution overnight at 4°C. Blocking subsequently was performed by 
incubating each well for 1 h at room temperature with 200 µL 1% BSA (Sigma Aldrich, 
Steinheim, Germany) solution in Dulbecco`s PBS (Invitrogen, Darmstadt, Germany). Between 
the incubation steps the wells were washed with PBS (12 mM phosphate, 137 mM sodium 
chloride, 2.7 mM potassium chloride), containing 0.05% Tween-20. All substances were of 
analytical grade and all buffers and solutions were prepared in highly purified water (Purelab 
Plus, USF Elga GmbH, Celle, Germany).  
7.2.8.1 Method A  
Serum samples (100 µL) were added to the muAb-coated wells at 1:10 dilution in a 
solution containing 14.4 mM tri-sodium citrate dihydrate, 1.1 M sodium chloride and 0.1 % 
polysorbate 20. After incubating 90 minutes and washing, 62.5 ng/mL of biotinylated muAb was 
added, incubated for 90 minutes and subsequently after five washing steps 1:16,000 fold 
diluted streptavidin peroxidase-conjugated anti-biotin antibody fragment (Sigma Aldrich, 
Steinheim, Germany) was added and the plate was washed. The bound peroxidase reacted 
with a substrate containing 0.65 mM hydrogen peroxide (Merck, Darmstadt, Germany) and 0.05 
mg/mL 3,3`,5,5`-tetramethylbenzidine (Fluka, Taufkirchen, Germany) dissolved in 
dimethylsulfoxide (Merck, Darmstadt, Germany). The reaction of peroxidase and substrate was 
stopped by the addition of 0.5 M sulfuric acid (Mallinckrodt Baker, Deventer, Netherlands) prior 
to measuring the absorbance with a FLUOstar Omega at 450 nm (BMG Labtech GmbH, 
Offenburg, Germany). Each serum sample was measured in duplicate. Serum samples were 
declared positive for ADAs when the mean absorbance values were at least three times higher 
than the upper 95
th
 percentile value for negative control serum samples from a total of 24 mice 
that had received either no injections (3 male and 3 female mice) or injections of placebo 
formulations containing only buffer (3 male and 3 female mice sacrificed on each of days 15, 
29, and 71).  
The suitability of method A to detect anti-muAb antibodies was validated by using a 
reference polyclonal rabbit antiserum (Biotrend Chemicals GmbH, Cologne, Germany) raised 
against native muAb. Rabbits were hyper-immunized with muAb and the induced rabbit anti-
muAb antibodies were chromatographically purified and spiked into to serum from naïve 
C57BL/6 mice, which was then analyzed as described above. 
7.2.8.2 Method B 
The presence of antibody-antigen complexes in serum presents a challenge for 
detection of ADAs in standard ELISA assays. Shomali et al. showed that addition of an acid 
dissociation step reduced interference from immune complexes and increased the amount of 
ADAs that could be detected in mice that had been immunized with ovalbumin as a model drug 
[Shomali et al., 2010].  In the present study, an additional acid dissociation step was added to 
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the ELISA protocol to dissociate potential antibody-muAb complexes prior to ADA analysis. In 
this step, 1:20 diluted serum samples were incubated in 300 mM acetic acid (resulting pH 2.5-
3.0) for one hour to dissociate potential immune complexes, after which time the pH was 
adjusted to 7.4 using 1 M Tris base pH 9.5. Under this low pH environment dissociation of 
immune-complexes is favored, but antibodies do not appear to lose their binding capacity 
[Patton et al., 2005]. 
In this method, the ELISA analysis was conducted as described in Method A, except 
that 1:15,000 diluted isotype-specific HRP-conjugated goat anti-mouse isotype (anti-IgM, anti-
IgG1, anti-IgG2b or anti-IgG3) antibodies (Jackson ImmunoResearch, West Grove, USA) were 
used for detection. 
7.2.9 Determination of drug levels in serum (pharmacokinetics, PK) 
For the determination of muAb in serum samples, an ELISA was developed using 
MaxiSorp 96-well plates. A volume of 150 µL/well of murine TNF-α (eBioscience Inc., San 
Diego, USA) at a concentration of 100 ng/mL in PBS was used as capture-antigen for muAb in 
serum samples. After blocking with 1% BSA in PBS and washing the plates, 1:80,000 diluted 
biotinylated goat anti-mouse-IgG2c (Southern Biotech, Birmingham, AL, USA) was used as 
primary detection antigen. As a secondary detection antigen a streptavidin peroxidase 
conjugated anti-biotin fragment in 1:16,000 dilution was added, after further washing steps. The 
bound peroxidase was measured by addition of 0.65 mM H2O2 and 0.05 mg/ml 3,3`,5,5`-
tetramethylbenzidine. After 15 minutes of incubation, the reaction was quenched by addition of 
0.5 M sulfuric acid and, the reaction product detected by absorbance at 450 nm using a BMG 
FLUOStar. For calibration muAb spiked to C57BL/6 serum (LPT - Laboratory of Pharmacology 
and Toxicology, Hamburg, Germany) was used. The serum samples were diluted individually in 
a solution containing 14.4 mM tri-sodium citrate dihydrate, 1.1 M sodium chloride and 0.1 % 
polysorbate 20 until the linear range of a calibration curve was reached. Each serum sample 
was measured in duplicate. 
 
7.3 RESULTS 
 
7.3.1 SEC Analysis of murine IgG2c after light exposure 
Prior to exposure to light, muAb samples were largely monomeric, with a small amount 
(1.20 ± 0.19 %) of the sample present as lower molecular weight species. After 48 hour 
exposure to light muAb samples formed roughly 15% insoluble aggregates. Furthermore, the 
populations of both higher molecular weight species and low molecular weight fragments 
increased dramatically, with a concomitant decrease in the amount of monomer present (see 
Figure 7-1).  
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Figure 7-1 – UV-size exclusion chromatograms at 214 nm of muAb. 
The blue line represents the placebo formulation, revealing a large peak at 47 minutes caused by 
histidine. The unstressed muAb formulation is displayed by the black line, and the muAb sample after 48 h 
of light exposure is shown by the red line. The light exposed sample shows a strong decrease of monomer 
peak (retention time 36 min) as well as an increase of aggregates and fragments. 
 
After centrifugation to remove insoluble aggregates, the remaining ~ 85 % of initially 
present muAb contained 15.3 ± 1.7 % of monomer, accompanied by 55.9 ± 2.6 % aggregates 
and 28.7 ± 4.3 % fragments. 
7.3.2 Analysis of anti-drug antibody levels using two ELISA formats 
Figure 7-2 provides the schematic mode of operation of the utilized ELISA formats. All 
samples were first analyzed using method A, which did not include an acid dissociation step. 
Furthermore, this set-up relied on the availability of a second free Fab part of the anti-drug 
antibodies in the samples. The performance of the assay was tested by the reference antibody 
generated in hyper-immunized rabbits.  
The sensitivity of the method depends on the concentration of the reference antibody 
(see Figure 7-3). The limit of detection of the reference antibody was determined to be ~27 ng 
(3 x δ) and the limit of quantification was determined to be ~41 ng (10 x δ).  
 
Light exposed muAb 
MuAb control Buffer peak 
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Figure 7-2 – Schematic representation of the two ELISA formats used.  
The enzymatic reaction for detection resulting in coloration is pictured by the arrow. A) Design of method 
A: muAb (shown in solid black) was coated on the surface of the well plate (1), the serum contains muAb 
as well as anti-muAb antibodies (shown in solid white), which form immune complexes (2). Bridging 
reactions of anti-muAb antibody between muAb coated and muAb labeled with biotin ( ) are displayed in 
(3). B) Design of method B: muAb (shown in solid black) was coated on the surface of the well plate (1). In 
method B, immune complexes are dissociated by incubation with acetic acid prior to applying to the well 
plate. Therefore the circulating muAb molecules are free (4) and not complexing anti -muAb antibodies and 
hence these are able to bind via Fab fragments to the coated muAb (2). Detection was performed with 
HRP – labeled ( ) goat anti-mouse antibodies (grey dashed antibody draft), binding to the Fc domain of 
anti-muAb antibodies. 
 
B) 
A) 
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Figure 7-3 – Absorbance results of different concentrations of the reference antibody using 
method A. 
The reference material was generated in rabbits. The error bars represent the standard deviation of 
measurements in triplicate. 
 
In contrast, method B included an additional incubation step wherein the serum 
samples were incubated with a weak acid to dissociate immune complexes that might have 
formed between muAb and the anti-muAb in serum. Instead of using biotinylated muAb as a 
detection antibody, which would require free Fab arm of ADA for binding, the detection in 
method B was based on goat anti-mouse isotype-specific antibodies binding to the Fc portion of 
potential ADAs.  
The results obtained from these two ELISA setups were compared within this study. 
The ADA detection by method A was performed at LMU Munich, Department of Pharmacy, 
whereas ELISA method B was conducted by our academic cooperation partner at University of 
Colorado in Boulder. The group of Theodore W. Randolph and especially Maliheh Shomali 
performed this part of the studies. After completion of the in vivo studies and analysis of serum 
samples using method A, the left-over serum samples were shipped to Colorado. They kindly 
provided the results for better comprehension of the entire thesis. However, this small part is 
property of the University of Colorado and was not conducted on my own. 
For each setup a background absorbance was averaged from the values determined in 
the sera of 6 naïve mice and 18 mice that received the placebo formulation. Due to the 
diverging number of repetitions of sample measurements performed either by method A 
(triplicates) or method B (duplicates), the standard error of the mean was calculated, which 
refers to the sample size. 
The results of the measurement of the serum samples from the mice that were injected 
with the placebo formulation are shown in Figure 7-4 A-E. Each bar represents an individual 
animal, since the mice were sacrificed for bleeding. Analysis of sera from mice injected with 
buffer only showed a constant background response when analyzed by Method A 
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(Figure 7-4 A).  A similar result was obtained when the sera were analyzed for IgG1, IgG3 and 
IgM by  Method B (Figures 7-4 B, D and E, respectively. However, background responses 
against IgG2b detected by Method B increased over time, particularly for females 
(Figure 7-4 C). The reason(s) for this apparent increase in background signal over time are 
unclear. 
  
  
 
Figure 7-4 - Absorbance measurements of ELISA for detection of anti-drug antibodies in mice 
having obtained the placebo formulation.  
A) detection of ADA by method A (n=3, error bars represent standard error of the mean) B) detection of 
IgG1 directed against muAb by method B C) detection of IgG2b directed against muAb by method B D) 
detection of IgG3 directed against muAb by method B E) detection of IgM directed against muAb by 
method B (n=2, error bars represent standard error of the mean). The plain grey bars represent the data 
obtained from 3 male mice, and the checkered bars represent the data obtained from 3 female mice. The 
horizontal line represents the predefined benchmark of non-responders and responders for each assay 
set-up (the upper 95
th
 percentile of background absorbance values from 24 mice). Because animals were 
sacrificed for blood collection, each bar represents a separate animal. 
  
A) B) 
C) D) 
E) 
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Figure 7-5 - Absorbance measurements of ELISA for detection of anti-drug antibodies in mice 
having obtained the formulation containing native muAb.  
A) detection of ADA by method A (n=3, error bars represent standard error of the mean) B) detection of 
IgG1 directed against muAb by method B C) detection of IgG2b directed against muAb by method B D) 
detection of IgG3 directed against muAb by method B E) detection of IgM directed against muAb by 
method B (n=2, error bars represent standard error of the mean). The plain grey bars represent the data 
obtained from 3 male mice, and the checkered bars represent the data obtained from 3 female mice. The 
horizontal line represents the predefined benchmark of non-responders and responders for each assay 
set-up (the upper 95
th
 percentile of background absorbance values from 24 mice). Because animals were 
sacrificed for blood collection, each bar represents a separate animal. 
 
The results of the measurement of the serum samples from the mice that were injected 
with the formulation containing native muAb are shown in Figure 7-5 A-E. Method A did not 
detect ADA for mice sacrificed on day 15 or day 29, and detected only very low positive ADA 
levels in one mouse that was sacrificed on day 71 (Figure 7-5 A). The detection of anti-muAb 
IgG1 levels with the comparative Method B shows a positive response in  a single  male mouse 
C) D) 
E) 
A) B) 
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on day 15 (Figure 7-5 B). In contrast, two IgG2b absorbance values from female mice were 
higher than the upper 95% confidence level for the mean of controls (Figure 7-5 C), but these 
IgG2b levels cannot be definitively classified as positive responses, because the placebo also 
showed similar increases, which were also more pronounced in female mice. The results of 
anti-muAb IgG3 in Group B are shown in Figure 7-5 D. In 2/6 samples from day 29 and 3/6 
samples from day 71 positive responses were detected. No increased anti-muAb IgM response 
was detected (Figure 7-5 E) in any serum sample of Group B. 
  
  
 
 
Figure 7-6 - Absorbance measurements of ELISA for detection of anti-drug antibodies in mice 
having obtained the formulation containing a low dose of aggregated muAb.  
A) detection of ADA by method A (n=3, error bars represent standard error of the mean) B) detection of 
IgG1 directed against muAb by method B C) detection of IgG2b directed against muAb by method B D) 
detection of IgG3 directed against muAb by method B E) detection of IgM directed against muAb by 
method B (n=2, error bars represent standard error of the mean). The plain grey bars represent the data 
obtained from 3 male mice, and the checkered bars represent the data obtained from 3 female mice. The 
horizontal line represents the predefined benchmark of non-responders and responders for each assay 
set-up (the upper 95
th
 percentile of background absorbance values from 24 mice). Because animals were 
sacrificed for blood collection, each bar represents a separate animal. 
A) B) 
C) D) 
E) 
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ADA levels in serum samples from the mice injected with the low dose of aggregated 
protein (5 µg protein in total per injection) are shown in Figure 7-6 A-E. Using method A, ELISA 
analysis of the majority of the samples (17 out of 18) from mice that received the low dose of 
aggregated protein resulted in absorbance values that were near or below the defined response 
cutoff value. Only one serum sample from a female mouse bled on day 29 shows a substantial 
anti-drug antibody response under these circumstances (Figure 7-6 A). Serum from the same 
female also showed a high anti-muAb IgG1 response when method B was used (see below). In 
other mice tested by Method B for IgG1, responses were detected in 2/6, 2/6, and 2/6 mice 
sacrified on days 15, 29, and 71, respectively (Figure 7-6 B).  Two  mice (one male and one 
femle) showed moderate IgG2b responses to low-dose aggregates (Figure 7-6 C), but as 
discussed above this could not be unequivocally assigned to an ADA response because the 
increased anti-IgG2b response seen at later time was also observed in the placebo samples 
(Figure 7-4 C). The results of anti-muAb IgG3 detection using method B show 2/5 weakly 
positive serum samples at day 71 (Figure 7-6 D). Finally, two serum samples obtained on day 
71 show also positive responses in the IgM assay of method B (Figure 7-6 E). 
The fourth dosing Group D received the formulation containing the high dose of light 
exposed muAb (50 µg of protein in total per injection), spiked with the same number of 
aggregated protein particles as were administered to the low-dose group. Figure 7-7 shows the 
results of the measurement of anti-muAb antibodies in the serum samples from those mice. No 
mice that received the high dose of muAb show positive ADA responses when using detection 
method A (Figure 7-7 A). In contrast, strong positive responses for Anti-muAb IgG1 levels were 
detected using method B. On day 15, four out of six sera showed positive anti-muAb IgG1 
responses (Figure 7-7 B). On day 29, the blood of one male mouse clotted immediately during 
bleeding, hence no serum could be produced and investigated. All of the remaining samples 
(5/5) resulted in positive IgG1 responses directed against muAb, comparable to the 4/6 
responding mice on day 71. The absorbance of the sera from responders on days 29 and 71 
were higher than those on day 15. Analysis of the sera for anti-muAb IgG2b levels showed 2 
responders on day 71 (Figure 7-7 C), but was inconclusive for reasons discussed above. When 
tested for anti-muAb IgG3 levels, 2/6 serum samples obtained on day 71 were positive and both  
were received from female mice (Figure 7-7 D). Substantial IgG3 responses against muAb were 
not detected at earlier time points. None of the mice that received the high dose of muAb 
generated substantial  amounts of anti-muAb IgM (Figure 7-7 E). 
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Figure 7-7 – Absorbance measurements of ELISA for detection of anti-drug antibodies in mice 
having obtained the formulation containing the high dose of aggregated muAb.  
A) detection of ADA by method A (n=3, error bars represent standard error of the mean) B) detection of 
IgG1 directed against muAb by method B C) detection of IgG2b directed against muAb by method B D) 
detection of IgG3 directed against muAb by method B E) detection of IgM directed against muAb by 
method B (n=2, error bars represent standard error of the mean). The plain grey bars represent the data 
obtained from 3 male mice, and the checkered bars represent the data obtained from 3 female mice. The 
horizontal line represents the predefined benchmark of non-responders and responders for each assay 
set-up (the upper 95
th
 percentile of background absorbance values from 24 mice). Because animals were 
sacrificed for blood collection, each bar represents a separate animal. 
 
As noted above, using method A, ADA levels well above the positive response cutoff  
were detected in only one of 36 sera of mice that received the formulations containing muAb 
aggregates (Figure 7-6 A, Figure 7-7 A). This animal had received the low dose aggregated 
antibody formulation (5 µg per time point). To assure that the one positive sample detected with 
method A (later on referred to as mouse serum C29+) was truely an ADA against muAb, a 
A) B) 
C) D) 
E) 
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duplicate of the serum sample was spiked with 100 ng/ml of the native protein (muAb). True 
anti-muAb antibodies would bind to added muAb molecules in solution and thus not bind to 
muAb coated in wells and washed away, leading to loss of signal at the end of the assay. 
Addition of 100 ng/ml muAb to the serum sample, C29+, resulted in a complete 
inhibition of the response (Figure 7-8). The formation of immune complexes between muAb and 
specific anti-muAb antibodies in C29+ inhibited the binding of ADA to the coated muAb 
molecules. The high absorbance signal of this specific animal thus was proven to originate from 
ADAs. Additionally, the strong influence of free drug circulating in the serum was shown. As 
expected, when analyzed by method B, this same sample was also positive for anti-muAb 
ADAs.  
 
Figure 7-8 – Inhibition of positive ADA response in serum of mouse C29+ by adding native muAb. 
Absorbance results of the positive serum sample (white circles) using method A and after adding 
100 ng/mL muAb to the serum (black triangles). (Error bars = standard deviation of three measurements) 
 
7.3.3 Detection of serum levels of muAb – pharmacokinetics 
In addition to the determination of ADAs, the pharmacokinetics (PK) of the murine 
antibody was of great importance in this study. It was important to determine how fast the 
antibody was cleared in the animal and if the presence of unbound antibody in the blood could 
result in false negative results regarding the ADAs. Each serum sample was analyzed in 
duplicate. No muAb was detected in the PK assay in the serum samples of the mice that 
received the placebo formulation (Group A) at all sampling times (data not shown). Similar 
results were observed in the sera of mice which received the low dose formulation. A different 
result was observed in the samples of the mice that received the native antibody muAb (see 
Figure 7-9). The levels of the muAb in the serum were quite high for the group that received the 
native protein formulation. Even after a six week recovery period (with no additional muAb 
injection), concentrations in the upper nanogram per ml range were determined. The long half 
  ANGELIKA FREITAG         DISSERTATION        IMMUNE COMPLEX DISSOCIATION IN ELISA 
 
136 
 
life is a well known quality of monoclonal antibodies [Carpenter et al., 2009]. Therefore, the high 
levels of muAb detected in Group B are not very surprising. On day 15 the measured amounts 
of muAb in Group B reach up to about 100 µg/ml. On day 29 the amounts showed stable values 
of around 50 µg/ml before the values decreased by day 71.  
 
Figure 7-9 – Results of ELISA determining the concentration of muAb in the serum samples of 
mice that obtained 50 µg of the native antibody per injection. 
The plain grey bars represent the data obtained from 3 male mice, and the checkered bars represent the 
data obtained from 3 female mice. (Triplicate measurements per sample, error bars represent standard 
deviation) 
 
The formulation containing aggregates still consisted of considerable amounts of 
monomeric muAb (see Figure 7-1) and is thus expected to result in detectable muAb levels in 
serum. Figure 7-10 shows the results for sera of the mice that received the high dose 
formulation. The calculation of the amount of muAb within the aggregated formulations was 
made using the aggregated formulation as calibration standard. In the sera obtained on day 71 
no muAb was detected and on days 15 and 29 the recovery was much lower compared to the 
native Group B. The levels detected in these sera were about 10 times lower than the serum 
levels of mice in Group B. The results of Group A and Group C are not shown, because these 
were below the limit of detection. 
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Figure 7-10 – Results of ELISA determining the concentration of muAb in the serum samples of 
mice that obtained 50 µg of the aggregated antibody per injection. 
The plain grey bars represent the data obtained from 3 male mice, and the checkered bars represent the 
data obtained from 3 female mice. (Triplicate measurements per sample, error bars represent standard 
deviation) 
 
 
7.4 DISCUSSION 
 
The study was initiated to establish a bioanalytical method for prospective in vivo 
studies concerning the immunogenicity of aggregates of a murine antibody (muAb) in mice. 
Two different ELISA protocols were designed for the detection of anti-muAb antibodies, whose 
generation was strongly expected after the repeated administration of various kinds of 
aggregates of muAb in contrast to the repeated administration of native muAb. 
The data from two ELISA methods showed significant differences. After analyzing the 
serum samples using method A, one might think the negative results could either mean that no 
anti-muAb antibodies were generated in most animals, that mainly false negative samples were 
obtained due to a lack of detection, or that the antibodies generated were not directed against 
muAb. Looking only at these results, it is not possible to clarify whether ADAs were produced 
against the administered samples or not.  
Since the native muAb is a self-protein for C57BL/6 mice, the mice in Group B (native 
muAb) showed the formation of only very few positive anti-muAb antibodies. Using method A, 
only very weak immune response to native muAb could be detected. However, method B 
showed increased levels of anti-muAb antibodies of various subclasses.  
Administering the ten-times higher amount of aggregated protein considerably 
increased the incidence of anti-muAb IgG1 formation, though this dose concomitantly failed to 
induce an ADA response detectable by method A. A difference between the responses of both 
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genders was determined in anti-muAb IgG1 levels (Figure 7-7 B). Two female mice on day 15 
and all female mice on days 29 and 71 responded, whereas only two male mice each on days 
15 and 29 and one on day 71 resulted in minor formation of IgG1 towards muAb. Differences 
between the higher and the lower dose of aggregated protein were not significant for IgG3 class 
ADAs.  
No strong responses of IgG3 directed against muAb were observed over time in any 
group. IgG3 responses are frequently associated with T-cell independent immune responses 
[Swanson et al., 2010]. The lack of IgG3 response is thus consistent with a T-cell dependent 
mechanism for immune response to muAb, although more detailed immunological studies 
beyond the scope of the current work would be required to provide conclusive evidence. 
Anti-muAb IgM was only generated in mice to which low-dose aggregates were 
administered. Interestingly, these response were observed only at the last bleed point on day 
71. IgM responses to soluble antigens are typically short-lived [Murphy et al., 2008]. It is 
speculated that a possible depot effect of the aggregated protein may have led to the delayed 
IgM response. However, a detailed investigation of IgM response towards muAb would have 
required the inclusion of several bleeds within the first two weeks and is outside the scope of 
the present study.  
The most probable reason for not detecting existing ADAs when method A was used is 
the formation of complexes between free drug (muAb) and ADAs circulating in the blood. The 
definitive influence of small amounts of circulating drug was shown by the complete inhibition of 
the only positive response by adding muAb to the respective serum sample. Furthermore, the 
immune complexes formed may be eliminated quickly from the blood stream [Murphy et al., 
2008]. Using method B leads to different results: ADAs could be detected in most of the animals 
treated with aggregates of muAb. This set-up of ELISA included an acid dissociation step in 
order to break immune complexes. Therefore, the interference of circulating drug is presumably 
reduced, resulting in diminished interference of immune complexes with the ELISA assay. 
Furthermore, the biotinylated muAb as a detection reagent was replaced by HRP-labelled goat 
anti-mouse immunoglobulins of isotypes IgM, IgG1, IgG2b and IgG3. This approach added to 
the data interpretation by supplying additional information about the isotypes of ADAs 
generated. Whether the acid dissociation step in method B, the exchange of detection 
antibodies, or both is the reason for these differences was not investigated in this study. The 
mode of detection seems not to be crucial to the differences between the methods. This 
assumption is supported by the single highly positive result obtained using Method A. It is most 
likely that this single animal showed enhanced metabolic kinetics and/or an accelerated 
clearance of the drug and thus not enough muAb was left circulating in the blood stream to form 
complexes with the ADAs. Presumably this is the reason for the strongly positive response 
detected.  
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One must be careful about the baseline reactivity of immunoglobulins in the mouse 
sera for the test antigen, muAb. This could be differentiated by testing the pre-bleeds from each 
mouse. Some immunoglobulins in pre-bleeds might bind to muAb and could give rise to false 
positives. Since the study design scheduled bleedings by necropsy, no initial level for each 
animal can be determined, but the serum of three naïve animals of each gender was included in 
the calculation of a background.  
The results were complemented by the pharmacokinetics assays that were used to 
determine the amount of muAb present in the sera that was capable of binding TNF-α. The 
detected drug levels in Group D in the µg/ml range at days 15 and 29 support the assumption of 
immune complex formation in these samples. This would imply that all anti-drug antibodies 
being generated in the animals are complexed to circulating drug molecules and could not be 
detected using method A. Since monoclonal antibodies usually offer a half-life of 10-21 days in 
plasma, an excess of circulating drug molecules is presumably available.  
In conclusion, there probably were plenty of drug molecules circulating, much more 
than anti-drug antibodies generated. The high levels of up to 100 µg/ml drug detected in serum 
samples of Group B prove the long lasting availability of numerous free drug molecules. This 
imbalance caused the lack of detection of ADAs if no dissociation step was included. One 
animal showed a strong ADA response that was detected using method A even without the 
dissociation step. As discussed before, we assume that to be a statistical outlier with an 
accelerated clearance of the drug and free ADA molecules.  
Several obstacles were encountered when the serum samples of the mouse study were 
analyzed. First was the lack of a positive control. The immunogenicity of aggregates was 
anticipated and some of the epitopes exposed in protein aggregates might provoke antibodies 
that cross-react with native muAb. Furthermore, it was expected that samples from the 
formulation that contained both a variety of aggregate types and the highest concentrations of 
aggregates would be most immunogenic. Unexpectedly, when using method A, no strong 
positive ADA response from this formulation was detected, likely because immune complexes 
interfered with the analysis. Finally, the alternative method B, including the acid dissociation 
step to dissociate immune complexes, was able to detect significant increases in anti-muAb 
IgG1 levels in the majority of mice of test Group D. These IgG1 responses towards muAb were 
clearly more pronounced and appeared with higher incidence than in those samples obtained 
from the mice that received only one-tenth of the same formulation which included both 
monomer and soluble aggregates. These results confirmed the hypothesis that the immune 
response generated in the animals depends on the amount of aggregates administered and 
increases with the application of more aggregates of the same type.  
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7.5 CONCLUSION 
 
To some degree, all therapeutic proteins are potentially immunogenic, and their 
aggregated forms are of great concern for immunogenicity. Singh et al. reviewed package 
inserts of approved biopharmaceutics and literature and stated that ADAs were seen in almost 
all cases [Singh, 2011]. 
The investigation of different aggregates is of great interest, because it is still unclear 
whether aggregates in general or only aggregates with specific structural properties have an 
impact on immune response. Supported by the European Medicines Agency (EMA) “Guideline 
on Immunogenicity assessment of biotechnology-derived therapeutic proteins” animal models 
are often used to evaluate the safety of protein drugs leading to the question which species 
should be used to predict immunogenicity in humans [Pendley et al., 2003; Roskos et al., 2004]. 
The use of transgenic animals is quite common but very expensive and their immune system is 
artificially altered. The use of naïve animals without any alteration in the immune system is an 
advantage compared to transgenic mice, and this is an approach very close to the therapeutic 
situation of human antibodies in human patients. This study in principal proves the suitability of 
using wild type mice to investigate murine antibodies compared to the transgenic approach. 
This study shows that the detection of anti-drug antibodies depends on a thorough 
development of a proper assay format. It can be concluded that including an acid dissociation 
step to the ELISA results in the detection of anti-drug antibodies that could not be detected in 
serum samples without the acid dissociation step. Dissociation of immune complexes is thus 
essential for an adequate detection of ADAs; otherwise potential immune reactions could be 
missed or overlooked. Therefore, it is recommended to include this approach in the analysis of 
in vivo studies as well as in clinical studies when immunogenicity is assessed. 
The mode of detection, either based on free Fab arms of the ADAs or on a binding to 
the Fc part of the ADAs, was not investigated in more detail. The use of subtype specific 
detection antibodies is recommended and entails the advantage of additional information about 
the subclass of ADAs generated.  
The pharmacokinetic behaviour of the drug should be investigated in parallel. 
Monoclonal antibodies have an especially long half-life in blood and therefore have a chance to 
have a significant impact on the formation of immune complexes. The strong binding between 
small amounts of circulating drug and anti-drug antibodies emphasizes the relevance of ADAs 
in vivo. If ADAs are generated during a drug therapy they can potentially bind the drug and 
strongly reduce its activity.  
Considerable efforts still have to be undertaken to extend the knowledge of the relation 
between immunogenicity and various types of aggregates that might be generated in 
biopharmaceuticals for an improved safety and efficacy of this growing class of drugs.  
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8  INVESTIGATIONS ON THE IMMUNOGENICITY OF 
PROTEIN AGGREGATES OF A MURINE MONOCLONAL 
ANTIBODY IN WILD-TYPE MICE 
 
 
 
8.1 INTRODUCTION 
 
Besides many other factors, immunogenicity is particularly supposed to be related to 
aggregates and particles which are suspected to activate the immune system and to initiate the 
elicitation of antibodies by B cells [Braun et al., 1997; Carpenter et al., 2009; Hermeling et al., 
2005]. However, it is still unknown, if aggregates in general, or only some particular structures 
are responsible for this activation of the immune system. This study focuses on the aggregates 
of a murine monoclonal antibody, whose immunogenic potential was investigated in wild type 
mice. Using that approach, foreignness of the antibody to the in vivo model can be excluded 
and additionally the therapeutic situation of administering a human monoclonal antibody to 
human is imitated well.  
The current method to determine immunogenicity of protein aggregates is the 
measurement of anti-drug antibody (ADA) levels in the serum. These ADAs can either bind to 
the drug molecule, leading to an accelerated elimination, or neutralize the effect of the drug. 
Both mechanisms entail a loss in efficacy of the drug. In more severe circumstances, the ADAs 
can even neutralize endogenous human proteins, which might lead to life-threatening 
complications [Schellekens, 2005; Schernthaner, 1993].  
In this study, five different types of aggregates of a murine monoclonal antibody of 
IgG2c subtype were prepared from pure protein by stirring, shaking, light exposure and 
exposure to heat. All four mechanisms represent relevant stress factors that can potentially 
occur during protein manufacturing and might lead to protein aggregation [Schoeneich, 2010; 
Wang, 2005]. The aggregates were analyzed using different analytic techniques and separated 
either by centrifugation or by AF4. Subsequently, all samples were administered to C57BL/6 
and BALB/c mice and antibodies directed against the drug as well as the pharmacokinetic 
profile of the drug were investigated by serum sample analysis.  
The purpose of the study was to detect immune responses in the mice that received 
aggregates of the murine antibody. The detection of discrepancies in the quality of the immune 
responses after administration of different aggregates within one mouse strain would be an 
indication that aggregate features influence the response of the immune system. Furthermore, 
the experiment aimed to detect differences in the immune response of two mouse strains to 
similar aggregates. 
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8.2 MATERIALS AND METHODS 
 
8.2.1  Materials 
8.2.1.1 Murine IgG2c antibody (muAb)  
A murine monoclonal anti-mouse TNF-α IgG2c antibody (muAb) produced in C57BL/6 
mice was kindly provided by Abbott Bioresearch Center (Worcester, USA) in a formulation 
comprising 20 mM histidine, pH 6.0, and a protein concentration of 33 mg/mL. Histidine, 
sucrose and hydrochloric acid were purchased from Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany). Highly purified water was generated in-house using a PURELAB Plus instrument 
from USF Elga (Celle, Germany). All reagents were of analytical grade. 
8.2.1.2 Animals 
Female C57BL/6J and female BALB/c mice were obtained from Janvier, Le Genest-
Saint-Isle, France. All mice were used from approximately 6-8 weeks of age and had access to 
tap water (autoclaved, acidified, pH 2.5-2.8) and food (R/M-H pellets rodent diet, Ssniff, Soest, 
Germany) ad libitum. Mice were allowed at least two weeks to acclimate (predosing period) 
before the dosing period commenced. Mice were maintained under specific pathogen free 
(SPF) conditions in groups of 3 to 4 animals in M2-L cages with bedding and enrichment. The 
environmental conditions were set at a room temperature of 22°C and humidity of 60% RH. 
Rooms were set on a 12-hour daily light cycle (light from 7 a.m. to 7 p.m.) except as required 
for sample collection or other study procedures. Ten animals were investigated for each 
formulation group. 
All animal experiments were carried out at the LMU Munich in accordance with the 
international ethical guidelines for the care and use of laboratory animals and were approved by 
the local animal ethics committee of the Regierung von Oberbayern (Reference number 
Az.55.2.1.53-2532.12.11). 
8.2.2  Methods 
8.2.2.1 Sample preparation 
The formulation buffer for the preparation of all dosing groups was a sterile filtered 
20 mM histidine buffer pH 5.7. The protein concentration used for preparation of aggregates 
was 10 mg/mL and the pH was adjusted to 5.7 using hydrochloric acid. One milliliter of this 
solution was filled in 2 R vials, glass type 1 (Schott AG, Mainz, Germany) which were closed 
using Teflon
®
-coated rubber stoppers from West Pharmaceutical Service, Inc. (Lionville, USA). 
In total eight different formulations were prepared. The placebo formulation included 
histidine buffer and 8% (w/v) sucrose to adjust tonicity. All protein formulations were diluted to a 
final protein concentration of 25 µg/mL by the histidine-sucrose buffer. For the preparation of an 
  ANGELIKA FREITAG        DISSERTATION          IMMUNOGENICITY OF PROTEIN AGGREGATES 
 
145 
 
adjuvant containing formulation, aluminum hydroxide gel (Alu-Gel-S suspension, Serva 
Electrophoresis GmbH, Heidelberg, Germany) was added in 40 fold excess to the protein 
solution. This protein containing suspension was gently stirred at 200 rpm for 13 hours before 
injection to provide sufficient time for the protein to adsorb to the aluminum hydroxide. The final 
concentration was 25 µg/mL of total protein and 8% sucrose (w/v) at pH 5.7. The adjuvant 
containing protein suspension was freshly prepared due to the instability of alum suspensions 
during freezing. 
Six vials containing 10 mg/mL muAb solution were exposed to light. Three vials were 
irradiated for 48 h and three vials for 120 h using a Suntest CPS (Heraeus Holding, Hanau, 
Germany). A xenon lamp with a wavelength spectrum from 200 to 1000 nm was used for light 
exposure and the radiation was fixed at 55 ± 5 W/m². A filter made of sheet glass was installed, 
to obtain a radiation close to the real light.  
Soluble oligomers in the sample exposed to light for 48 h were separated by 
asymmetrical flow field-flow fractionation (AF4). The oligomer fractions of 10 injections were 
collected in glass tubes and concentrated by centrifugation using disposable Protein 
concentrators
®
 (Thermo Scientific, Pierce Biotechnologies, Rockford, USA). The membrane 
inside was made of regenerated cellulose with a molecular weight cut-off (MWCO) of 9 kDa. 
Centrifugation was performed at 4000 x g and the concentration of the resulting fractions was 
determined by UV absorbance spectroscopy in a quartz cuvette at 25°C using an Agilent 8453 
UV-visible spectrophotometer (Agilent Technologies, Waldbronn, Germany). Finally, samples 
were diluted to 25 µg/mL total protein concentration and subsequently stored at -80°C.  
Aggregates were obtained by stirring for 48 h at 25°C and 400 rpm using Teflon
®
-
coated stirring bars of 6 x 3 mm in size (VWR International, Darmstadt, Germany). To obtain 
aggregates from shaking, samples were shaken in horizontal circles for 48 h at 25°C and 
800 rpm. To obtain aggregates by heating the protein solution was stored at 60°C for 48 h. 
Each process (stirring, shaking, and heating) was conducted in three different vials that were 
pooled directly after termination of the incubation step. All samples were diluted at a 1:1 ratio 
with placebo buffer before centrifugation at 4000 x g for 10 minutes using a Megafuge 1.0 R 
and the corresponding 7570F rotor (Heraeus Instruments, Santa Clara, USA). The pellets 
formed by centrifugation were re-suspended in the placebo buffer to a final concentration of 
approximately 25 µg/mL protein. This calculation was based on the concentration of protein 
determined in the supernatant and the volume of supernatant. The amount of protein in the 
supernatant was subtracted from the original protein concentration of 10 mg/ml and the residual 
mass of protein had to be present in the insoluble pellets after centrifugation. All samples 
except the alum-containing sample were stored at -80°C prior to injection. Prior to injection into 
animals each group was analyzed in triplicate by light obscuration using a Pamas SVSS 
instrument (Pamas, Rutesheim, Germany) to determine the particle loading. 
8.2.2.2 Size exclusion chromatography (SEC) 
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Size exclusion chromatography to determine concentration and size of soluble protein 
species in the muAb samples was conducted as described in section 7.2.2. 
8.2.2.3 Asymmetrical flow field-flow fractionation (AF4) 
The set-up of the AF4 measurements was previously described in chapter 6 (see 
section 6.2.2). A sample volume of 100 µl was injected into the system and the fractions of ten 
single runs were collected.  
8.2.2.4 Light obscuration (LO) 
Light obscuration measurements were conducted as described in section 7.2.3. 
8.2.2.5 Turbidity measurements 
Turbidity was analyzed according to section 3.2.3.3.  
8.2.2.6 Endotoxin testing 
The endotoxin load in the samples was analyzed as described in section 7.2.4. 
8.2.2.7 Fourier transform infrared spectroscopy (FTIR) 
For the determination of changes in secondary structure of the protein, native and 
aggregated formulation samples except the alum-containing formulation were analyzed directly 
after preparation at 10 mg/mL by FTIR in attenuated total reflection (ATR) mode. 20 mM 
histidine buffer at pH 5.7 served as background. A Bio-ATR II unit of a Tensor 27 spectrometer 
(Bruker Optics GmbH, Ettlingen, Germany) at 20°C was used. Spectra were collected from 
4000 cm
-1
 to 850 cm
-1 
with a resolution of 4 cm
-1
. 120 scans were averaged for each sample 
measurement. Each spectrum was background corrected and vector normalized on the amide I 
band. Finally, the second derivatives of the spectra were calculated and smoothened on 17 
points according to the Savitzky-Golay algorithm.  
8.2.2.8 Ultraviolet (UV) absorbance spectroscopy at 280 nm 
UV absorbance spectroscopy to determine protein concentration was either performed 
in a quartz cuvette at 25°C using an Agilent 8453 UV-visible spectrophotometer (Agilent 
Technologies, Waldbronn, Germany) or in a 96 well-plate made of quartz at 25°C using a 
FLUOstar Omega (BMG Labtech GmbH, Offenburg, Germany). For each measurement a linear 
calibration curve including at least three different concentrations of muAb was prepared and the 
concentration of the samples was calculated based on the Lambert-Beer-law. Each 
measurement was background corrected.  
8.2.2.9 Immunization protocol 
All formulations were administered subcutaneously into the scruff of the neck at a dose 
of 5 µg of protein drug. Each time 200 µL of the formulations containing 25 µg/mL of protein 
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were injected. Histidine buffer (20 mM, pH 5.7, containing 8% (w/v) sucrose) served as 
formulation buffer and negative control. Injections were carried out on days 1, 2, 4, 6, 13, 20, 27 
of the study followed by a six week recovery period.  
8.2.2.10  Collection of blood samples 
Blood were obtained from the tail vein by collecting 120 µL of blood on days 1 (prior to 
any injection), 6, 13, 20, and 27. All mice were sacrificed on day 71 of the study using a lethal 
dose of anesthetic (Ketamine/Xylazine) and blood was withdrawn from the Vena cava. Blood 
samples were collected in polypropylene tubes (no anticoagulant) and immediately centrifuged 
for 5 minutes at 4000 x g (Eppendorf MiniSpin 
®
, Eppendorf AG, Hamburg, Germany) at room 
temperature. The serum was separated and stored at -80°C before analysis.  
8.2.2.11  Determination of anti-drug antibodies (ADAs)  
The detection of anti-drug antibodies towards muAb was performed based on the 
method established in the previous study. Please refer to section 7.2.8.2 for details. In this 
study only the concentration of the detection antibodies (HRP-labeled goat anti-mouse 
immunoglobulines) was adjusted. A 1:75,000 dilution of isotype-specific (anti-IgG1, anti-IgG2a, 
anti-IgG2b and anti-IgG3) antibodies was used throughout this study. 
Each serum sample was measured in triplicate in a 1:100 dilution. The results were 
normalized by calculating the absorbance ratio of each animal by dividing the absorbance 
measured on each day by the absorbance of day 1 (before any injection). 
8.2.2.12  Determination of drug levels in serum (pharmacokinetics, PK) 
For the determination of muAb in serum samples triplicate measurements of each 
serum sample according to the method described in section 7.2.9 were performed. 
8.2.2.13  Statistical analysis 
Each dosing groups had ten replicates and where applicable, the results are expressed 
as mean ± standard error of the mean. Statistical analysis was carried by an analysis of 
variance (ANOVA) and the probability (p) was calculated. A probability of > 95 % (p < 0.05) was 
defined as significant. 
 
 
8.3 RESULTS 
 
The aim of this study was to investigate the immunogenic potential of protein 
aggregates of a murine monoclonal antibody in mice. As the aggregates were artificially 
prepared in the lab, a number of complementary analytical techniques were employed to 
analyze if and how the native murine monoclonal antibody was affected by the applied stress.  
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8.3.1 Preparation and analysis of aggregates  
The native protein stock solution contained 33 mg/mL of the monoclonal murine 
antibody (muAb). Size exclusion chromatography revealed 97.98 ± 0.40 % monomer, 0.91 ± 
0.22 % fragments and 1.08 ± 0.21 % aggregates in the native protein stock solution (data not 
shown).  
After 48 h of light exposure soluble oligomers were separated by AF4. A total protein 
amount of 1 mg of the light exposed sample and 0.5 mg of the native muAb was injected, 
respectively. The fractograms of the irradiated samples and the native muAb are shown in 
Figure 8-1. At concentrations higher than 0.5 mg or 1 mg, overloading effects were observed. 
The irradiated sample was composed of 17.4 ± 3.9 % monomer, 4.0 ± 0.3 % fragments and 
74.4 ± 3.9 % oligomers with a total recovery of 86.9 ± 4.6 %, meaning that some insoluble 
aggregates had also been formed which cannot be detected by AF4. The fraction eluting 
between 29.5 minutes and 35.5 minutes (illustrated by the green lines) was collected (see 
Figure 8-1). Previous studies revealed a mean approximate size of the soluble aggregates of 
20 – 100 nm determined by dynamic light scattering (data not shown). 
 
Figure 8-1 – UV 280 nm fractograms and molar mass of murine IgG2c samples. 
Time dependent UV detector voltage at 280 nm and molar mass detection by MALLS of light exposed 
muAb (red line) and native muAb (black line) after separation by Eclipse 2.0. The collection period is 
displayed by the green lines. 
 
Light obscuration measurements were carried out immediately after completion of the 
generation of the aggregates and after a storage time of at least 7 days at -80°C. No 
differences were observed in the particle size distribution and total particle numbers (data not 
shown) between the samples immediately after preparation and the stored samples.  
The by far highest numbers of subvisible particles were counted in the stirred samples, 
which contained more than 100,000 particles ≥ 1 µm. The total particle numbers per mL of 
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species ≥ 1 µm (see Table 8-1) in the other protein containing samples analyzed by light 
obscuration ranged from ~1000 (native muAb) to ~21000 (insoluble species from light 
exposure). The fractionated soluble aggregates generated by light exposure were smaller than 
1 µm in size and low numbers of particles in the micrometer range were detected within that 
sample. None of the formulations contained more than 300 particles larger than 10 µm. The 
light obscuration measurements were conducted at the final concentration of 25 µg/ml and after 
several days of storage at -80°C. 
Turbidity measurements were carried out in triplicate and are summarized in Table 8-1. 
Slightly increased turbidity values were obtained in the dosing groups containing aggregates. 
Stirring leads to the strongest elevation of turbidity, whereas the turbidity of the sample 
containing insoluble aggregates generated by light exposure is comparable to the solution 
containing native muAb. 
Table 8-1 – Summary of turbidity measurements and particle counts per ml of the different 
formations investigated in this study. 
Dosing 
group 
Description 
Turbidity 
[FNU] 
Particle counts 
≥ 1 µm per mL 
Particle counts 
≥ 10 µm / ≥ 25 µm 
1 Placebo 0.60 170 21 / 5 
2 Native muAb 0.80 900 5 / 2 
3 Native muAb + Adjuvant N/A N/A N/A 
4 
Soluble aggregates from 
light exposure 
2.20 5000 27 / 1 
5 
Insoluble aggregates from 
light exposure 
0.84 21000 59 / 2 
6 
Insoluble aggregates from 
stirring 
3.97 107000 292 / 2 
7 
Insoluble aggregates from 
shaking 
2.25 9000 4 / 1 
8 
Insoluble aggregates from 
heating 
1.77 8000 14 / 1 
 
The formulations were investigated by FTIR to observe changes in the secondary 
structure of the antibody after the different stress conditions. Figure 8-2 displays the 2
nd
 
derivative FTIR spectra of the muAb containing formulations (except the formulation containing 
native muAb plus Alum) directly after preparation.  
The analysis of the FTIR spectra obtained from the different formulation shows that 
processing conditions such as stirring and shaking do not lead to a substantial alteration of the 
secondary structure of the antibody (Figure 8-2) as the spectra are very similar to those of the 
native muAb. In contrast, light exposure as well as storage at elevated temperatures of 60°C 
implied strong modifications in the conformation of the muAb and resulted in a strong decrease 
of the intramolecular β-sheet band at around 1638 cm
-1
. At the same time, the absorbance of 
the intermolecular β-sheet band around 1622 cm
-1
 showed a strong increase in light exposed 
and heated samples.  
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Figure 8-2 – 2
nd
 derivative FTIR spectra of the muAb samples for in vivo use directly after 
stressing.  
The black line represents the spectrum of the native muAb, the blue line represents the spectrum of the 
stirred sample, and the red line represents the spectrum of the shaken sample. The light green light 
represents the secondary structure of the protein after 48 h light exposure, the dark green line represents 
the sample after 120 h light exposure, and the yellow line represents the muAb sample after storage at 
60°C. 
 
8.3.2 Preparation and analysis of the adjuvant samples 
For the preparation of the adjuvant containing samples, the murine monoclonal 
antibody was adsorbed to aluminum hydroxide. The supernatant of the adjuvant containing 
sample after centrifugation was analyzed and 3.0 ± 0.01 µg/mL of muAb were detected by UV 
absorbance spectroscopy. In conclusion, approximately 22 µg/mL (approximately 90 %) of 
protein had been adsorbed to the surface of the aluminum hydroxide particles. 
8.3.3 Testing of the samples for the presence of endotoxins 
Prior to the study, all formulations except the adjuvant sample were analyzed for the 
presence of endotoxins, and endotoxin levels below 0.25 EU/mL. Therefore, the generation of 
undesirable immune responses triggered by pyrogens which may have biased the results of this 
study can be excluded. Due to the high turbidity of the adjuvant sample, no endotoxin 
determination was feasible.  
8.3.4 Detection of immune response – Anti-drug antibodies towards muAb 
In this study, a murine monoclonal antibody was investigated in C57BL/6 and BALB/c 
mice. No cross-reactive antibodies against the native molecule were expected in the C57BL/6 
animals. A minor response to the administered muAb was expected in BALB/c mice [Martin et 
al., 1998]. Nonetheless, the generation of anti-drug antibodies directed against aggregates is 
assumed to be stronger compared to the immune response of BALB/c mice that received the 
native muAb. Different IgG subtypes were analyzed and the results of the three control groups 
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in both mouse strains are shown in Figure 8-3. The placebo and the native muAb group served 
as negative control groups, whereas the adjuvant-containing formulation served as a positive 
control for the generation of anti-drug-antibodies, as alum has been described in literature to 
induce a reliable antibody (Th2) response [Petrovsky et al., 2004].   
8.3.4.1 anti-muAb antibodies in C57BL/6 mice 
Figure 8-3 provides an overview of different IgG isotype results from anti- muAb 
antibody detection in C57BL/6 mice. Figures 8-3, A1 to A3 represent the results of anti-IgG1 
muAb antibodies, B1 to B3 the results of anti-IgG2b muAb antibodies and C1 to C3 represent 
the results of anti-IgG3 muAb antibodies. 
In C57BL/6 mice, the placebo formulation as well the formulations containing the native 
muAb or the native muAb plus adjuvant induced a rather weak immune response which was 
detectable by the generation of anti-muAb antibodies of IgG1, IgG2b and/or IgG3 isotype. In 
IgG1 isotype only the native muAb shows a reponse on days 27 and 71. The absorbance ratios 
of IgG2b detection show a very similar minor increase of all three control groups throughout the 
study. Significantly (p < 0.05) increasing absorbance ratios were detected for group 3 (adjuvant 
plus native muAb) on days 20, 27 and 71 and for group 2 (native muAb) on days 27 and 71 in 
IgG3 ELISA. Confirming the expectations, after administration of the placebo formulation to 
C57BL/6 mice, the absorbances relative to day 1 (prior to any injection) were not substantially 
enhanced in any of the anti-muAb isotype assays.  
Increased IgG1 levels in C57BL/6 mice directed towards muAb were detected after the 
administration of the soluble aggregates generated by light exposure and fractionated by AF4. 
The results showed steadily increasing anti-muAb IgG1 levels from day 6 to day 27 that drop 
back to the base level or even below that after the recovery of 6 weeks on day 71 (Figure 8-
3, A3). A maximum absorbance ratio of 2.5 was observed on day 27. Subsequently, the IgG1 
levels directed towards muAb decrease within the 6 week recovery phase. On day 71, the 
absorbance ratio was below the basic value of day 1, before any injection. The IgG1 immune 
response directed towards muAb after administration of the soluble aggregates was 
significantly enhanced compared to the response after administration of all other investigated 
formulations including the native muAb, serving as reference. The insoluble aggregates 
(Groups 5-8) failed to induce a significantly higher immune response of IgG1 antibodies than 
the native muAb in C57BL/6.  
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8-3 A Control groups  
IgG1 
 
 
 Agitation Light and Temperature 
IgG1 
  
 
Figures 8-3 A – Absorbance unit ratios of anti-IgG1 muAb detection in C57BL/6 
 
8-3 B Control groups  
IgG2b 
  
 Agitation Light and Temperature 
IgG2b 
  
 
Figures 8-3 B – Absorbance unit ratios of anti-IgG2b muAb detection in C57BL/6 
A1 
A2 A3 
B1 
B2 
B3 
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8-3 C Control groups  
IgG3 
  
 Agitation Light and Temperature 
IgG3 
  
 
Figures 8-3 C – Absorbance unit ratios of anti-IgG3 muAb detection in C57BL/6  
 
Figures 8-3 A-C: 
The results of the control groups are shown in A1, B1 and C1: placebo in white, native muAb in black and 
native muAb + alum in grey. Figures A2, B2 and C2 represent the anti-muAb results for the mice that 
received aggregates generated by agitation (stirring in blue and shaking in red) compared to the native 
muAb (black). And Figures A3, B3 C3 represent the anti-muAb results of the mice that received 
aggregates from light stressed (soluble aggregates in light green, and insoluble aggregates in dark green) 
or heated muAb (yellow). The error bars represent the standard error of the mean of ten animals per 
group.  
 
However, these aggregated species resulted in immune responses expressed by the 
increases of other IgG isotypes. The aggregates generated by stirring were capable of eliciting 
antibodies of anti-muAb IgG2b isotype in C57BL/6 starting on day 6 which constantly increased 
until day 71. The other aggregates, either soluble or insoluble, and the native muAb resulted in 
increased absorbance ratios especially on day 71, though the anti-muAb IgG2b release in those 
animal groups was on a similar level and none of the aggregates exceeded the induction of 
ADAs by the native protein. 
Considering the IgG3 isotype levels all aggregate containing formulations resulted in a 
significant increase in C57BL/6 mice starting on day 6 (p < 0.05). Slightly higher anti-muAb 
IgG3 levels were detected after administration of the formulation containing soluble aggregates 
when the results were compared to the administration of native muAb from day 13 onwards. 
Strongly elevated absorbance ratios were detected for anti-muAb IgG3 after administration of 
insoluble aggregates generated by light exposure or stirring. On days 27 and 71 the highest 
C1 
C2 
C3 
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ratios were observed within both groups. The aggregates generated by shaking and those 
generated by storage at 60°C show only a minor IgG3 response towards muAb. 
In summary, the C57BL/6 mice showed minor immune responses to the native muAb 
(Group 2) after repeated administration, expressed in slightly enhanced IgG1, IgG2b and IgG3 
levels on day 71. The response to the adjuvant group (Group 3) was not significantly higher 
compared to the native muAb group (Group 2). Regarding the aggregate containing test 
formulations the insoluble aggregates obtained either by stirring or by light exposure revealed 
the highest anti-muAb antibody levels, especially of IgG3 isotype, compared to the 
administration of native muAb. Additionally, the soluble aggregates obtained by light exposure 
resulted in enhanced IgG1 levels concomitant to repetitive administration of these species, that 
not persist throughout the recovery phase.  
8.3.4.2 anti-muAb antibodies in BALB/c mice 
Figure 8-4 provides an overview of the different anti-muAb IgG isotypes results in 
BALB/c mice. In BALB/c mice, the administration of the placebo formulation did not result in 
enhanced anti-muAb IgG1 generation (p < 0.01) whereas formulations containing the native 
muAb or native muAb plus adjuvant resulted in strongly enhanced anti-muAb IgG1 levels 
(Figure 8-4, A1), commencing on day 13. This level of anti-muAb IgG1 remained on a stable 
level until day 71. The level of anti-muAb IgG1 was significant higher (p < 0.01) in mice that 
received the adjuvant containing formulation (Group 3) than in the mice that obtained the native 
muAb (Group 2).  
8-4 A Control groups  
IgG1 
 
 
 Agitation Light and Temperature 
IgG1 
  
Figure 8-4 A – Absorbance unit ratios of anti-IgG1 muAb detection in BALB/c 
A1 
A2 A3 
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8-4 B Control groups  
IgG2b 
 
 
 Agitation Light and Temperature 
IgG2b 
  
Figure 8-4 B – Absorbance unit ratios of anti-IgG2b muAb detection in BALB/c 
 
8-4 C Control groups  
IgG3 
 
 
 Agitation Light and Temperature 
IgG3 
  
Figure 8-4 C – Absorbance unit ratios of anti-IgG3 muAb detection in BALB/c 
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8-4 D Control groups  
IgG2a 
 
 
 Agitation Light and Temperature 
IgG2a 
  
Figure 8-4 D – Absorbance unit ratios of anti-IgG2a muAb detection in BALB/c 
 
Figures 8-4 A-D: 
The results of the control groups are shown in A1, B1, C1 and D1: placebo in white, native muAb in black 
and native muAb + alum in grey. Figures A2, B2, C2 and D2 represent the anti-muAb results for the mice 
that received aggregates generated by agitation (stirring in blue and shaking in red) compared to the 
native muAb (black). And Figures A3, B3, C3 and D3 represent the anti-muAb results of the mice that 
received aggregates from light stressed (soluble aggregates in light green and insoluble aggregates in 
dark green) or heated muAb (yellow). The error bars represent the standard error of the mean of ten 
animals per group.  
 
A slight but significant enhancement in the generation of ADAs of IgG2b isotype in 
BALB/c was initiated by native muAb samples, starting on day 13 (Figure 8-4, B1). Instead, the 
anti-muAb IgG2b responses to the placebo formulation and the adjuvant-containing formulation 
did not significantly increase over the duration of the study. None of those three formulations 
resulted in anti-muAb IgG3 release in BALB/c mice (Figure 8-4, C1). As shown in Figure 8-4, 
D1 a continuous increase of anti-muAb IgG2a levels in BALB/c mice from day 6 onwards was 
observed, resulting from the administration of the native muAb. From day 13 onwards also anti-
muAb IgG2a levels were observed after administration of the adjuvant-containing formulation.  
It is important to note that, in BALB/c mice, the two formulations consisting either of 
native muAb or of soluble aggregates did not differ in the generation of anti-muAb antibodies. 
After administration of this aggregate species IgG1, IgG2a and IgG2b isotypes directed towards 
muAb were generated in BALB/c mice, all of them starting on day 13 and steadily increasing 
D1 
D2 D3 
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over time and maintaining high absorbance ratios on day 71. The magnitude of the absorbance 
ratios achieved was comparable to that of the mice that received the native muAb formulation. 
In this respect no increased immunogenicity of these soluble aggregates compared to the 
native protein could be determined in BALB/c mice.  
The animals that received insoluble aggregates from light exposure (Figure 8-4, A3), 
stirring or shaking (Figure 8-4, A2), showed significantly higher absorbance ratios in their serum 
samples compared to those that received the native protein (p < 0.05), whereas the other 
aggregate containing formulations (soluble aggregates from light exposure or insoluble 
aggregates from heating (Figure 8-4, A3)), did not show any enhancement compared to the 
native muAb formulation. The highest ratios (around 10) were detected in IgG1 levels after 
administration of the insoluble species generated by light irradiation (Group 5), followed by 
those generated by stirring (Group 6) and shaking (Group 7). Both latter groups of insoluble 
aggregates generated by agitation predominate the response of IgG2a isotype as well (Figure 
8-4, D2). On day 13, these groups showed approximately five times higher absorbance values 
compared to day 1. The mean values slowly increased until day 71. The other groups that 
obtained aggregates (Groups 4, 5 and 8, Figure 8-4, D3)) showed a slow increase over time as 
well, though never outreaching the response to the native muAb. Regarding ADAs of isotype 
IgG2b, the administration of none of the aggregates initiated a stronger generation compared to 
the native muAb. Finally, all eight formulations investigated did not induce an IgG3 response 
directed towards muAb in BALB/c mice.  
In summary, the anti-muAb antibody response in BALB/c was dominated by significant 
antibody levels elicited by the administration of native muAb. Comparing the different ADA 
isotypes incorporated in this study, the IgG1 response is the most important in BALB/c mice. 
The adjuvant containing formulation as well as three out of five aggregate containing 
formulations resulted in higher IgG1 responses compared to the native muAb formulation: 
insoluble aggregates from light exposure, stirring, and shaking. Insoluble aggregates from 
stirring and shaking but not from light exposure additionally exceed the IgG3 response to native 
muAb. In none of the ADA isotypes the soluble aggregates obtained by light exposure or the 
insoluble aggregates obtained by storage at elevated temperatures ever top the immune 
response to the native muAb molecule. Furthermore, in BALB/c mice no alteration in the IgG3 
levels were detected at all.   
8.3.4.3 Comparison of C57BL/6 mice and BALB/c mice 
The repetitive administration of the muAb formulations revealed completely different 
ADA responses in C57BL/6 and BALB/c mice. The anti-drug antibody responses towards the 
control groups substantially differ between the two mouse strains. No substantial immune 
response against the placebo formulation was detected in either mouse strain, but the 
responses towards the native muAb formulation (Group 2) and adjuvant containing formulation 
(Group 3) significantly differ between the two strains: BALB/c mice show strongly elevated 
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immune responses (especially of IgG1 isotype) to the native muAb and adjuvant containing 
formulations compared to the C57BL/6 mice. Interestingly, the alum containing positive control 
sample resulted only in an increase of IgG1 ADAs in the BALB/c mice, though a high immune 
response in both species and more IgG subtypes was expected.Figure 8-5 provides a summary 
of the diverging IgG1 responses against native muAb in both mouse strains.  
 
Figure 8-5 – IgG1 absorbance unit ratios of Group 2 at the different blood sampling time points.  
The black bars represent the results of C57BL/6 mice and the white bars represent the results of BALB/c 
mice. The error bars represent the standard error of the mean of ten animals per group.  
 
The enhanced absorbance ratios pursued in the IgG1 responses towards the test 
groups of BALB/c mice that received aggregate containing formulations. In these mice, three 
test groups exceeded the IgG1 immune response of the native muAb group: insoluble 
aggregates from light exposure, stirring, and shaking. In none of these groups an IgG1 immune 
response was detected in C57BL/6 mice. The latter mouse strain only revealed slightly 
enhanced IgG1 ADA levels to soluble aggregates from light exposure. However, the insoluble 
aggregates from light exposure and stirring elicited ADAs of IgG3 isotype in C57BL/6 mice, 
whereas no IgG3 response was detectable in BALB/c (see Figure 8-6).  
Diverging immune responses were also detected for IgG2b antibody levels. Compared 
to the administration of native muAb the aggregates from stirring induced significantly higher 
numbers of anti-muAb antibodies of IgG2b isotype in C57BL/6 mice but not in BALB/c mice. 
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Figure 8-6 – IgG3 absorbance unit ratios of groups 5 and 6 at the different blood sampling time 
points.  
A shows the results for group 5 (insoluble aggregates from light exposure) and B shows the results from 
group 6 (insoluble aggregates from stirring). The black bars represent the results of C57BL/6 mice and the 
white bars represent the results of BALB/c mice. The error bars represent the standard error of the mean 
of ten animals per group.  
 
8.3.5 Detection of muAb circulating in the blood stream – pharmacokinetics  
The determination of the pharmacokinetics is of great importance since it is crucial to 
determine how fast the drug is cleared from the blood stream in the presence and absence of 
ADAs. It can be assumed that significant amounts of ADAs could strongly reduce circulation 
time and serum concentration of the monoclonal antibody. An ELISA based on murine TNF-α, 
the antigen to the monoclonal antibody, was performed. The recovery of muAb  in the 
formulations prior to injection was determined. In all formulation, except for the formulation 
containing only insoluble aggregates after light exposure, substantial amounts of muAb were 
quantified with the ELISA (data not shown). Figure 8-7 provides an overview of the results 
obtained for muAb pharmacokinetics. 
The mice that received the placebo formulation or the formulations containing the 
insoluble aggregates showed no quantifiable amounts of muAb in the serum samples, neither in 
C57BL/6 nor in BALB/c mice (data not shown). In C57BL/6 mice both, the native muAb 
formulation and the native muAb plus adjuvant formulation, show serum levels that do not point 
to the generation of ADAs. The maximum serum levels of muAb were measured on day 6, after 
three booster injections on days 1, 2 and 4. Later on, when only administered weekly, the levels 
decreased slowly reaching the basic level after 6 weeks washing out phase. Since monoclonal 
antibodies are characterized by half-lifes of several days to weeks the results obtained for those 
groups are reflecting a regular, undisturbed pharmacokinetic profile.  
However, the results for the native muAb formulation and the adjuvant formulation were 
considerably different in BALB/c mice, were muAb was only detected on day 6. This is similar in 
mice of groups 2 and 3 (see Figure 8-7, A2 and B2). Neither after administration of native muAb 
formulation nor after administration of native muAb plus adjuvant circulating muAb molecules 
were detectable at any other bleeding time point than day 6.  
A B 
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The repetitive administration of the formulation containing soluble aggregates resulted 
in no detectable free circulating muAb molecules in C57BL/6,  whereas levels of muAb were 
detectable in BALB/c. The absorbance ratios in group 4 of BALB/c were lower compared to 
those on day 6 in animals of groups 2 or 3 and had a maximum on day 13 that was constantly 
decreasing until on day 27 the basic value was achieved again. 
C57BL/6 mice Group BALB/c mice 
 
 
(2) 
Native 
muAb 
 
 
 
(3) 
Native 
muAb 
+ 
adjuvant 
 
 
 
(4) 
Light 
Solubles 
 
Figure 8-7 – Absorbance unit ratios of PK ELISA in C57BL/6J and BALB/c mice. 
A) After receipt of the native muAb formulation. B) After receipt of the formulation consisting of native 
muAb + adjuvant. C) After receipt of the soluble aggregates after 48 h of light exposure. 
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8.4 DISCUSSION 
 
The study for the first time investigates the immune response to protein aggregates in 
two different wild-type mouse strains. The C57BL/6 animals were selected, since the 
monoclonal antibody investigated in this study was generated in this strain. Additionally BALB/c 
mice were selected, because of their well-known strong Th2 immune response, resulting in 
strong antibody elicitation [Watanabe et al., 2004]. The subcutaneous route of administration 
was chosen as this is commonly used in patient’s therapy using monoclonal antibodies besides 
the intravenous administration [Berger et al., 2002]. Also, the subcutaneous administration is, in 
general, thought to be more immunogenic than other administration routes [Wierda et al., 2001]. 
The antibody elicitation after administration of five different aggregate formulations of 
muAb was investigated. Those formulations were prepared under different conditions and 
consisted of aggregates differing in size and structural properties. According to the immunon 
model hypothesized by Dintzis et al., aggregates of large sizes and repeating epitopes on their 
surface are capable to induce an immune response [Dintzis et al., 1976]. The mechanisms 
behind immune responses to protein aggregates have not yet been clarified. Currently, 
administrative organizations and industrial research focus on anti-drug antibodies that 
potentially can have an impact on the efficacy of the drug, altering pharmacokinetics and thus 
the success of the therapy. Thus, it is supposed, that aggregates with structural properties 
close to the native protein are foremost crucial in the formation of ADAs. However, it is entirely 
conceivable that antibodies towards aggregate-specific structures can be generated as well, 
which probably do not have a large impact on the pharmacokinetics of the therapeutic protein, 
but might lead to adverse effects such as allergic reactions.  
The structure and size of the administered species was investigated beforehand. The 
secondary structure of the native and the aggregated muAb samples was investigated by FTIR 
after the completion of the stress procedure, but not of the final injection samples, since the 
final concentration of 25 µg/mL of total protein is too low for FTIR analysis. Of the five 
formulations containing aggregates, three contained protein species with a strongly modified 
secondary structure (Groups 4, 5 and 8). Exposure to light (Groups 4 and 5) as well as storage 
at elevated temperatures (Group 8) resulted in strong changes of the protein as indicated by 
unfolding, whereas after shaking (Group 7) and stirring (Group 6) the protein mostly maintained 
its secondary structure. 
Unfolding and structural modifications might imply the formation of antibodies that are 
not capable of binding to muAb. In this case, the ADAs will not be detected in this assay. 
Therefore, in theory the subcutaneously injected formulations of aggregated antibody in this 
study should still be able to bind to the antigen, indicating a native-like structure and ensuring 
the generation of antibodies directed towards the original native structure of the drug molecule. 
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For the duration of the study, the animals were maintained in SPF conditions. Despite 
the repetitive administration of the native muAb to the host strain, the meticulous cleaning and 
preparation of all instruments and samples was suggested to keep constantly low background 
levels of immunoglobulins. The results detected in C57BL/6 mice indicated the absence of 
pathogens; however these mice are known to elicit fewer antibodies when compared to other 
mouse strain [Mills et al., 2000]. The study only determined the generation of antibodies 
directed against the native muAb, but not towards the aggregates administered to the mice. 
Therefore, the results do not reflect the total levels of IgG isotype in the serum samples, but the 
levels specifically directed towards the muAb molecule.  
8.4.1 Pharmacokinetics of muAb 
After administration of the placebo formulation no muAb was detectable in the serum of 
the mice. The discrepancies between the pharmacokinetics profiles of the native drug in the 
control groups 2 and 3 of both mouse strains are obvious (see Figure 8-7). The C57BL/6 mice 
reveal the expected undisturbed profile possessing a maximum on day 6 and subsequently 
decreasing until day 71. In BALB/c, the maximum serum levels of muAb were reached on day 6 
due to the repeated administration, although the absorbance ratios were lower than in C57BL/6. 
On day 13 no drug molecules were circulating any more in BALB/c mice of these dosing groups 
(Figure 8-7, A2 and B2). This profile strongly suggests the formation of anti-muAb antibodies 
after administration of native muAb and native muAb + adjuvant. The generated ADA molecules 
obviously captured the circulating muAb molecules and the resulting immune complexes were 
rapidly eliminated. The generation of antibodies by the human immune system is known to last 
several days [Vollmar, 2005] and to be similar to the murine immune system [Haley, 2003]. 
Thus the formation of ADAs is the reason for the inability to detect muAb after day 6.  
The high recoveries of muAb in the sera of C57BL/6 mice that received the native 
muAb formulation or the native muAb plus adjuvant formulation indicate no substantial ADA 
formation. If ADAs would have been present, the immune complex formation would interfere 
with the detection of muAb in C57BL/6 mice. The slowly decreasing muAb levels in both groups 
(2 and 3) point in the same direction.  
Interestingly, within each mouse strain the profiles are rather similar between the 
animals that received the native muAb and the animals that received the adjuvant plus native 
muAb. The expected “positive control” was not capable to induce ADA formation in C57BL/6 
mice, presumably due to their preferred Th1 response. In BALB/c mice both formulations elicited 
ADAs. However, on day 6, the recovery of muAb in the serum was higher in the adjuvant group 
than in the native group. This finding suggests, that the progress of generation of ADAs started 
earlier in the native group. A slower absorption of the protein adsorbed to the aluminum 
hydroxide particles from the s.c. injection site and thus a sustained recognition by the immune 
system can be assumed.   
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Within the test groups, only the formulation containing soluble aggregates from light 
exposure resulted in low but detectable amounts of muAb circulating in the blood. Interestingly, 
the BALB/c mice that received this formulation revealed a slowly decreasing pharmacokinetic 
profile indicating that these aggregates did not induce an ADA generation as fast as after 
administration of native muAb or adjuvant plus native muAb. In C57BL/6 mice these aggregates 
induce fast ADA formation and thus minor muAb levels were detected on day 6. 
8.4.2  Immunogenicity of muAb in the control groups 
The administration of the formulation buffer did not induce significant levels of ADAs, 
neither in C57BL/6 nor in BALB/c mice. Since C57BL/6 has been reported as a mouse strain 
typically showing cellular immune responses, with only minor elicitation of antibodies, the anti-
drug antibody responses to the aggregate containing formulations are anticipated to be low. 
Confirming the results from pharmacokinetic ELISA, the ADA levels detected in animals that 
received native muAb or adjuvant plus native muAb remained close to the baseline values. The 
intended positive control consisting of the native muAb plus an adjuvant did not result in the 
expected strongly increasing levels of IgG1, IgG2b or IgG3 directed towards muAb.  
Anti-muAb IgG2a levels were determined in BALB/c but not in C57BL/6 mice, because 
the latter are known to be incapable to generate this isotype [Martin et al., 1998]. BALB/c mice 
were assumed to recognize the native muAb as foreign molecule, but were included in this 
study because of the typically strong generation of antibodies. The exclusive administration of 
the native muAb served as a reference in these animals, since the aim was to detect increased 
immunogenicity of formulations containing aggregates, compared to those of the native drug 
molecule. Therefore, a significant immune response to an aggregate always related to the 
response of mice of the same strain, on the same bleeding time point, that received the native 
muAb formulation. This assumption was supported by the increased levels of IgG1, IgG2a and 
IgG2b after administration of the formulation containing the native muAb. They were 
significantly higher than those after administration of placebo formulation (p < 0.01). The 
positive control including alum as an adjuvant resulted in increased levels of IgG1 and IgG2a as 
well. For anti-muAb IgG1 they were even higher than after administration of the native muAb (p 
< 0.01), whereas for IgG2a they were on a similar level. The animals receiving the adjuvant 
resulted in anti-muAb IgG2b levels comparable to the animals receiving placebo. It can be 
concluded that the effect of the adjuvant Alum on the formation of anti-muAb antibodies is 
weak.  
8.4.3 Soluble aggregates of muAb 
The oligomers that were formed after light exposure and separated by field -flow 
fractionation (Group 4) were stored at -80°C prior to injection. The stability of those aggregates 
during storage was shown in previous studies [Freitag et al., 2011]. These aggregates are also 
known to be of reversible constitution and tend to dissociate back into monomeric species when 
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stored in an unfrozen state. It can be assumed, that such weakly associated (dissociable) 
aggregates will not exist for a long time after subcutaneous injection. However, the exposure to 
light induced some chemical alterations and oxidation processes to the molecules that will still 
be present after dissociation. Interestingly, the application of soluble aggregates after light 
exposure resulted in an IgG1 ADA profile deviating from all other dosing groups in C57BL/6 
mice. The progressively increasing absorbance ratio tremendously dropped during the six-week 
recovery phase. In comparison, all other immune responses determined throughout this study 
resulted in the generation of persistent levels of ADAs. This observation suggests the 
generation of IgG1 ADAs that are rapidly eliminated when the antigen is not present anymore. 
The elimination presumably was accelerated by immune complex formation with native muAb 
released from the soluble aggregates. Considering the reversibility of these soluble aggregates, 
an enhanced availability of native muAb several days after the last administration is supposed. 
However, in the FTIR spectra of the muAb sample containing these aggregates substantial 
alterations of the secondary structure where detected, suggesting that also after dissociation 
non-native structures are present. If no additional aggregates are applied, the muAb content 
can either level or even exceed the ADA content, and no more positive IgG1 ADA results are 
obtained anymore because of immune complex formation. The ADA profiles of IgG2b and IgG3 
induced by the same aggregate species did not show these tendencies. The increases within 
the first four weeks of the study were slower than for IgG1 and no drop was detectable after the 
recovery phase. 
8.4.4 Insoluble aggregates of muAb 
Insoluble aggregates are very large particles composed of associated protein 
molecules. They can be either visible or subvisible and some tend to precipitate, while others 
do not. The insoluble aggregates investigated in this study were all separated from soluble 
species by centrifugation. Four different stress factors lead to the rapid formation of 
considerable amounts of such large particles.  
The absorption or degradation of subcutaneously administered aggregates, especially 
the particulate structures, has not yet been reported in literature. The differences in the 
immunoglobulin profiles (regarding e.g. IgG isotypes, time and strength of immune response) 
observed after administration of insoluble aggregates for example after stirring and shaking in 
our study, might arise from the sustained absorption to the lymphatic system and are probably 
not directly related to a lower or higher immunogenicity. The resulting absorbance unit read out 
of the ELISA related to the value before any injection of each individual animal cannot easily be 
converted into total concentrations of anti-drug antibodies, since no appropriate reference was 
available. This lack of appropriate references is a disadvantage of using a murine antibody in a 
wild-type mice model instead of using a human antibody in transgenic mice. In a transgenic 
animal model the process of creating tolerance against the human protein would meanwhile 
entail the formation of mouse anti-human protein antibodies before tolerance is achieved. 
These immunoglobulines will later on serve as reference for antibodies elicited e.g. by protein 
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aggregates. However, using the wild-type model one can distinguish between the magnitudes 
of the absorbance ratios to rank the immunogenic potential of those aggregates. The most 
relevant aggregates in this study seem to be insoluble aggregates. Especially those generated 
by light exposure are able to rapidly induce the generation of ADAs. 
8.4.4.1 Aggregation by light exposure 
The insoluble aggregates after light exposure showed substantial alterations in 
secondary structure. The results of the ELISA which was used to determine the recovery of 
muAb in the injected samples indirectly confirmed these changes, since the muAb in this 
formulation was the only one of the stressed protein species that was not at all able to bind 
TNF-α within the pharmacokinetics ELISA. It can be suggested that the complementarity 
determining region (CDR) was structurally modified due to light irradiation and therefore the 
elicited ADAs are not directed towards CDR. Results from mass spectrometry furthermore 
indicate that those aggregates possess chemically altered sequences and oxidized patches in 
the CDR region of the antibody (data not shown). Hence, other insoluble aggregates with a 
more native-like structure were expected to be more immunogenic in the sense that they induce 
ADAs directed towards the native muAb. 
Surprisingly, the insoluble aggregates generated by light exposure rapidly induced the 
formation of ADAs, even significantly exceeding the formation of ADAs after administration of 
the positive control on days 20, 27 and 71 (p < 0.01). These results indicate that aggregates 
from light exposure with chemical and structural changes induce binding antibodies towards 
muAb, and thus can also have a strong impact on pharmacokinetics and efficacy. Compared to 
the soluble aggregates generated by light exposure, all generated ADAs persisted over the 
entire study. That suggests an influence of the size of the aggregates or the more pronounced 
structural changes on the mechanisms of ADA formation.   
8.4.4.2  Aggregation by mechanical stress 
Two other formulations that induced ADA release of many IgG isotypes are those 
consisting of aggregates from stirring or shaking (Groups 6 and 7). In both formulations the 
native structure of muAb is maintained, but subvisible particle formation occurred. The 
formulation obtained by stirring included the highest numbers of subvisible particles compared 
to all other formulations. The administration of these aggregates induced significant ADA levels 
of at least two isotypes in each mouse strain. This indicates a relation between the loading of 
subvisible particles in a formulation and the immune response. The aggregates generated by 
shaking resulted in lower numbers of subvisible particles detectable by light obscuration and 
induced significant amounts of anti-muAb antibodies in BALB/c mice but not in C57BL/6 mice. 
Overall and cautiously, a qualitative correlation of the number of particles and ADA generation 
can be assumed. However, the enhanced IgG1 and IgG2a levels in BALB/c induced by those 
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aggregates are on a very similar level and thus no ranking between the immune response of 
both aggregate species is possible in this species.  
8.4.4.3  Aggregation by elevated temperature 
The aggregates generated by storage at 60°C possess the most distinct altered 
secondary structure of all muAb formulations. At the same time, this formulation shows less 
subvisible particles ≥ 1 µm than all other insoluble aggregate formulations. The heated species 
failed to induce an immune response exceeding the response to the native muAb in BALB/c. In 
C57BL/6 mice slightly enhanced IgG3 levels were detected after administration of aggregates 
obtained from heating. The strong structural changes within the aggregates might have 
impeded the formation of antibodies directed towards the native structure of muAb and thus 
only minute ADAs were detected. Within the ELISA format to determine the recovery of muAb 
in the formulations a marginal binding to TNF-α was detected. This was not surprising due to 
the heavy structural changes discovered in those aggregate species.  
8.4.5 Species differences 
It was already reported, that immune responses of C57BL/6 and BALB/c mice differ 
between the strains [Mills et al., 2000]. The most obvious reason is the known preferential Th2 
response in BALB/c mice. Hence, there may be more than one explanation for the varying IgG 
profiles detected in the two strains. The foreignness of muAb to BALB/c is probably one reason 
for the higher absorbance ratios in the ADA assays and the completely modified 
pharmacokinetic profile. The differences discovered in the isotypes of generated ADAs within 
one mouse strain are well-known phenomena. Interestingly, the IgG1 isotype is the one with the 
highest incidence in BALB/c mice (the preferential Th2 responders), whereas C57BL/6 (the 
preferential Th1 responders) primarily elicit ADAs of IgG3 isotype. Coutelier et al. reported in 
1988 the dependence of IgG subclass generation on the present antigen in mice. Antibodies 
towards proteins and carbohydrates were found to be restricted to the IgG1 and IgG3 subclass, 
whereas antiviral antibodies predominantly belonged to the IgG2a subclass [Coutelier et al., 
1988]. A predominant mechanism of the Th1 immune response implies the release of IFN-γ and 
enhances the secretion of IgG2a [Stevens et al., 1988]. However, since C57BL/6 are not able to 
generate IgG2a subclass [Martin et al., 1998], these immunoglobulins were not investigated in 
this study. Instead, IgG3 preponderated in this mouse strain. In BALB/c mice, being 
predominantly Th2 responders, the cytokine IL-4 is mainly secreted leading to strong IgG1 
responses [Ramakrishna et al., 2003]. Although the Th2 mechanism is preferred, a minor Th1 
response will be present as well, inducing the IgG2a subclass. In BALB/c the dominating IgG 
ADA subclass was also shown to be dependent on the route of administration [Feltquate et al., 
1997]. However, throughout this study, the samples were administered subcutaneously and 
therefore no impact on the IgG subclass was expected.  
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None of the investigated aggregate formulations was capable to induce each of the 
investigated IgG isotypes of ADAs, though each formulation induced at least one 
immunoglobulin isotype. The differences in the aggregate features therefore seem to result in 
different profiles of immunogenicity and in diverging immunoglobulin patterns. Significant 
differences were detected between the insoluble aggregate species mostly consisting of 
micron-sized particles. These aggregates were characterized by diverging numbers of 
subvisible particles per ml and by distinct secondary structures, determined by FTIR 
spectroscopy. Additionally, the immune responses to the aggregates obtaining a substantially 
altered secondary structure of the protein vary a lot. Especially the aggregates generated by 
light exposure were capable to induce a strong immune response, whereas the aggregates 
generated by heating revealed only minor formation of IgG ADAs. The aggregates from stirring 
and shaking, revealing a native-like structure, resulted in similar responses in BALB/c mice, but 
the ADA levels in C57BL/6 did not resemble each other. Therefore, more detailed information 
on the aggregates is preferably needed to explain the differences in their immunogenic 
potential.  
In this study, only 5 µg of protein were injected at each time point. Otherwise, with high 
doses of a potentially immunogenic material tolerance might have been induced, leading to 
false negative results and covering the responses. However, the injected formulations consisted 
of almost pure aggregates. This finally implied the administration of very high doses of 
aggregates to each animal, compared to only trace amounts in typically administered liquid 
formulations of therapeutic proteins. This high dose of immunogenic material resulted in an 
altered pharmacokinetic profile in BALB/c mice and probably would have entailed a complete 
loss of efficacy of the drug. The dose dependency was not subject of this study but has to be 
investigated in future. It would be of interest to get more information if low amounts of only a 
few percent of aggregates in the presence of > 90% native drug within a formulation can have 
such a dramatic impact as well. However, this first study aimed to see whether aggregates have 
an immunogenic effect in wild-type animals at all and therefore based on high doses.  
 
8.5 CONCLUSION 
 
This study for the first time proves the immunogenicity of various well-defined 
aggregates of a monoclonal antibody (muAb) in a wild-type animal model. All selected 
aggregates might potentially occur during protein manufacturing and are thus defined as 
relevant for immunogenicity testing. Compared to many other recently published in vivo studies 
a murine monoclonal antibody (muAb) was investigated in wild-type mice. The selection of the 
mouse strain to investigate the immune response to a murine protein has an impact on the 
results. Though the genetic background of C57BL/6 and BALB/c mice differs only marginally, 
the immune responses in terms of the generation of anti-drug antibodies is substantially 
different. A murine protein can even be foreign to mice. The same aspect might hold true for 
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human proteins globally administered to various human races, leading to diverging incidences 
of immunogenic side reactions to therapeutic proteins. 
All aggregates incorporated show increasing ADA levels of one or another 
immunoglobulin isotype. The exposure to light and elevated temperatures, stirring, and shaking 
are therefore relevant parameters that can entail immunogenicity to a therapeutic protein due to 
aggregation. However, the resulting immune response strongly depends on the type of 
aggregate that is administered and cannot be generalized for all aggregates of a certain protein. 
It was already expected beforehand, that there is a relation between features of the aggregate 
species and the kinetics of elicitation of ADAs and the resulting IgG isotype. This study clearly 
approved this assumption. For example the results indicate that weak/reversible aggregates 
can result in completely different ADA profiles compared to the situation for more stable 
aggregates. However, little is known what happens to aggregates after subcutaneous injection. 
Thus, detailed studies tracking protein aggregates in vivo, for example by labeling them, have 
to be conducted, if one wants to determine possible relations between the duration of aggregate 
uptake and the immune response. The divergence in aggregate uptake and metabolism might 
also be a reason for some aggregates not reaching the same absorbance ratios in IgG ADA 
assays at the same time as the native muAb in BALB/c mice.   
An interesting novelty the results of this study reveal is that the most critical aggregates 
seem to be of large insoluble nature and these aggregates do not necessarily have to maintain 
a native-like structure. Especially insoluble aggregates from light exposure and stirring lead to 
rapid formation of high ADA levels. Both species can be considered to be a particular 
contamination potentially occurring during production and handling of the drug, presented to the 
immune system. The light exposed samples possess an oxidized amino acid sequence, 
whereas the stirred samples preserve a native-like structure but consist of much higher particle 
numbers. The evident improvements in quality and purity of therapeutic protein production can 
largely exclude these impurities. Purification steps can be extended to reduce the amount of 
oxidized molecules. Several new techniques to improve the detection of subvisible particles in 
protein formulations emerged within the last years [Zoells et al., 2012]. Based on this progress, 
a limitation of the numbers of subvisible particles in the range from 1 - 10 µm for approval is 
currently under debate in industry, academics and authorities [Carpenter et al., 2009; Singh et 
al., 2010].  
However, the smaller and soluble aggregates generated by light exposure that were 
preliminary shown to be dissociable, were immunogenic as well. Therefore, the size of 
aggregates is not reclusively responsible for ADA formation. The detection of such soluble 
aggregates during production by size-exclusion chromatography is rather simple, though no 
fixed limits for the maximum percentage of soluble aggregates in a therapeutic protein 
formulation have yet been set. Interestingly, these aggregates resulted in non-persistent IgG1 
ADAs in C57BL/6 mice, indicating another mechanism of antibody elicitation. 
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Chromatographic purification is suitable to separate soluble aggregates from a 
formulation (though only throughout production but not after storage), whereas especially 
subvisible particles are difficult to remove. Regarding the strong detected immune responses 
towards particulate (insoluble) aggregates, the discussion on analytical techniques to quantify 
small subvisible particles in therapeutic protein formulations is justified [Carpenter et al., 2009; 
Singh et al., 2010].  
The obtained immunogenic differences between two inbred wild-type mouse strains 
that possess rather similar genetic characteristics are considered to be another important 
outcome of this study.  
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9  FINAL SUMMARY AND CONCLUSIONS 
 
 
The overall aim of this thesis was to investigate the immunogenicity of protein 
aggregates in vivo. The objectives of this work originate from consolidated findings reported in 
earlier studies that protein aggregates can induce immunogenicity [Braun et al., 1997; Fradkin 
et al., 2009; Hermeling et al., 2006; Rosenberg, 2006]. However, the previous studies all 
utilized transgenic animal models that artificially were made tolerant towards foreign (especially 
human) proteins. This study was initiated to use for the first time wild-type animals and a protein 
originated from the same species: a murine monoclonal antibody was investigated in mice. 
Additional motivation of the thesis was the separation of aggregates from non-aggregated 
protein species before application to the animals. This approach would imply a close correlation 
between a certain aggregate species and an immune response – independent from potentially 
accompanying species such as fragments. Due to the increasing importance of monoclonal 
antibodies in therapeutic perspectives, the study focused on a monoclonal antibody as model 
protein. Finally, the ambiguity whether all aggregates or only a certain species exhibiting 
specific characteristics can trigger immunogenicity, was a major question that should be 
addressed during the studies in this project.  
The thesis can be subdivided in two major parts: First, the generation and 
characterization of the aggregates was carried out. These studies include a detailed 
physicochemical characterization of the protein and the separation of the generated aggregates 
from concomitant protein species. The second part of the thesis presents animal studies that 
investigate the effect of aggregates in vivo. A proper assay format to determine the 
immunogenicity was required and established. The immunogenicity of various aggregates was 
investigated using the implemented methods.  
Chapter 1 describes the objectives of the thesis.   
In chapter 2 a general introduction into the topic of protein aggregation and 
immunogenicity is given. A focus of the discussion is put on the currently accepted pathways of 
protein aggregation. Five major mechanisms are discriminated by the most important scientific 
reviews [Chi et al., 2003; Philo et al., 2009; Wang, 2005]. The pathways are generally classified 
firstly according to the structure of the protein species involved in aggregation, being 
conformationally altered, chemically modified or native, and secondly according to external 
triggers that can provoke aggregation, such as surfaces and “critical nuclei” that arise in the 
formulation. The most common techniques to characterize protein aggregates of different type 
are described in chapter 2 as well. A special focus during the analytical part is put on field-flow 
fractionation, since this technique represents a crucial part of the overall work. Furthermore, the 
introduction discusses factors that potentially influence immunogenicity of protein therapeutics 
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and a rough overview of the mechanisms of immune responses in human. The elicitation of 
antibodies that are directed towards the protein are the main focus of the immunogenicity 
studies in this work. Finally, a short introduction in structure and pharmacokinetics of 
monoclonal antibodies (mAbs) is given as well, since this thesis bases on mAbs as model 
proteins.  
Chapter 3 describes a first aggregation study using a human model protein. The aim of 
this chapter is to prepare for the following chapters. Information on the aggregation of the mAb 
is collected and analytical methods to characterize the aggregates are developed, that 
subsequently (chapter 4) are transferred to the protein of interest. 
A human IgG1 antibody was stressed by a variety of methods that were defined to be 
relevant conditions reflecting different steps during production, shipment and handling of 
biopharmaceuticals. The mechanical stress methods stirring and shaking first and foremost 
induce particulate aggregates that are detectable by increasing turbidity and generation of 
subvisible particles. Light exposure and storage at elevated temperatures induce the generation 
of soluble protein species like aggregates and fragments, detected by size exclusion 
chromatography. Repetitive freeze-thaw cycles did not result in substantial formation of 
aggregates or substantial changes in the protein structure. Thus, this approach to generate 
aggregates is not followed up throughout this work. A variety of physicochemical methods to 
evaluate the protein structure and aggregate content are described and compared. The 
methods complement one another and give a broad overview about the consequences of the 
stress methods on protein stability. The most striking modifications in protein structure are 
induced by exposure to light. 
In chapter 4 the previously developed methods to generate and analyze protein 
aggregates are transferred to a murine monoclonal IgG2c antibody. The aggregation behavior 
of this protein is similar to the human protein investigated in the previous chapter: (i) Stirring 
and shaking induce particulate aggregates but no soluble species. (ii) Light exposure and 
storage at elevated temperatures result in the formation of soluble aggregates and fragments. 
(iii) Light exposure induces drastic structural alterations in the murine antibody as well. 
Concerning the later in vivo studies all four stress methods are considered to be relevant and 
suitable to induce a sufficient amount of aggregates from the murine antibody. Light exposure 
turned out to be the only incubation method that reveals huge amounts of soluble aggregates. 
Therefore, this type of stress will be utilized to implement a method to preparative use 
asymmetric flow field-flow fractionation (AF4) to separate soluble aggregates from monomeric 
protein.  
In chapter 5 a preparative AF4 method using the human model antibody after light 
exposure was developed. The key point is the successful implementation of a semi-preparative 
channel prototype and a fraction collector to the system. Subsequently, a method to collect 
large amounts of aggregates generated by light exposure is developed. The dilution in 
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consequence of the fractionation principle limits the directly achievable protein concentration in 
the collected aggregate fraction. Therefore, a concentration step is necessary. Different 
disposable concentrators are evaluated in chapter 5. Protein aggregate concentrations up to 
~650 µg/mL were achieved. The stability of these fractions during storage at 2 – 8°C and at -
80°C was found to be sufficient for supporting an in vivo study. 
In the following chapter 6 the preparative use of AF4 was successfully transferred to 
the murine antibody. The focus of this chapter is put on the low endotoxin level in the final 
aggregate fraction. A meticulous cleaning procedure of the entire AF4 instrument and all 
devices used was established. The collected and subsequently concentrated fractions meet the 
requirements of the European Pharmacopoeia (< 0.25 EU/mL) [PhEur 0169, 2011]. A sufficient 
protein concentration of approximately 600 µg/mL was achieved in the final aggregate fraction. 
The low endotoxin level of < 0.1 EU/ml and the proper stability during storage at -80°C prove 
the applicability of the developed fractionation procedure of the murine antibody in preparation 
of an in vivo study. 
The conducted animal studies are described in chapters 7 and 8. First of all, in chapter 
7, two different ELISA set-ups are described. Both were used to detect the immunogenicity of 
anti-drug antibodies towards the murine monoclonal antibody used. It has to be mentioned that 
one part of this study was performed at the University of Colorado in the research group of 
Theodore W. Randolph. The entire sample preparation and animal handling for this first study 
was performed at the site of an industrial partner under command and responsibility of the 
Department of Pharmaceutical Technology and Biopharmaceutics at the LMU Munich by 
myself. Solely the analytics using a second ELISA method were conducted abroad in Colorado 
after shipping the left-over serum samples to our colleagues. However, for better understanding 
and comprehension of the second animal studies, these results are provided as well. The assay 
design was found to be crucial for reliable results in immunogenicity investigations. The need of 
acid dissociation of immune complexes in the serum samples is proven in chapter 7. The long 
half-life of monoclonal antibodies implies the circulation of native drug molecules that capture 
Anti-drug antibody molecules and thus elude them from detection by ELISA. The ADA detection 
without an acid dissociation step revealed no immunogenicity of the mixture of muAb 
aggregates used throughout this study. Two different doses of soluble and insoluble aggregates 
generated by light exposure and stirring were included in this study to cover a broad range of 
aggregate features. The inclusion of an acid dissociation step can be used to overcome that 
effect. Dissociating the immune complexes enables the detection of ADAs in the animals that 
received muAb aggregates.  
Besides the method development, this study shows that the murine antibody sample 
containing various types of aggregates and fragments induces a substantial immune response 
in wild-type mice. This immunogenic potential is concluded to be related to the presence of 
muAb aggregates and/or fragments, since no foreigness of muAb in the mice is expected. 
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Furthermore, the higher dose of aggregates applied to the mice results in higher ADA levels 
showing the dose dependency of immunogenicity of protein aggregates. 
The study described in this chapter for the first time investigated the immunogenicity of 
protein aggregates (murine) in wild-type animals (mice) and proves the suitability of this 
approach closely resembling the therapeutic situation of human proteins in human patients. 
The final and pivotal animal studies are described and discussed in chapter 8. A variety 
of different well-defined aggregates from the murine IgG2c antibody were separated from the 
monomer and fragments to the extent possible. The detection of anti-drug antibodies of 
different IgG isotypes based on the assay set-up developed in the previous section. The ELISA 
results prove that protein aggregates can elicit an immune response in terms of anti-drug 
antibodies. 
Two different mouse strains are included in this study. Though the genetic background 
of C57BL/6 and BALB/c mice differs only marginally, the immune responses in terms of the 
generation of anti-drug antibodies is substantially different. A murine protein can even be 
foreign to mice. This is an interesting aspect with regards to the different human races. Different 
incidences of immunogenic side reactions to therapeutic proteins triggered by protein 
aggregates in various populations might be the consequence.  
All aggregates included in this study induced an immune response. Since only 
aggregates relevant for production and handling of therapeutic proteins are investigated, it has 
to be concluded that in general all aggregates and particles determined in a drug product 
should be reduced to the extent possible before release of the drug.   
However, the experiments also prove that different aggregates result in different 
immune responses. The responses for example differ in strength, duration as well as in the IgG 
isotypes preferentially generated by the individuals. Two features of the aggregates are 
concluded to be crucial for immunogenic reactions: the size and chemical modifications in the 
molecule. A high and persisting immune response is detected after repeated application of 
insoluble aggregates obtained from light exposure, from stirring and from shaking. In 
conclusion, large protein aggregates and subvisible particles can induce strong immune 
response. As far as investigated in this study smaller soluble aggregates result in a weaker and 
short-term increase of ADAs. Interestingly, aggregates possessing strong structural alterations 
due to chemical modifications reveal high ADA levels. Against all expectations aggregates that 
failed to bind the desired antigen because of a heavily altered structure induced immense 
immune responses in mice. Thus the generation of anti-drug antibodies not necessarily requires 
unmodified CDR regions of the monoclonal antibody molecules incorporated in the aggregate.  
The generated immunoglobulin isotype of ADAs towards the aggregates strongly differ 
between C57BL/6 mice and BALB/c mice. As expected, BALB/c mice preferably generate 
antibodies of IgG1 isotype, whereas C57BL/6 mice show the highest levels in IgG3 isotype. The 
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generated immunoglobulin isotypes differ also within one mouse strain. This aspect might be 
related to variations in kinetics and mechanisms of absorption of the aggregates after 
subcutaneous injection but is not subject of this study.  
This thesis touches the huge topic of the relation of protein aggregates and 
immunogenicity. For the first time, this study has shown the suitability of using wild type mice to 
investigate murine antibodies compared to the transgenic approach. The immunogenicity of a 
variety of aggregates of a monoclonal antibody was proven and revealed remarkable 
differences between the aggregates, with regards to strength and type of ADAs generated. 
Besides these major findings the work showed, that a proper assay format is crucial for the 
detection of anti-drug antibodies and that the immune response differs between different mouse 
strains. Based on the established assay format, further investigations should be conducted to 
gain a more detailed understanding of the immunogenicity of protein aggregates in wild type 
animals.  
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ADA  - Anti-drug antibody 
AF4   - Asymmetrical flow field-flow fractionation 
ANS  - 8-Anilinonaphthalene-1-sulfonate 
APC  - Antigen presenting cell 
ATR  - Attenuated total reflectance  
AU  - Absorbance units 
a.u.  - arbitrary units 
AUC  - Area under the curve 
BALB/c  - Inbred mouse strain BALB/c 
µ-BCA  - Micro bicinchoninic acid assay 
BCR  - B cell receptor 
BSA  - Bovine serum albumin 
C57BL/6 - Inbred mouse strain C57BL/6 
CD4+  - T-helper cells 
CDR  - Complementarity determining region 
CH  - Constant region of heavy chain  
CHO  - Chinese hamster ovary 
CL  - Constant region of light chain 
CPMP  - Committee for Proprietary Medicinal Products 
DC  - Dendritic cell 
DLS  - Dynamic light scattering 
DMSO  - Dimethylsulfoxide 
DNA  - Deoxyribonucleic acid 
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dn/dc  - Refractive index increment 
µ-DSC  - Micro differential scanning calorimetry 
DTT  - Dithiothreitol 
ECD  - Equivalent circle diameter 
ELISA  - Enzyme-linked immuno sorbent assay 
EMA  - European Medicines Agency  
EU  - Endotoxin units 
Fab  - Antigen-binding fragment 
Fc  - Crystallizable fragment 
FcRn  - Neonatal Fc receptor 
FDA  - U.S. Food and Drug Administration 
FFF  - Field-flow fractionation 
FIM  - Flow Imaging Microscopy 
FIn  - Channel inlet flow 
FNU  - Formazine nephelometric units 
Fout  - Channel outlet flow 
FTIR  - Fourier transform infrared spectroscopy 
Fx  - Cross-flow 
G-CSF  - Granulocyte colony-stimulating factor 
GI  - Gastrointestinal tract 
GM-CSF - Granulocyte macrophage colony-stimulating factor 
GPC  - Gel permeation chromatography 
HAMA  - Human anti-mouse antibody 
HMW  - High molecular weight 
H2O2  - Hydrogen peroxide 
HP-SEC - High performance size exclusion chromatography 
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HPW  - Highly purified water 
HRP  - Horseradish peroxidase 
huAb  - human monoclonal antibody 
ICH  - International Conference on Harmonization 
Ig  - Immunoglobulin 
IgG  - Immunoglobulin class G 
IM  - Intramuscular  
IMW  - Intermediate molecular weight 
IV  - Intravenously  
kDa  - Kilo Dalton 
LAL  - Limulus amebocyte lysate 
LMW  - Low molecular weight 
LO  - Light obscuration 
LOD  - Limit of detection 
LPS  - Lipopolysaccharide 
mAb  - monoclonal antibody 
MALLS  - Multi angle laser light scattering 
mg  - Milligram 
MHC-II  - Major histocompatibility complex class II 
ml  - Milliliter 
µm  - Micrometer 
µM  - Micromolar 
muAb  - murine monoclonal antibody 
MW  - Molecular weight 
MWCO  - Molecular weight cut-off 
n/a  - not applicable 
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nm  - Nanometer 
NTA  - Nanoparticle tracking analysis 
PAGE  - Polyacrylamide gel electrophoresis 
PAMP  - Pathogen-associated molecular pattern 
PBS  - Phosphate buffered saline 
PCS  - Photon correlation spectroscopy 
PDI  - Polydispersity index 
PES  - Polyethersulfone  
PhEur  - European Pharmacopoeia  
PK  - Pharmacokinetics 
PTFE  - Polytetrafluoroethylene  
QELS  - Quasi-elastic light scattering 
RI  - Refractive index 
RP-HPLC - Reversed phase high performance liquid chromatography 
rpm  - rounds per minute 
SC  - Subcutaneously  
S.D.  - Standard deviation 
S.E.  - Standard error of the mean 
SDS  - Sodium dodecyl sulfate 
SEC  - Size exclusion chromatography 
SP1  - Semi-preparative channel Prototype 1 
SPF  - Specific pathogen free 
SV-AUC - Sedimentation velocity analytical ultracentrifugation 
TCR  - T cell receptor 
TEM  - Transmission electron microscopy 
Th1/Th2  - T-helper cells Type 1 and Type 2 
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Tm  - Melting temperature 
TMB  - 3,3’,5,5’-Tetramethylbenzidine 
TNFα  - Tumor necrosis factor α 
Trp  - Tryptophane 
Tyr  - Tyrosine 
USP  - United States Pharmacopoeia 
UV  - Ultraviolet 
VH  - Variable region of heavy chain 
VL  - Variable region of light chain 
VX  - Cross flow 
W/m²  - Watt per square meter  
Zave  - Z-average diameter 
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